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Abstract
Multi-parametric magnetic resonance imaging (mpMRI) of localized prostate
cancer has the potential to support detection, staging and localization of tumors, as well
as selection, delivery and monitoring of treatments. Delineating prostate cancer tumors
on imaging could potentially further support the clinical workflow by enabling precise
monitoring of tumor burden in active-surveillance patients, optimized targeting of imageguided biopsies, and targeted delivery of treatments to decrease morbidity and improve
outcomes. Evaluating the performance of mpMRI for prostate cancer imaging and
delineation ideally includes comparison to an accurately registered reference standard,
such as prostatectomy histology, for the locations of tumor boundaries on mpMRI. There
are key gaps in knowledge regarding how to accurately register histological reference
standards to imaging, and consequently further gaps in knowledge regarding the
suitability of mpMRI for tasks, such as tumor delineation, that require such reference
standards for evaluation.
To obtain an understanding of the magnitude of the mpMRI-histology registration
problem, we quantified the position, orientation and deformation of whole-mount
histology sections relative to the formalin-fixed tissue slices from which they were cut.
We found that (1) modeling isotropic scaling accounted for the majority of the
deformation with a further small but statistically significant improvement from modeling
affine transformation, and (2) due to the depth (mean±standard deviation (SD) 1.1±0.4
mm) and orientation (mean±SD 1.5±0.9°) of the sectioning, the assumption that histology
sections are cut from the front faces of tissue slices, common in previous approaches,
introduced a mean error of 0.7 mm.
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To determine the potential consequences of seemingly small registration errors
such as described above, we investigated the impact of registration accuracy on the
statistical power of imaging validation studies using a co-registered spatial reference
standard (e.g. histology images) by deriving novel statistical power formulae that
incorporate registration error. We illustrated, through a case study modeled on a prostate
cancer imaging trial at our centre, that submillimeter differences in registration error can
have a substantial impact on the required sample sizes (and therefore also the study cost)
for studies aiming to detect mpMRI signal differences due to 0.5 – 2.0 cm3 prostate
tumors.
With the aim of achieving highly accurate mpMRI-histology registrations without
disrupting the clinical pathology workflow, we developed a three-stage method for
accurately registering 2D whole-mount histology images to pre-prostatectomy mpMRI
that allowed flexible placement of cuts during slicing for pathology and avoided the
assumption that histology sections are cut from the front faces of tissue slices. The
method comprised a 3D reconstruction of histology images, followed by 3D–3D ex vivo–
in vivo and in vivo–in vivo image transformations. The 3D reconstruction method
minimized fiducial registration error between cross-sections of non-disruptive histologyand ex-vivo-MRI-visible strand-shaped fiducials to reconstruct histology images into the
coordinate system of an ex vivo MR image. We quantified the mean±standard deviation
target registration error of the reconstruction to be 0.7±0.4 mm, based on the postreconstruction misalignment of intrinsic landmark pairs. We also compared our fiducialbased reconstruction to an alternative reconstruction based on mutual-information-based
registration, an established method for multi-modality registration. We found that the
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mean target registration error for the fiducial-based method (0.7 mm) was lower than that
for the mutual-information-based method (1.2 mm), and that the mutual-informationbased method was less robust to initialization error due to multiple sources of error,
including the optimizer and the mutual information similarity metric. The second stage of
the histology–mpMRI registration used interactively defined 3D–3D deformable thinplate-spline transformations to align ex vivo to in vivo MR images to compensate for
deformation due to endorectal MR coil positioning, surgical resection and formalin
fixation. The third stage used interactively defined 3D–3D rigid or thin-plate-spline
transformations to co-register in vivo mpMRI images to compensate for patient motion
and image distortion. The combined mean registration error of the histology–mpMRI
registration was quantified to be 2 mm using manually identified intrinsic landmark pairs.
Our data set, comprising mpMRI, target volumes contoured by four observers and
co-registered contoured and graded histology images, was used to quantify the positive
predictive values and variability of observer scoring of lesions following the
Prostate Imaging Reporting and Data System (PI-RADS) guidelines, the variability of
target volume contouring, and appropriate expansion margins from target volumes to
achieve coverage of histologically defined cancer. The analysis of lesion scoring showed
that a PI-RADS overall cancer likelihood of 5, denoting “highly likely cancer”, had a
positive predictive value of 85% for Gleason 7 cancer (and 93% for lesions with volumes
>0.5 cm3 measured on mpMRI) and that PI-RADS scores were positively correlated with
histological grade (ρ=0.6). However, the analysis also showed interobserver differences
in PI-RADS score of 0.6 to 1.2 (on a 5-point scale) and an agreement kappa value of only
0.30. The analysis of target volume contouring showed that target volume contours with
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suitable margins can achieve near-complete histological coverage for detected lesions,
despite the presence of high interobserver spatial variability in target volumes.
Prostate cancer imaging and delineation have the potential to support multiple
stages in the management of localized prostate cancer. Targeted biopsy procedures with
optimized targeting based on tumor delineation may help distinguish patients who need
treatment from those who need active surveillance. Ongoing monitoring of tumor burden
based on delineation in patients undergoing active surveillance may help identify those
who need to progress to therapy early while the cancer is still curable. Preferentially
targeting therapies at delineated target volumes may lower the morbidity associated with
aggressive cancer treatment and improve outcomes in low-intermediate-risk patients.
Measurements of the accuracy and variability of lesion scoring and target volume
contouring on mpMRI will clarify its value in supporting these roles.

Keywords
Magnetic resonance imaging, MRI, prostate cancer, registration, 3D reconstruction, focal
therapy, radiology, radiation oncology, pathology, histology, histopathology.
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Chapter 1.
Introduction
Imaging of localized prostate cancer, and in particular multi-parametric magnetic
resonance imaging (mpMRI), has the potential to support multiple stages of the clinical
workflow, including detection, staging and localization of tumors, as well as selection,
delivery and monitoring of treatments. Delineation of prostate cancer tumors on imaging
has the potential for further improving the clinical workflow, potentially enabling precise
monitoring of tumor volumes in active-surveillance patients, optimal targeting of
biopsies, and targeted delivery of treatments with lower morbidity or improved outcomes
for suitable patients.
Spatially accurate comparisons of prostate images and delineations to an accepted
reference standard for the location and clinical significance of prostate cancers, could
support evaluation and improvement of prostate cancer imaging and lesion delineation in
the clinical workflow. Currently, the most readily accepted reference standard for the
location and aggressiveness of prostate cancer is histological examination of
prostatectomy specimens. Some applications of such a histological reference standard to
investigate prostate cancer imaging and delineation require accurate registration to the
images being investigated. However, there are key gaps in knowledge regarding how to
accurately register histological reference standards to imaging, and how accurate the
registration needs to be. Consequently, there is also a gap in knowledge regarding the
suitability of imaging for tasks, such as lesion delineation, that require such reference
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standards for evaluation. These gaps in knowledge will be described in further detail in
Section 1.2.
The work described in this thesis focuses on (1) developing tools for accurately
registering and evaluating a histological reference standard for prostate cancer imaging
and lesion delineation, and (2) evaluating the accuracy and variability of delineating
prostate cancer lesions on mpMRI by comparison to this accurately registered reference
standard. This evaluation could potentially inform clinical guidelines on the suitability
and use of mpMRI-derived target volumes for applications in localized prostate cancer
diagnosis, treatment and monitoring.

1.1 Background
1.1.1 Prostate cancer epidemiology
Prostate cancer is the most commonly diagnosed non-skin cancer in Canadian
men, with an estimated 23,600 new diagnoses in 2014 [1]. One in eight men will be
diagnosed with prostate cancer during his lifetime [1]. It is the third most common cause
of male cancer death, with an estimated 4,000 deaths in Canada in 2013. Additionally,
prostate cancer has a substantial impact on patients' ongoing quality of life, because the
most common prostate cancer treatments have high risks of life-changing side effects and
living with untreated cancer has a high psychological burden.
The natural history of prostate cancer is highly variable: some prostate tumors
become metastatic and potentially lethal, but many do not. In fact, autopsy studies of 80–
90-year-old men deceased from unrelated causes have found that 70–90% had
histological evidence of prostate tumors [2]. As screening tests have become more
sensitive and more widespread, more of these latent non-lethal cancers have been
2

diagnosed and treated [3], which impacts patients' quality of life. Accordingly, prostate
cancer is commonly described as over-diagnosed and over-treated [3] (for low-risk
patients), while, at the same time, resulting in many deaths (of high risk patients).
Thus, key challenges in prostate cancer lie in identifying patients who do not need
treatment, supporting therapy delivery for those that need aggressive treatment to extend
their lives in spite of potential side effects, and developing treatment approaches for
borderline patients that will survive with less aggressive treatments and will benefit from
lower morbidity.
Delineation of prostate cancer may have a role in addressing each of these
challenges: supporting accurate stratification of patients through optimized targeted
biopsy procedures, monitoring low-risk patients through longitudinal measurements of
tumor burden, and targeting curative-intent therapies for both aggressive and less
aggressive treatments.

1.1.2 Prostate cancer diagnosis
Detection and diagnosis of prostate cancer is performed in two stages: initial
detection and biopsy confirmation.
1.1.2.1 Initial detection
Two techniques are currently widely used to initially detect prostate cancer in
symptomatic men and as a screening tool in asymptomatic men: prostate-specific-antigen
(PSA) testing and digital rectal examination (DRE).
PSA testing is a procedure where a blood sample is taken, and the level of PSA, a
protein produced primarily by prostate cells, is quantified. A PSA level above 4.0 ng/mL
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has been considered suspicious for cancer, and positive PSA tests result in more cancer
diagnoses than other tests [4]. However, other conditions such as prostatitis and benign
prostatic hyperplasia (BPH) can also increase PSA levels [5]. Furthermore, in the Prostate
Cancer Prevention Trial, 15% of men with consistently lower PSA levels had a positive
biopsy and 2% had a positive biopsy showing high-grade cancer [6]. The increase in
detection of latent cancer has, in part, been attributed to the sensitivity of the PSA test,
and its application in screening populations [1].
DRE is a procedure wherein a physician palpates the patient’s prostate through
the rectal wall with a gloved finger to identify tissue that has abnormally high density or
asymmetry, properties which raise suspicion for prostate cancer [4]. DRE alone has a
reported sensitivity of 37% and a positive predictive value (PPV) of 27%; however, DRE
is typically used in conjunction with PSA testing where it yields an incremental
sensitivity of 18%. In patients who would not be identified with PSA testing (i.e. PSA <
4.0 ng/mL), the PPV was 13% [7].
In order to detect cancers at an earlier, more treatable stage, DRE and PSA testing
have been widely used to screen asymptomatic men; however, the practice remains
controversial, due to uncertainty about the benefits and risks of screening [1]. The
Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial found that men who
underwent DRE and PSA screening had a higher incidence of prostate cancer, but the
same mortality, as a control group [8]. In contrast, the European Randomized Study of
Screening for Prostate Cancer trial found that the men randomized to the screening group
had a higher incidence, but lower mortality, than the control group [9]. As a result of this
evidence, the United States Preventive Services Task Force has recommended against
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screening of asymptomatic men [10]. Correctly stratifying patients identified through
high sensitivity screening could improve mortality for high-risk patients, while avoiding
the overtreatment of low-risk patients.
1.1.2.2 Biopsy
Patients with findings that are suspicious for prostate cancers will be referred for
prostate biopsy to confirm the suspicion. Prostate biopsy is a procedure where tissue
samples are taken from the prostate using a biopsy needle, through the rectal wall or the
perineum, under the guidance of transrectal ultrasound. Typically 6–12 biopsy samples
are taken using a systematic protocol that primarily samples the peripheral zone, where
the majority of cancers are located [11, 12]. Biopsy tissue is examined microscopically to
determine the number of cores containing cancer, and the extent of cancer in each core.
This information is used for staging according to the "TNM Classification of Malignant
Tumours" system (commonly abbreviated to the TNM system, where TNM refers to
tumors nodes and metastases). For example, T1c denotes that the tumor was found in a
needle biopsy performed as a result of a PSA test and T2a denotes that the tumor is in
less than half of one of the prostate lobes for a palpable tumor. Cancer that is identified
on biopsy is assessed according to the Gleason grading system by grading the
microscopic architecture and differentiation of prostate glands on a 5 point scale [13]
(illustrated in Figure 1.1), and reporting a Gleason score as the sum of the most prevalent
grades. The Gleason score, clinical TNM stage and PSA levels can be used in pathologic
and prognostic nomograms [14-16] to guide therapy selection. However, grading biopsy
tissue remains challenging, with a 40% rate of discrepancy between biopsy and
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prostatectomy Gleason grade [17, 18], due, in part, to challenges in acquiring
representative samples of prostate tumors.
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Figure 1.1: Illustrated Gleason patterns from the updated Gleason grading system.
Reproduced with permission from Epstein et al. The 2005 ISUP Consensus Conference
on Gleason Grading of Prostatic Carcinoma. The American Journal of Surgical
Pathology, 29(9) 1228–1242.
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1.1.2.3 A potential role for imaging and lesion delineation
Prostate cancer screening tests are sensitive, identifying many patients with lowrisk disease. Challenges remain in correctly stratifying such patients based on systematic
biopsy. However, biopsies that are targeted at suspicious regions delineated on imaging
may have a higher probability of sampling high-grade foci [19]. As the likelihood of
sampling tissue from a lesion depends on its size and shape [20], accurate and precise
delineation of intraprostatic cancer foci on imaging, and quantification of the uncertainty
in delineation, could support the development of optimized planning of targeted biopsy
procedures.

1.1.3 Localized prostate cancer management
Organ-confined prostate cancer is primarily managed with (1) expectant
management without therapy, with low direct morbidity but with the psychological
burden of living with untreated cancer or (2) radical therapies (radiation or surgery) that
target the whole prostate with curative intent, with high rates of life-changing side
effects. Emerging treatments that target the prostate cancer preferentially may offer an
intermediate curative intent treatment with reduced side effects for suitable men. This
section describes these treatments, and the roles that imaging and lesion delineation
might play.
1.1.3.1 Expectant management
Expectant management refers to multiple approaches where the patient is not
given treatment: watchful waiting, where treatment is delivered if the patient becomes
symptomatic; and active surveillance, where the patient is closely monitored for signs of
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progression with frequent biopsy and blood tests. If progression is detected, these patients
can proceed to curative-intent treatments. In patients who do not progress, there are no
treatments, and, therefore, no direct side effects. However, there are indirect effects that
negatively affect patients’ quality of life, including anxiety and depression [21] and
increased long-term erectile dysfunction rates [22]. Patients' decisions to undergo
curative-intent treatment even without progression (7–13% of patients) have been
attributed, in part, to these side effects [23, 24]. Expectant management is suitable for
patients with low-risk cancer, defined by a Gleason score ≤6, PSA<10ng/ml and clinical
stage T1c–T2a (i.e. the tumor occupies less than half of one lobe), constituting 50% of
newly diagnosed prostate cancer [25]. In one cohort of 299 active-surveillance patients,
the prostate-cancer-specific survival rate was 99.3% after 8 years of follow-up and only
35% of active-surveillance patients progressed to delayed curative-intent therapy [25].
Although differences in recurrence rates due to delayed treatment of patients who do
progress have not yet been demonstrated [26, 27], delayed treatment does result in higher
pathological grade at time of treatment [27]. Thus, there may be value in identifying the
patients who do progress earlier. Prostate cancer imaging may have a role in ongoing
monitoring of patients on active surveillance [28]. Additionally, there may be a role for
prostate cancer delineation in longitudinal measurements of tumor volume [29, 30], a
factor that has been found to be correlated with Gleason grade, stage, tumor progression
and survival and that may have independent prognostic importance [31].
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1.1.3.2 Prostate-focused therapies
The most common treatments for localized prostate cancer, radical prostatectomy
and radical radiotherapy, treat the whole prostate to the same degree with curative intent,
and with little or no adjustment for the location of the cancer within the gland.
1.1.3.2.1 Radical prostatectomy
Radical prostatectomy is a procedure wherein the prostate is removed through
open or minimally invasive surgery. Radical prostatectomy has the potential for cancer
cure in patients with cancer that does not extend beyond the surgical margin, and is an
appropriate treatment option for men with low−intermediate-risk prostate cancers,
including those with organ-confined tumors containing Gleason pattern 4 or 5 [4].
However, prostatectomy patients have high rates of erectile dysfunction (34–90% [32,
33]), urinary incontinence (8–13% [32, 34]) and other complications (10–30%
perioperatively and 4–10% within a year [32, 35]). Nerve-sparing radical prostatectomy,
in which one or both sets neurovascular bundles lateral to the prostate are not resected,
may result in lower rates of complications [34, 36]. Prostate cancer imaging and accurate
delineation of tumor boundaries may support selection of nerve-sparing surgeries in
patients with unilateral or bilateral cancer that is at an acceptable distance from the
surgical margin.
1.1.3.2.2 Radical radiation therapy
Radiation therapy refers to several procedures wherein the prostate is irradiated to
damage DNA (preferentially in highly proliferative cancer cells). Examples include
external beam radiation, where high energy x-rays generated outside the body are focused
on the prostate from multiple angles, low-dose-rate brachytherapy where radioactive
10

seeds are permanently inserted into the prostate, and high-dose-rate brachytherapy where
a highly radioactive emitter is moved within the prostate during the procedure and then
removed. Radiation therapies may be suitable for low–intermediate-risk patients
including those with PSA levels >10ng/ml and with organ-confined cancer with Gleason
scores >7, particularly with dose escalation or adjuvant hormonal therapy [4]. As with
radical prostatectomy, radiation therapy patients have high rates of morbidity: erectile
dysfunction (8–50% [37, 38]), urinary complications (7–23% [38, 39]) and fecal
incontinence (2–58% [40]).
1.1.3.3 Lesion-focused therapies
Emerging treatments that preferentially target the prostate cancer lesions may
allow for escalating treatment in tumors in patients to achieve better outcomes, reducing
treatment in healthy tissue to achieve lower morbidity, or both.
1.1.3.3.1 Whole-gland radiation with focal boost
After radical radiotherapy, local recurrence can occur within the prostate, which
typically occurs at the site of the dominant lesion [41]. Advances in technologies for
planning and delivering radiation have enabled radiation oncologists to deliver different
doses to different regions within the prostate. Intensity-modulated-radiation-therapybased and brachytherapy-based delivery of whole-gland radiation, with additional dose
delivered to intraprostatic gross tumor volumes, have been proposed as strategies to
improve outcomes [42, 43]. An alternative approach, where a reduced dose is delivered to
the whole gland and an additional dose is delivered to intraprostatic lesions, with the aim
to maintain control rate while reducing toxicity, is also being considered [44]. Accurate
and precise delineation of lesions on imaging may support the conformal delivery of
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higher dose to the dominant lesion, potentially reducing local recurrence and/or
improving morbidity, while minimizing dose to surrounding organs at risk.
1.1.3.3.2 Prostate-sparing and lesion-only therapies
Prostate cancer is multifocal in 67–82% of patients [45-47]; however, there is a
subset of patients whose cancer is aggressive enough to require treatment but consists of
a dominant lesion surrounded by primarily non-cancerous tissue. Furthermore, there is
evidence that the risk of recurrence and biochemical failure, even in multifocal prostate
cancers, depends primarily on the size and grade of only the largest focus [47]. Therefore,
some emerging therapies aim to preserve healthy prostate tissue by leaving portions, or
even the majority of the gland, entirely untreated. High-intensity focused ultrasound [48],
cryotherapy [49], photodynamic therapy [50], laser ablation [51] and radiation
therapy [52] are all being evaluated for focal therapy applications in the prostate. Control
rates for focal therapies have not yet been well-established; however, early evidence from
studies of several focal therapies suggests that they successfully reduce the side effects
prevalent in radical therapies. For example, studies of cohorts undergoing cryotherapy
have reported incontinence rates lower than 5% and erectile dysfunction rates of 10–
35% [49]. Studies of cohorts undergoing high-intensity focused ultrasound have reported
incontinence rates less than 10% and erectile dysfunction rates of 5–11% [53]. While
focal therapy can be delivered as a hemi- or “hockey-stick” ablation (1/2 or 3/4 of the
prostate), based on coarse localization of prostate cancer [54], conformal delivery to
ablate the cancer while minimizing damage to surrounding healthy tissue and organs at
risk requires that the cancer within the prostate be delineated on imaging. A recent
consensus panel suggested that this delineation should be performed using mpMRI [55].
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Thus, prostate cancer imaging and lesion delineation could play an important role in focal
therapy planning.
1.1.3.4 Summary of potential roles for imaging and lesion delineation
Imaging and lesion delineation have several potential roles in supporting
management of low–intermediate-risk patients. Longitudinal imaging-based
measurements (such as tumor burden) may support earlier identification of activesurveillance patients who would eventually progress to curative-intent therapies.
Accurate delineation of tumors may support conformal delivery of lesion-targeted
therapies for low–intermediate-risk patients to minimize damage to surrounding tissue
and organs at risk, potentially further lowering side effects. Delineation of tumors may
support focal boosting of radiotherapy dose to reduce local recurrence rates. Finally,
imaging and lesion delineation may support the decision to deliver nerve-sparing
surgeries for suitable candidates. Accurate and precise delineation of cancerous lesions
on imaging could support each of these goals.

1.1.4 Prostate cancer imaging
Prostate cancer imaging has the potential to extract spatial information noninvasively to support the detection, staging, grading, therapy selection, treatment
planning and treatment delivery of primary and metastatic prostate cancer. Many imaging
modalities can be used at different stages of the clinical workflow. mpMRI of localized
prostate cancer is the focus of this thesis, and will be described in detail; however, the
clinical application of ultrasound, x-ray computed tomography and nuclear imaging will
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also be briefly discussed in the following sections. Figure 1.2 shows an illustrative
comparison of these modalities for the same patient and anatomy.
1.1.4.1 Magnetic resonance imaging
MRI has shown promise for detection [56], staging [57, 58], localization [59-61],
therapy planning [43, 55, 62], and therapy monitoring [63] for localized prostate cancer,
and may be suitable for lymph node staging with suitable contrast agents [64]. MRI can
provide rich anatomical and pathological detail as it enables flexible control of soft tissue
contrast with different acquisition sequences, and can have submillimeter resolution for
some sequences.
The performance of individual MRI sequences for localized prostate cancer
detection varies substantially [55], depending, in part, on the sequence used, and the
location and grade of the cancer [65, 66]. Consensus guidelines [56] for detection of
localized prostate cancer have been developed, recommending the use of multiple MRI
sequences, comprising T2-weighted (T2W) imaging, and at least 2 functional sequences
(e.g. diffusion-weighted (DW) imaging, dynamic contrast-enhanced (DCE) imaging, or
MR spectroscopy). The cancer detection rate of the combination of T2W, DW and DCE
imaging also varies (sensitivity: 53%–95%, specificity: 74%–96%, PPV: 51%–95%,
negative predictive value [NPV]: 65%–94%) [67]. The following sections describe
sequences and imaging protocols that have been investigated for imaging localized
prostate cancer.
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A) T2W MRI

B) DW MRI

C) ADC map

D) DCE MRI

E) 3D TRUS (side fire)

F) CT

G) 18F choline PET/MR

H) Histology

Cancer
(GS 4+3+5)
BPH

Figure 1.2: Multiple modalities of prostate cancer imaging showing approximately the
same anatomical location. A large Gleason score 4+3 cancer with tertiary grade 5 is
present in the anterior prostate, alongside a small region of BPH, a common feature that
mimics cancer on many modalities.

1.1.4.1.1 T2W MRI
T2W MRI is one of the basic MRI pulse sequences. It is sensitive to the
transverse relaxation of precessing protons, which is different, for example, between
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dense cellular tissue and fluid-filled cystic spaces. T2W MRI clearly depicts prostate
zonal anatomy, due to its high spatial and contrast resolution [68]. In the peripheral zone,
dense tumors appear hypointense on T2W MRI relative to the typically bright peripheral
zone signal, although sparse tumors may not show such contrast [69]. In the central
gland, homogenous low-intensity, ill-defined irregular boundaries, lenticular shape and
invasion of the anterior fibromuscular stroma have been used to identify tumors [70].
T2W MRI has been reported to correlate with Gleason score, potentially offering
prognostic information [71], although there was overlap in signals between grades, and
this finding has not been widely replicated. T2W MRI interpretation is limited by the
similar MR appearance of non-cancerous abnormalities, including chronic prostatitis,
atrophy, scars, BPH, and post-biopsy hemorrhage [72].
1.1.4.1.2 DW MRI
DW MRI is sensitive to diffusion of water molecules which decreases with the
increased cellular density associated with cancer [73]. Interpretation of DW MRI for
prostate cancer uses both DW MR images and post-processed apparent diffusion
coefficient (ADC) maps. Prostate cancer appears hyperintense on DW MR images taken
with high b-values (a parameter controlling sensitivity to diffusion [74]). Prostate cancer
appears hypointense on ADC maps computed from multiple DW MR images taken with
different b-values [56]. DW MRI has superior sensitivity for central gland tumors
compared to other MRI sequences [65, 73]. ADC values in peripheral zone tumors have
been shown to be correlated with Gleason score, potentially providing prognostic
information [75-78], although there is overlap in ADC values between Gleason scores.
Interpretation of DW MRI is challenged by the low resolution (1×1 mm2 to 2×2 mm2 in-
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plane resolution with 4–5 mm spacing) of typical acquisitions [56, 73], and frequently
suffers from distortion artifacts [74, 79].
1.1.4.1.3 DCE MRI
DCE MRI is sensitive to changes in vascular characteristics associated with
angiogenesis due to cancer [80, 81]. DCE MRI comprises a rapid temporal sequence of
T1-weighted MR images (at 1–90 s intervals) immediately prior to and for 5–10 minutes
after injection of a gadolinium-chelate contrast agent. The contrast agent washes in and
out more quickly in cancerous tissue than in non-cancerous tissue. Faster sequences,
combined with estimates of the arterial input function, allow for precise modeling of
pharmacokinetic parameters [80, 81], some of which (e.g. the contrast transfer coefficient
[ktrans] and the rate constant [kep]) have been correlated with the presence of cancer [82].
DCE MRI interpretation is challenged by patient motion and by the presence of noncancerous abnormalities that mimic cancer, including prostatitis in the peripheral zone,
and highly vascularized BPH in the central gland [81]. Pharmacokinetic modeling is
further challenged by the need to estimate the arterial input function [81].
1.1.4.1.4 MR spectroscopy
MR spectroscopy (MRS) measures the spatial distribution of the relative
concentrations of metabolites within the prostate that can be distinguished by their proton
resonance frequencies, including choline, creatine, and citrate [83]. Cancerous tissue
typically has elevated choline and decreased citrate compared to non-cancerous tissue. As
the signals of choline and creatine are difficult to separate from each other [80], the
(choline +creatine)/citrate ratio is frequently reported. MRS shows different metabolic
ratios for tumor vs. normal tissue in the transition zone; however, signal strength and
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interpretation remain challenging [84]. (Choline+creatine)/citrate ratios have been shown
to be correlated with Gleason score [85], potentially providing prognostic information,
and a retrospective study reported areas under the receiver operator characteristic curve
from 0.70 to 0.78 for distinguishing low-grade from high-grade tumors using different
measures based on MRS [86]. Interpretation of MRS is challenged by contamination of
the signal from nearby lipids, high sensitivity to shimming, operator variability, and the
presence of non-cancerous abnormalities, such as inflammation and BPH, that mimic
cancer [80, 82-84].
1.1.4.1.5 Emerging MRI techniques
Although MRI is showing promise for imaging prostate cancer, there remain
substantial areas for improvement, particularly in detection of central gland tumors [55],
and distinguishing cancer from confounders [72]. New imaging protocols such as
endogenous sodium imaging [87, 88] and hyperpolarized carbon imaging [89, 90] are
under development, and simultaneous hybrid imaging scanners incorporating positron
emission tomography are becoming available. Additionally, new derived images
computed from existing sequences are being evaluated, such as extrapolated high b-value
DW images [91], diffusion compartment-model imaging [92] and alternative DCE
parametric maps [93].
1.1.4.2 Transrectal ultrasound
B-mode transrectal ultrasound (TRUS) imaging is commonly used to estimate
prostate volume, and for image guidance during biopsy and needle-based-therapy
procedures, as it enables rapid (10–20 frames per second) visualization of the prostate
gland and the boundary between prostate zones. Prostate cancer in the peripheral zone,
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where the majority of lesions are located, can appear hypoechoic (darker); however, the
sensitivity for detecting prostate cancer on TRUS is low (59%–88%) [94-97]. Several
ultrasound techniques are being investigated for prostate cancer imaging, including color
and power Doppler imaging and micro-bubble-contrast-enhanced imaging [96].
1.1.4.3 X-ray computed tomography
X-ray computed tomography (CT) imaging is commonly used in the assessment
of metastases and in planning for whole-gland radiotherapy. CT is sensitive to differences
in attenuation due to electron density, yielding good tissue-to-bone contrast, which
supports detection of bone metastases [97]. CT is also used to detect lymph node
metastases based on lymph node size and shape; round lymph nodes 8–10 mm in size or
oval lymph nodes >10 mm in size had high specificity for metastasis [64]. Although CT
is not used for detection of intraprostatic tumors due to poor soft tissue contrast [97], it is
routinely used for planning whole-gland radiotherapy [4]. CT allows visualization of
pelvic anatomy including nearby sensitive structures (e.g. the rectum and the bladder) and
supports delineation of the prostate. Because CT and radiotherapy both involve the
attenuation of electromagnetic radiation, measurements of electron density from CT can
also be used in the planning of radiation therapy. Furthermore, in some external beam
therapies, x-ray images can be acquired within the treatment system, supporting pre- or
intraprocedural patient registration.
1.1.4.4 Nuclear imaging
Nuclear imaging is commonly used in the assessment of metastases, and can also
be used to detect intraprostatic cancer. Nuclear imaging measures radiation from
radioactive atoms incorporated into radiotracers that preferentially accumulate at sites of
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interest, such as metastatic bone tumors or intraprostatic tumors. For detecting
metastases, a common form of nuclear imaging involves radiolabeled diphosphonate,
which accumulates in regions of bone damage, including metastases. These bone scans
have high sensitivity (95%) for osteoblastic metastases in patients with PSA levels above
20 ng/mL [97]. In prostate cancer, 111In capromab pendetide (marketed as ProstaScint) is
a radiolabeled antibody that binds to the prostate specific membrane antigen (PSMA),
which is preferentially expressed on prostate cells, including metastatic cells that
originated from the prostate. For intraprostatic cancer detection, a number of radiotracers
have been proposed. 18F-fluorodeoxyglucose, the most commonly used positron
emission tomography (PET) tracer in other anatomical sites, is challenged by low
metabolic glucose activity in prostate tumors and the masking effect of tracer
accumulation in the bladder [98]. Several choline-based radiotracers, including 11Ccholine and 18F-fluorocholine, show higher uptake in some primary and metastatic
prostate cancers than in healthy tissue [99] and have less accumulation in the
bladder [100]. Preliminary evidence suggests choline-based tracers may support detection
of central gland tumors [101] and differentiation of tumor from confounders such as BPH
and prostatitis [99].
1.1.4.5 Justification for evaluating mpMRI for intraprostatic lesion delineation
Many imaging modalities are used in the prostate cancer clinical workflow;
however, not all of these are suitable for delineation of intraprostatic lesions. TRUS and
CT do not have the spatial and contrast resolution to support delineation of intraprostatic
tumors. Nuclear imaging has been used for delineation of intraprostatic tumors [102,
103]; however, the low spatial resolution (e.g. 5 mm [104]) of clinical PET may
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challenge accurate delineation of cancer boundaries. mpMRI has good soft tissue contrast
showing anatomical detail, has high spatial resolution (0.5–2.0 mm in-plane [56]) and has
shown promise for visualization of prostate cancer in detection, staging and coarse
localization of intraprostatic cancer. Therefore, this thesis focuses on the evaluation of
mpMRI for prostate cancer imaging and lesion delineation.

1.1.5 Histological reference standards
Evaluations of prostate cancer imaging and lesion delineation ideally include
comparisons to a registered accepted reference standard. Typically, the most readily
accepted reference standard for the presence, location and grade of prostate tumors is
histological examination of prostate tissue (i.e., a pathologist's microscopic examination
of tissue properties on ~4-µm-thick sections of tissue).
1.1.5.1 Clinical importance of histology in prostate cancer
In prostate cancer, histological examination is used at several points in the clinical
workflow. Histological examination of biopsy tissue provides the first definitive
diagnosis of prostate cancer, and is used as a follow-up to initial detection in screening
populations, for ongoing monitoring in active surveillance, and to confirm recurrence in
some post-treatment populations. Histological examination of resected prostate
specimens is used to assess prognosis for patients post-prostatectomy [14], and to guide
decisions about adjuvant therapy [4]. The importance of histology in the prostate cancer
clinical workflow is due, in part, to the high prognostic value of the Gleason grading
system. Initially developed in 1966 and updated in 2005, the Gleason grading system
categorizes tissue based on its microscopic morphological appearance including
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glandular differentiation and growth patterns within the stroma (Figure 1.1). It was
initially evaluated in nearly 5000 men in randomized clinical trials, and shown to
correlate well with survival. Since its initial development, the system has undergone
multiple revisions [13], and has been adopted into international clinical guidelines [105].
1.1.5.2 Biopsy vs. prostatectomy histology as a reference standard
For the validation of prostate cancer imaging, histological examination of biopsy
or prostatectomy specimens has been used as a reference standard. Histology from
prostatectomy specimens is the most powerful predictor of progression after
prostatectomy [14], and is frequently used as the reference standard for the
aggressiveness and location of prostate cancer [65, 71, 82, 84, 85, 106-109]. However,
the use of prostatectomy specimens also limits the study population to patients
undergoing prostatectomy, limiting the generalization of imaging findings to low-risk
active surveillance and focal therapy cohorts. Histology from targeted- or templatemapping-biopsy samples, on the other hand, could be collected for such cohorts.
However, biopsies are small sparse samples of tissue (~1 mm in diameter). These are
commonly used for determining the presence or absence of cancer at a targeted location,
but precisely determining the histological boundary of cancer from such samples would
be challenging unless the sampling was impractically dense. Spatial error in biopsy
targeting (3.5 mm for one MR–TRUS-fusion biopsy system as estimated by a recent
analysis [20]) and the poorer reliability for assessing grade (40% rate of over- and
underestimating Gleason grade with respect to prostatectomy specimens [17, 18]) would
introduce further uncertainty into the analysis. For the some evaluations of lesion
delineation, where the accurate spatial registration is critical to precisely evaluate the
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accuracy of lesion boundaries, prostatectomy specimen histology is the more appropriate
reference standard, although care must be taken in generalizing findings.

1.2 Problem domain
1.2.1 Key gaps in knowledge
The previous section identified applications in diagnosis, patient monitoring and
therapy delivery where prostate cancer imaging and lesion delineation may have a role in
the clinical workflow, and identified mpMRI as a suitable modality for this delineation
and whole-mount histology as a suitable reference standard for evaluating the accuracy of
delineation. Histology-based evaluation of the spatial accuracy of prostate cancer
delineations requires that information about the histological tumor boundaries be
registered into the spatial coordinates of the mpMR images being delineated. The
following sections describe two key gaps in knowledge: (1) the lack of techniques for
histology-imaging registration that are sufficiently accurate, robust and non-disruptive to
the clinical pathology workflow; and consequently (2) the lack of knowledge about the
accuracy and variability in lesion delineation on mpMRI which could lead to appropriate
clinical guidelines.

1.2.2 Research challenges
To address these gaps in knowledge, this thesis focuses on (1) the development
and evaluation of accurate, robust and non-disruptive techniques for registering a
histological reference standard to mpMR images; and (2) applying these techniques for
the evaluation of accuracy and variability of lesion contouring on mpMRI. This section
describes key research challenges in addressing these goals.
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1.2.2.1 Evaluation of lesion contouring
The accuracy and variability of lesion delineation on mpMRI can be measured
along many dimensions. Ideally, lesion contouring could be evaluated with respect to
patient outcome; however, this would require long follow-up, and may preclude paired
analyses evaluating the delineations of multiple observers on one image. As a surrogate,
one can evaluate spatial boundary-error measurements between the lesions on mpMRI of
different observers (to assess interobserver variability), and between the lesions on
mpMRI and the underlying tumor on the histological reference standard (to assess
accuracy). Unlike the evaluation of staging and grading from mpMRI, where only a gross
correspondence between the same tumor on in vivo imaging and on the reference
standard must be established, the evaluation of spatial boundary errors requires densely
defined information about the spatial relationship between the histology and mpMR
images. This evaluation is further complicated by uncertainty in the boundary error
measurements due to spatial errors in the registration of the histological reference
standard to the mpMR images.
The complexity of information contained in a lesion delineation raises additional
challenges. Different types of boundary errors may have different implications for
different applications. A single type of boundary error measurement may not capture all
of the clinically important information about the error. For example, low volumetric
overlap may indicate poor overall accuracy of a contour, high boundary distance errors
may indicate spicules of cancer or healthy tissue not captured by a contour, and volume
differences may indicate a systematic over- or under-contouring of a focus. Thus, the
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evaluation of lesion contouring requires the use of multiple metrics to yield a thorough
assessment.
1.2.2.2 Evaluation of registration accuracy
The accuracy of the registration of the reference standard to the mpMR images is
critical to the evaluation of lesion contouring accuracy, because registration error induces
uncertainty in the boundary error measurements. There can be compromises associated
with achieving higher accuracy [110], including greater human interaction to guide
registration algorithms to correct solutions, higher required image quality, and higher
computational cost. When performing research on clinical specimens, this is particularly
important as there may be compromises between disruption to the clinical pathology
workflow and registration accuracy. Thus, it is important to identify the maximum
acceptable level of registration error; however, the criteria for sufficiently accurate
registration vary depending on the application [111]. The key determinant of the
necessary target registration error (TRE) is the central question of the research that
depends on the registrations. For example, a registration used to identify large cancer foci
as homologous on histology and mpMRI would have less stringent registration
requirements than one used to measure differences in the boundaries of mpMRI lesions
and histological foci. Establishing application-specific thresholds for maximum
acceptable error has been identified as a key challenge in registration [110, 111].
1.2.2.3 Registration of histology to mpMRI
The registration of diagnostic prostate histology with mpMR images faces
challenges due to three factors: (1) the disruptive process of acquiring histology tissue
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from prostatectomy specimens, (2) the constraints on handling of clinical specimens, and
(3) the properties of the resulting images.
The cutting of histology from prostatectomy specimens is a complex and
disruptive process. Prostate specimens are formalin-fixed (inducing shrinkage), and are
cut into 3–5-mm-thick tissue slices (resulting in the loss of the spatial relationship
between slices). Any water in the slices is chemically replaced with paraffin (inducing
deformation) and a single 4-µm-thick histology section is cut from each paraffin block
(resulting in further deformation and loss of 3D spatial information). Due to requirements
for the archival preservation of diagnostic tissue, sections are only cut from near the faces
of the tissue slices (resulting in a sparse sampling of tissue and loss of information about
the 3D context of the tissue). The operator variability in the cutting of whole
prostatectomy slices on a microtome introduces variability into the spatial relationships.
Reconstructing the spatial relationships between histology sections is complicated
by constraints on the allowable treatment of clinical tissue. For example, the acceptable
imaging modalities and the duration of imaging may be constrained to avoid disrupting
the physical appearance of tissue and its chemical reactivity. The types of fiducial
markers that can be used may be limited by clinical needs for patient treatment (e.g.
precluding the use of fiducials in vivo), preservation of diagnostic tissue and avoidance of
disruptions to clinical pathology workflows and diagnoses. Additionally, these
constraints may vary from institution to institution, potentially limiting the reuse of
existing methods.
Finally, several properties of the resulting images may introduce challenges for
registration. The histology sections are sufficiently thin to be considered 2D, but the
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histology images must be registered to a 3D image of a prostate specimen. Without the
3D context of the histological tissue, determining out-of-plane correspondences is
challenging. Due to the non-linear deformation between the images, the section of the 3D
image representing the tissue from which histology was cut may not even be planar, so
that an operator may not be able to see the corresponding tissue from both images until a
deformable registration is nearly complete; this complicates even the interactive
registration of these images. Finally, the types of information contained in the two images
are substantially different, as histology images denote the chemical affinity of tissue to
chemical dyes, and MR images reflect properties of hydrogen atoms.
The combination of loss of 3D context from histology images, flexible
deformation, variability in the histology acquisition processes, complex relationships
relating image information, and constraints on the tools that can be used to mitigate these
challenges makes the accurate registration of histology to mpMR images challenging.
There are four criteria that I have used to evaluate approaches for registering a
histological reference standard to mpMRI:


Minimally disruptive: The ideal method would work on either quartered or
whole-mount histology collected according to usual clinical pathology protocols,
in order to enable retrospective studies leveraging the large volume of existing
mpMRI and histology data. Failing that, the method must not be disruptive to the
pathological diagnosis: it should not result in changes to the collected histology
that affect clinical diagnosis; it should not require the specimen to be out of
formalin for an excessive amount of time; and it should not result in cutting tissue
that is normally preserved for future diagnosis. Ideally, it would also be minimally
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disruptive to the clinical pathology workflow. As workflows vary between
centers, this is challenging to assess. Factors that could be considered include:
minimizing delays that would impact the timeliness of the pathology report,
avoiding alteration of standard cutting protocols, minimizing additional work for
pathology assistants and pathologists, minimizing alteration of the specimen, and
avoiding additional imaging (particularly imaging that cannot be performed in a
pathology department).


Spatially accurate: The 3D target registration error [112] should be evaluated
using homologous point features (intrinsic landmarks or extrinsic fiducials)
distributed throughout the gland on a substantial number of subjects. This error
should be sufficiently low for the desired application; however, the maximum
acceptable error has not yet been established for evaluation of prostate cancer
imaging and delineation.



Robust: The variability in performance and the failure rate of the method should
be published. The method should be robust to intersubject variation in prostate
anatomy and imaging appearance, and to the presence or absence of disease.



Widely implementable: The method should minimize the need for specialized
equipment or special expertise that may not be widely available. Software
algorithms should be made available, or be easily re-implemented.
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1.2.3 Previous work addressing these challenges
1.2.3.1 Evaluation of GTV contouring
Previous evaluations of mpMRI have yielded quantifications of the sensitivity and
specificity of staging and grading from different combinations of mpMR images,
validated against histological information. Often this information is in the form of graded
biopsies [76] that are corresponded with clinical imaging based on the origin of the
biopsy. However, biopsies do not have the necessary information about the boundaries of
foci to assess the accuracy of contouring. Evaluations of stage and grade that do compare
against histological examination of prostatectomy specimens typically use a coarse
partitioning of prostate anatomy [113, 114], or consensus between pathologists and
radiologists [75] to establish correspondences between tumor foci on histology and
mpMR images. These approaches may identify corresponding foci, but do not yield the
spatial relationships between the histology and mpMR images required for evaluating
contouring accuracy. Evaluations of the variability of contouring of the entire prostate
and nearby organs at risk from imaging have been performed [115, 116]; however, these
do not generally evaluate accuracy with respect to a histological reference standard and
do not include measurements of cancer foci that would support focal therapy.
Two studies have recently been performed to evaluate the accuracy and variability
of lesion contouring for conformal focal therapy on mpMRI [106, 117]. Rischke et al.
evaluated target volumes defined on mpMRI by 5 radiation oncologists with access to the
MRI report, measuring the accuracy and variability as a Dice overlap coefficient with
respect to a radiologist's delineations. These measurements, while potentially important
in the context of therapy, may not be representative of variability of observers not
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informed by a common previous report, and rely on a reference standard with unknown
accuracy and variability. Anwar et al. evaluated the histological coverage of target
volumes defined by 2D margin expansion around lesions identified on mpMRI and
delineated on a single 2D slice of T2W MRI. The histology-MRI registration error was
reported as 2 mm in-plane, measured using the landmarks used to define the registration
(i.e. a fiducial registration error, which typically is lower than the target registration
error), and out of plane error was not estimated. Histological coverage was measured by
breaking the histological focus and MR lesion boundaries of each focus into segments
covering equal angles (from a central point that is not specified) and measuring the mean
differences in distances to the central point. These measurements were aggregated across
all subjects and observers, precluding evaluation of interobserver and intersubject
variability. Margins of 5 mm and 8 mm were identified as covering 95% and 100% of the
measurements.
To the best of my knowledge, there have been no studies to date evaluating the
accuracy and variability (blinded to previous reporting on the images) of lesion contours
in 3D against an accurately registered histological reference standard.
1.2.3.2 Evaluation of registration accuracy
In some applications of registration, maximum acceptable registration accuracies
have been identified. For example, in image-guided interventions where registration can
be used to guide the tools used in the intervention, criteria have been proposed for
specific interventions and imaging modalities based on clinical opinion [118] or models
of what constitutes a successful intervention [119]. In registrations used to support
imaging evaluation studies, some criteria have been proposed for sufficient registration
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accuracy [120]; however, these criteria have not been tied to the outcomes of the studies
supported by the registrations. Instead of defining criteria for registration accuracy, some
approaches instead mitigate the effect of registration error on the study outcome.
Examples include constraining the sizes of regions analyzed [121, 122], and qualifying
study conclusions to acknowledge error as a confounder [123]. To the best of my
knowledge, evaluation criteria have not been identified for the registration of prostate
histology to mpMR images for evaluation of lesion contouring, and furthermore,
accepted approaches for defining such criteria have not been identified.
1.2.3.3 Registration of histology to mpMRI
Techniques used in the registration of clinical histology to in vivo images
typically fall into two major categories: (1) techniques that alter the processes involved in
cutting histology sections from specimens to mitigate deformation, avoid loss of spatial
information or reduce variability; and (2) techniques that use assumptions about these
processes and information (e.g. images or measurements) collected before, during or after
the histology processing to virtually undo the deformation, reconstruct lost spatial
information or account for variability. Many reconstruction methods use a combination of
techniques from these two categories.
One common approach to the registration of whole-mount prostate histology to in
vivo images is to guide the cutting of prostatectomy specimens into 3–5-mm-thick tissue
slices [107, 120, 124], typically using image-guidance and specialized cutting equipment.
Shah et al. [124] used a 3D printer to construct a patient-specific plastic mold based on
the in vivo MRI, with slots to guide a custom multi-bladed knife along the in vivo
imaging plane. Jhavar et al. [125, 126] acquired images with imaging planes
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perpendicular to the posterior wall, and then cut the prostate perpendicular to the
posterior wall without image guidance using special cradles and multi-bladed knives to
obtain parallel slices for processing. Rouvière et al. [127] used injected fiducials (for ex
vivo or animal studies) to define an imaging plane, used a rotating platform within the
MR scanner to align these fiducials horizontally, and then embedded the specimen in wax
to enable slicing parallel to the imaging plane. These methods register histology to in vivo
images by assuming histology sections correspond to the specified slicing plane without
error, and align histology within this plane using a deformable 2D registration.
Kalavagunta et al. [125] used guided slicing (similar to Jhavar et al. [125, 126]) to
constrain orientation, but instead of assuming histology corresponded to a specified slice,
an expert observer manually identified the corresponding slice in MRI. These methods
constrain the position and orientation from which the histology is collected according to
an in vivo imaging plane, which may be disruptive to the clinical pathology workflow
when a pathologist prefers a specific orientation for diagnostic reasons. For example, the
clinical pathology protocol at London Health Sciences Centre involves removing ~1 cm
of the prostatic apex including the urethral sphincter for parasagittal sectioning to
minimize the extent of surgical margin that is not visible on histology. For a specimen
where the apex extends posterior and sufficiently inferior to the urethral sphincter (see
Figure 1.3 or Walz et al. [128] Figure 11 for illustrations of such anatomy), a 1-cm apex
cut perpendicular to the posterior wall may not include the sphincter. In such a case, a
pathologist may prefer that the apex be removed with a 1-cm cut that is oblique to the
posterior wall rather than a cut >1 cm (see Figure 1.3A) in order to minimize the amount
of surgical margin that is not seen and assessed by the pathologist (see Figure 1.3B–C).
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Additionally, these methods do not account for, or measure, out-of-plane error due to
errors in the guidance of slicing, variability in the histology sectioning depth within the
tissue slice, or error in the selection of the correct MR slice. Such underestimates of the
target registration error impede the assessment of whether the registrations are
sufficiently accurate for evaluating lesion contouring.
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Figure 1.3: Illustrative diagram showing positions of cuts for gross slicing a specimen
where constrained slicing may be disruptive to the clinical pathology workflow. (A) Side
view of prostate. 1-cm apex cut (for parasagittal histology) constrained to be
perpendicular to the posterior wall (red dotted line, red arrows show 1 cm) would not
include the urethral sphincter, but a 1-cm oblique apex cut (green solid line, green arrows
show 1 cm) would. To include the sphincter with a constrained cut, more tissue would
have to be included in the apex histology (blue dashed line). (B) Anterior view of apex
after cut along blue dashed line in (A). Pathologist makes diagnosis from histology taken
from blue lines. Red arrow denotes the extent of margin that will not be assessed for
extraprostatic extension and positive surgical margin. (C) Anterior view of apex after cut
along green solid line in (A). Pathologist makes diagnosis from histology taken from
green lines. Red arrow denotes the smaller extent of margin that will not be assessed for
extraprostatic extension and positive surgical margin.
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A second approach to the registration of whole-mount prostate histology to in vivo
images uses extrinsic fiducials and/or additional imaging of the 3–5 mm tissue slices to
reconstruct the spatial relationships between histology sections after they have been cut
according to the clinical pathology workflow. Extrinsic fiducials have been used to orient
histology images in 2D [129, 130], under the assumption that histology sections are
sectioned to be parallel at constant spacing. Bart et al. [130] temporarily pierced the
prostate with approximately parallel 1 mm needles running from apex to base, cut the
gland axially into 3-mm-thick tissue slices with parallel cuts using a meat slicer, and
interactively reconstructed histology based on the strong assumption that the needles did
not deflect (their report notes that the needles did, in fact, deflect). Hughes et al. [129]
adapted this method to use 3 oblique fiducial needles and collected step-sectioned parallel
histology at 1-mm intervals (4.5 times more densely spaced than many clinical pathology
protocols). Hughes used an automated fiducial finding algorithm, and an iterative
minimization of fiducial registration error under assumptions of non-deflecting needles to
align histology in plane. Alternatively, additional imaging has been used to orient
histology images and account for some in-plane deformation [109, 126, 131-133]. Orczyk
et al. [133] acquired photos of the tissue slices and used the posterior wall as a landmark
to manually align adjacent sections into a 3D structure, blinded to 3D imaging. Jackson et
al. [126] used anatomical landmarks in photos of the tissue slices to compensate for
deformation during histological processing. Xu et al. [132] acquired high-resolution ex
vivo MR images of the tissue slices for this purpose. Taylor et al. [131] and Groenendaal
et al. [109] combined the parallel-needle-fiducial approach with acquiring photographs of
the tissue slices to compensate for deformation during histology processing and to align
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adjacent slices. Nearly all of these methods controlled the cutting of the tissue slices to be
evenly spaced, with the exception of Taylor et al. [131], who measured the thicknesses of
the tissue slices after cutting. As with the guided-slicing methods, these methods assumed
that histology sections corresponded to the front faces of the tissue slices from which they
were cut and did not account for variability in the depth of the histology sectioning within
the tissue slice.
A third approach uses image content to retrospectively register histology to in
vivo or ex vivo MR images. The registration of histology directly to in vivo images [134138] holds the potential for minimal disruption to the clinical workflow; however, it
relies on the presence of image information that may be disrupted by anatomic
variability, disease processes or changes in imaging protocols.
Some methods required an expert to select a 2D MRI slice that corresponds to
histology. Chappelow et al. [136] used mutual information between extracted texture
features to register pseudo-whole-mount (PWM) histology (reconstructed from quartered
histology) to the selected T2W MRI slice in 2D. They reported an intersection/union area
ratio in the selected plane of 0.93 for 6 subjects. Kalavagunta et al. additionally required
experts to contour the prostate and internal anatomy (e.g. BPH) on the PWM histology
and the selected MR image slice. They used a variational minimization of overlap of
these segmented regions to align histology to the selected MR image in-plane. They
reported an in-plane TRE of 1.5 mm based on 103 intrinsic landmarks for 35 PWM
histology sections. As Kalavagunta noted, the assumption that the expert's slice selection
corresponds to the same cross-section of tissue is of "the utmost importance"; however,
neither of these methods assess the validity of this assumption.
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Other methods registered histology directly to the 3D MR image, with the
potential to account for variability in the histology cutting depth or out-of-plane error in
their initializations by identifying the section of the 3D image that corresponds to the
histology that was actually cut. Unfortunately, these methods have not been evaluated
using data sets and metrics that enable assessment of the robustness of the method or the
expected spatial alignment of the histological reference standard. Chappelow et al. [138]
leveraged the different sequences in mpMRI by first co-registering in vivo images, and
then registering PWM histology to the mpMRI ensemble. Only the post-minimization
value of the registration similarity metric was reported (for 25 subjects), which cannot be
used to infer the accuracy of the registrations [112]. Patel et al. [134] used a mutualinformation-based image registration, modified to weight voxels within the prostate more
heavily, to deformably align histology to in vivo mpMRI. A mean Dice overlap of 0.83
and a mean absolute boundary distance of 0.99 mm from 2 patients were reported. Nir et
al. [135] proposed a registration with particle-filtering-based optimization using an
overlap metric between manual segmentations of MRI and parallel evenly-spaced
histology images (that are not initially aligned in plane). They reported an in-plane mean
TRE of 2.1±1.3 mm based on the alignment of visually corresponding landmarks (N is
not reported) from 2 subjects. Prabu et al. [137] trained a statistical deformation model to
regularize a free-form deformation-based registration. They reported an RMS TRE of 0.8
mm based on alignment of "key structures" from 2 patients. The small sample sizes in
these analyses make it difficult to assess the robustness of these methods.
The use of ex vivo imaging as an intermediate registration target [139-142] allows
more control over imaging, enabling the acquisition of higher resolution images that may
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have more information in common with histology images. These methods address many
of the challenges of 3D histology reconstruction, leaving as the remaining step a singlemodality 3D ex vivo to 3D in vivo prostate MR image registration. However, these
methods still rely on the presence of image information that may be disrupted.
Chappelow et al. [141] used mutual information between extracted texture features to
register PWM histology to ex vivo MRI. They evaluated their registrations based on how
well they separated the MRI intensities of cancerous and non-cancerous regions mapped
from histology on data from 2 subjects. Zhan et al. [139] coarsely aligned and stacked 1.5
mm step-sectioned histology images (3 times more densely spaced than many clinical
pathology protocols), and then automatically extracted 3D landmarks on both 4 T ex vivo
MRI and reconstructed histology images. They corresponded landmarks (using shape
feature vectors on the boundary and intensity features within the gland) by alternately
updating correspondences to maximizing feature similarity and updating the
approximating thin-plate-spline transformation. They reported a 0.88 mm TRE measured
using anatomical landmarks (N is not reported) from 5 subjects. This may be a suitable
approach if high-field ex vivo imaging and 1.5 mm step-sectioned histology is available;
however, the small sample size and lack of detail regarding the evaluation makes this
assessment challenging, and the use of 1.5 mm step-sectioned histology may prevent its
use in clinical specimens at many centers. In a follow up to this work, Ou et al. [140]
noted that the intensity features used in this approach were disrupted by the presence of
cancer. To address this, Ou incorporated a subsequent registration that alternately
segmented cancerous tissue and refined the registration to maximize overlap of the
segmented regions; however, this introduces a bias toward aligning homogenous image
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features in the registrations that may render the registrations unsuitable for evaluating
prostate cancer imaging and lesion delineation. Nir et al. [142] addressed the ex vivo to in
vivo registration using a biomechanical model that incorporated elasticity measurements
from in vivo magnetic resonance elastography (MRE), yielding a 3.1±1.4 mean TRE (or
3.7±1.9 mm for a homogeneous elasticity model) based on the alignment of intrinsic
landmarks (N is not reported) averaged over 6 patients. This may be a suitable approach
for evaluating studies that already include MRE; however, the addition of vibrationinducing equipment and MRE acquisitions into in vivo protocols for registration purposes
may be a barrier to its wider use.
None of the existing methods have been shown to meet all the previously
described criteria for methods for registering a histological reference standard to imaging
(non-disruptive, spatially accurate, robust, and widely implementable). There is a need
for the development of more widely implementable, less disruptive methods with
appropriate evaluation of accuracy and robustness. Consequently, there is a deficit in the
evaluation of prostate cancer imaging [143] and in the evaluation of lesion delineation,
which requires accurate registration.

1.3 Thesis research questions and objectives
To address the gaps in knowledge regarding the suitability of mpMRI for prostate
cancer lesion delineation and the appropriate technology to evaluate prostate cancer
imaging and lesion delineation, this thesis aims to address four research questions posed
in this section through the completion of 7 research objectives. In doing so, this thesis
will take steps towards addressing the 4 criteria for histology-imaging fusion methods
described in Section 1.2.2.3 (non-disruptive, spatially accurate, robust, and widely
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implementable) by presenting an approach to 3D histology reconstruction that (1) allows
flexibility in the specimen slicing (to avoid disruption to the pathology diagnosis); (2)
uses extrinsic fiducials that do not interfere with the clinical interpretation of histology
(to avoid disruption to the pathology diagnosis) and are not dependent on intrinsic
contrast (to improve robustness); (3) has a spatial reconstruction error of 0.7 mm and
little sensitivity to initialization, which is evaluated using a 3D TRE computed from 232
homologous point landmarks in 37 whole-mount histology images from 10 patients (to
appropriately quantify accuracy and robustness). Our approach has been successfully
implemented at University Health Network, Toronto, demonstrating its potential
portability for more widespread use.

1.3.1 Research questions


How does registration error impact the statistical power of imaging validation
studies? This will be answered via the completion of Objective 1 below.



What is the performance (in terms of reconstruction error and robustness) of an
extrinsic-fiducial-based histology reconstruction method, and how does this
compare to alternative approaches based on image-guided slicing and intensitybased image registration? This will be answered via the completion of Objectives
2a and 2b below.



What is the variability of lesion scoring (using consensus-panel-recommended PIRADS guidelines [56]) and contouring on mpMRI? This will be answered via the
achievement of Objectives 2c, 3a and 3b below.
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What are appropriate margins around observers’ target volumes to achieve
histological coverage of detected cancers? This will be answered via the
achievement of Objectives 2c, 3a and 3c below.

1.3.2 Specific research objectives
1 – Impact of registration error on imaging validation studies: to establish
criteria for determining the necessary accuracy of histological-reference-standard
registrations for the assessment of prostate cancer imaging.
2a – 3D histology reconstruction: to develop methods for the 3D reconstruction
of prostate histology based on strand-shaped fiducials, as well as alternative approaches
based on image-guided slicing and intensity-based image registration.
2b – 3D histology reconstruction evaluation: to quantify the reconstruction
error and robustness (variability of error, and sensitivity to initialization) of the developed
methods in Objective 2a.
2c – Histology to in vivo MR image registration: to develop methods for
registration of reconstructed 3D histology images to in vivo 3D mpMRI and quantify the
registration accuracy.
3a – mpMRI observer study: to coordinate a multi-observer study of prostate
cancer lesion scoring and delineation on mpMRI.
3b – Variability of lesion scoring and delineation: to quantify the interobserver
and intersequence variability of lesion scoring and delineation, and factors that correlate
with them, such as Gleason grade, anatomical location and lesion volume.
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3c – Margin evaluation: to determine expansion margins around mpMRIdefined gross target volumes that would, with high likelihood, result in adequate
coverage of histological cancer.

1.4 Thesis Outline
1.4.1 Chapter 2: The impact of registration accuracy on imaging validation
study design: a novel statistical power calculation
The purpose of this work was to develop an approach for evaluating registration
accuracy via its impact on statistical power for imaging evaluation studies that use
registered reference standards (e.g. histology images). This work focused on studies to
detect differences in mean image signal between normal and abnormal regions. By
expressing registration error in terms of the overlap of the registered sampling regions
(from reference standard images) with the true regions on the study images, the
population mean and variance of sampled intensities could be expressed in terms of
registration error and incorporated into the classical power calculation formula. This
yielded a novel power calculation formula that can be arranged to answer three key
questions affecting study design: (1) What is the maximum acceptable registration error?
(2) How many subjects are needed? (3) What is the minimum detectable difference? A
case study to illustrate the application of this approach was included for discussion.

1.4.2 Chapter 3: 3D prostate histology image reconstruction: quantifying the
impact of tissue deformation and histology section location
The purpose of this work was to assess the impact of the histology cutting process
on the accuracy of methods for reconstructing whole-mount histopathology images into a
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3D spatial context. This work used pairs of intrinsic homologous landmarks identified on
histology images and MR images of formalin-fixed prostate tissue slices before
histological processing to identify the position and orientation from which the histology
was originally cut. This work showed that a rigid+isotropic scale transformation
accounted for the majority of in-plane deformation during histological processing, and
that histology was cut from a mean depth of 1.1 mm and a mean angle of 1.5º. We
showed that making the assumption, common in the literature, that histology is cut from
the surface of tissue slices resulted in 0.7 mm additional error under an isotropic scaling
deformation model. Although this error appears to be small, incorporating this error into
the power calculations described in Chapter 2 illustrated that assumptions about the
deformation model and position of histology section could have a substantial, and
potentially costly, impact on the required sample sizes for imaging validation studies
using a registered histological reference standard.

1.4.3 Chapter 4: Registration of prostate histology images to ex vivo MR
images via strand-shaped fiducials
The purpose of this work was to present and evaluate a method for reconstructing
whole-mount histology images into the 3D context of an ex vivo MRI. The method used
previously developed histology- and MRI-visible strand-shaped fiducials to construct a
form of stereotactic frame wrapped around and within the prostate, and minimized the
fiducial registration error between cross-section of the fiducials visible on histology and
the parametric curves of fiducials visible on MRI. The target registration error was
quantified to be 0.7 mm using 3–7 pairs of intrinsic landmarks on each of 34 histology
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images. This compared favorably to alternative algorithms based on image-guided slicing
1.2 mm) and additional imaging of tissue slices (0.9 mm).

1.4.4 Chapter 5: 3D prostate histology reconstruction: an evaluation of
image-based and fiducial-based algorithms
The purpose of this work was to compare the accuracy and robustness of the
fiducial-based reconstruction method to an alternative method based on an established
multimodality image-intensity-based registration method (mutual information). The two
methods were initialized using known perturbations from the optimal reconstruction (to
assess robustness to initialization) and using practically achievable initializations. The
image-intensity-based registration approach showed considerable sensitivity to
initialization, whereas the fiducial-based approach had almost zero sensitivity to
initialization. The resulting target registration errors for the practical initializations were
quantified to be 0.7 mm for the fiducial-based approach and 1.2 mm for the imageregistration-based approach using 232 pairs of intrinsic landmarks identified on 37
histology images and corresponding MR images. This work concluded that the fiducialbased approach was more accurate and more robust to initialization than the tested
image-intensity-based registration approach.

1.4.5 Chapter 6: Prostate cancer assessment and delineation on 3 T multiparametric MRI: interobserver and intersequence agreement
The purpose of this work was to evaluate mpMRI for scoring prostate cancer
lesions (following the Prostate Imaging Reporting and Data System [PI-RADS] [56]
detection guidelines) and for delineating suspicious lesions on different mpMRI
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sequences (T2W, DCE and ADC images). Four observers scored and delineated lesions
on images from each mpMRI sequence from 17 radical prostatectomy patients. We
measured the positive predictive values (PPVs) of lesion scores with respect to coregistered histology, interobserver variability in lesion scoring, and the interobserver and
intersequence variability in lesion delineation (using Dice overlap, mean absolute
distance and absolute volume difference measures), as well as the correlation of these
with interaction factors including lesion volume and histological grade. We found that a
PI-RADS likelihood score of 5 (denoting highly likely cancerous) had a positive
predictive value of 85% for Gleason 7 cancer, and a PPV of 93% if the delineated lesion
had a volume >0.5 cm3. However, many false positives were observed, especially for
lesions with PI-RADS likelihood scores of 3 and 4. The mean interobserver differences in
the four PI-RADS scores ranged from 0.6 to 1.2 (5-point scale), with an agreement kappa
of 0.30. ADC maps showed a trend towards superior interobserver contouring agreement
compared to T2W or DCE images for all metrics. The observed correlation between PIRADS scores and post-prostatectomy Gleason scores was promising; however, the
interobserver variability in PI-RADS scores may impede their interpretation, and the
prevalence of high PI-RADS likelihood scores for non-cancerous lesions suggests a need
for further investigation of mpMRI confounders. Lesion delineation showed substantial
variability, suggesting a need for standardized contouring guidelines and training.
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1.4.6 Chapter 7: Toward prostate cancer contouring guidelines on MRI:
dominant lesion gross and clinical target volume coverage via accurate
histology fusion
The purpose of this work was to evaluate a range of clinical target volume (CTV)
expansion margins for lesions (or gross target volumes [GTVs]) defined on mpMR
images with respect to their likelihood of yielding adequate coverage of midgland
histological cancer, and to evaluate CTVs resulting from margins that yield a high
likelihood of adequate coverage. Four observers delineated lesions on images from each
mpMRI sequence from 25 radical prostatectomy patients. Contoured and graded
histology images were co-registered with the mpMR images. CTVs were constructed
with 0–30 mm margins expanded isotropically (constrained to prostate tissue) from true
positive GTVs on each sequence and from composite GTVs from multiple sequences.
The proportion of residual midgland cancer (and, separately, high-grade midgland
cancer) remaining outside each CTV was quantified, and prediction intervals for residual
area were computed for each observer and for each type of single-sequence and
composite CTV. Margins yielding high likelihood (78–91%) of leaving less than 0%, 5%
and 10% residual cancer were identified, and the CTV absolute volumes and relative
volumes (compared to GTVs and histological cancer) were calculated. The minimal
margins with high likelihood of leaving 0–10% residual cancer were lowest for
composite GTVs using delineations on T2W, DCE and ADC images; however, there was
substantial variation between observers, with margins of 4.5–9.0 mm, 1.5–7.5 mm and
1.5–4.5 mm for 0%, 5% and 10% residual high-grade cancer, and 6.0–11.0 mm, 5.5–10.0
mm, and 3.0–9.5 mm for 0%, 5% and 10% residual cancer of any grade. However, the
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volume of the resulting CTVs from these three-sequence GTV delineations with smaller
margins was not consistently lower than the CTVs of other types with larger margins.
Across all observers and CTV types, 50–80% of CTVs for high-grade cancer had
volumes <10 ml, potentially suitable for focal radiation boosting, and 9–51% had
volumes <5 ml, potentially suitable for focal laser ablation. We concluded that lesion
delineation on mpMRI with appropriate margins has the potential to generate CTVs with
adequate histological coverage that are deliverable with some targeted techniques, but
that there may be value in developing methods for characterizing individual lesions, in
developing contouring guidelines and training programs to reduce variability, and in
investigating non-isotropic margin expansions to achieve adequate histological coverage
with smaller CTVs.

1.4.7 Chapter 8: Contributions of the thesis, applications and suggestions for
future work
This chapter summarizes the advances in knowledge related to each of the thesis’
research questions, and discusses practical applications of the thesis contributions along
with corresponding directions for future research.
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Chapter 2.
The impact of registration accuracy on imaging
validation study design: a novel statistical power
calculation †

2.1 Introduction
Imaging evaluation with respect to an accepted reference standard imaging
modality (e.g. on pathologist-contoured digital pathology images) may be a useful
surrogate for clinical evaluation due to the resulting lower costs and shorter timeframes.
Some aspects of these evaluations require the registration of images from the medical
imaging modality being studied (henceforth, study images) to the images from the
accepted reference standard modality (henceforth, reference images). Because of tradeoffs associated with achieving higher accuracy [1], it is important to identify the
maximum acceptable level of registration error. This threshold is applicationdependent [2], and establishing application-specific thresholds for maximum acceptable
error has been identified as a key challenge in the field [1, 2], but, to the best of our
knowledge, criteria for acceptable registration errors have not been identified for imaging
validation studies.
†A version of this chapter has been published: E. Gibson, A. Fenster, A. D. Ward, “The impact of
registration accuracy on imaging validation study design: a novel statistical power calculation.” Medical
Image Analysis 17:7 (2013).
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In this work, we focus on developing such a criterion for a particular class of
imaging validation studies: preliminary studies of the utility of an imaging modality for
disease localization that test whether any observed differences in the mean image
intensities (or other derived quantities) attributed to the presence of the disease (e.g.
cancerous tissue) are significant, or whether they are merely due to chance. Measurement
of image intensities in regions containing disease requires the localization of these
regions on study images, which in turn requires the registration of the study images to the
reference images, wherein the disease can be acceptably localized. An ideal (zero error)
registration maps each ground truth delineation of disease features of interest onto the
true region of interest (henceforth,

for the -th such region, as depicted in Figure 2.1a)

on the study image. A non-ideal registration (> zero error) maps the delineation onto a
region which we denote

. Registration error is ideally quantified using a measurement

of distance, such as the target registration error (TRE) [3-5]. However, because our
analysis depends on aggregated measurements of image intensities within regions
containing disease (i.e.

), but our measurements, due to non-ideal registrations, are

instead aggregated measurements taken from within the sampling region
of the regional overlap between

and

, the fidelity

is paramount, and is used as a surrogate

measure for registration accuracy. Our measure of this fidelity is the fractional overlap,
, where

is the number of voxels in the region . Fractional

overlap, which ranges from 0 to 1, serves as our surrogate measure of registration
accuracy throughout this chapter, with

serving as our surrogate measure of

registration error. Mapping errors that result in smaller overlap may lead to larger
required number of subjects to achieve a given minimum detectable difference (MDD) on
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imaging between pathologic and benign regions. This observation leads to three key
questions affecting study design. (1) What is the maximum acceptable registration
error? Specifically, for a fixed number of subjects and specified MDD, what is the
maximum acceptable image registration error? (2) How many subjects are needed?
Specifically, for a quantified image registration error and specified MDD, what is the
required number of subjects? (3) What is the minimum detectable difference?
Specifically, for a fixed number of subjects and quantified image registration error, what
is the MDD?
The common concept connecting these questions is statistical power, a measure
that describes the probability of a study finding a statistically significant result when
there is an underlying difference to be found. Statistical power and its relationship to
study designs have been actively investigated for nearly a century [6]. Calculations of
statistical power depends on many factors, including the number of subjects in the study,
the acceptable error rates, the size of the underlying difference, the characteristics of the
population being analyzed, the statistical test [7], the types of hypotheses being tested [8,
9], and the sampling methods used [10]. This statistical power is commonly expressed in
the form of a sample size calculation that relates how many subjects to recruit for a
particular study design or an MDD calculation that relates how small a difference can be
detected for a particular study design. Such statistical power calculations have been
derived for a wide variety of study designs; however, they have not been derived for
studies where the measurements rely on imperfect image registration, and the registration
error is an additional factor affecting statistical power.
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In the context of studies to determine whether focal disease affects intensity on
study images, we propose that the acceptable registration error can be defined relative to
the studies' statistical power. Thus, in this chapter, we provide a derivation that yields the
relationship between image registration error, number of subjects, and MDD, where
image registration is used to determine whether the presence of particular anatomy,
pathology or other features of interest in the underlying tissue is reflected in a change in
the mean intensity of study image voxels corresponding to the features of interest. The
derivation of a statistical power calculation that incorporates uncertainty due to
registration error yields a set of three equations that can be used to answer the three
questions enumerated above.
A preliminary version of this work [11] derived these relationships for a
simplified image data model that cannot account for the intervoxel correlations that are
pervasive in medical imaging [12]. This chapter generalizes the previous work to account
for a more realistic data model, provides a more rigorous derivation of the power
calculation formulae, expands the scope of the validation by measuring sensitivity to a
wider range of violations of model assumptions, expands the testing of the relationships
by measuring error in the number of subjects, MDD and required registration accuracy
predictions, and demonstrates the application of the theory to a case study of an imaging
validation project underway at our institution.
The remainder of this chapter outlines the derivation of an approximate
relationship between fractional overlap and statistical power for one study design
(Section 2.2), describes simulations used to validate components of the derivation
(Section 2.3), presents the results of the simulations (Section 2.4) and discusses the
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implications of these relationships and the application of these relationships in a case
study (Section 2.5). Appendix A contains further mathematical details of the derivation.

2.2 Statistical power calculations in imaging validation studies
A statistical power calculation, such as the sample size calculation, relates the
probability of detecting a true positive finding to other parameters of the study design
under a probabilistic model of the populations being studied [13]. This relationship is
based on the distribution of the test statistic, which depends on the type of statistical
analysis used in the study, and the assumptions made in the data model. An overview of
the data model used for this work is illustrated in Figure 2.1.
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Figure 2.1: Overview of the data model. (a) On this axial magnetic resonance image of a
brain, the true region of interest , in this case a high contrast glioma for illustration
purposes, is shown in red. Due to registration error, the sampling region (shown in
purple) partially overlaps the surrounding background tissue (shown in cyan). Because
the background sampling region is surrounded by other background tissue, we do not
model registration error for this region. (b) The distributions of voxel intensities in
regions and (top), (middle) and (bottom). Because contains samples from
and , its voxel intensity distribution
is a mixture of the distributions for regions
(
) and (
) (dotted lines). (c) The statistical properties of
are modulated
by registration error, because it affects the proportion of samples from the component
regions. By quantifying registration error in terms of the volume of
as a fraction
of the volume of , the fractional overlap, the model of its effect on the statistical
properties of
is simplified. (d) The correlation of voxel intensities within regions
(or similarly ) can be expressed by decomposing the total variance
into two
components, one reflecting the variation of the region means from region to region
, and the other residual variation from voxel to voxel within a single region.

2.2.1 Specification of statistical analysis and data model assumptions
In this chapter, we derive and evaluate statistical power calculations for a specific
statistical analysis: comparing the mean of a pool of samples drawn from
sampling regions
regions

to the mean of another pool drawn from

identified
background

using an unpaired Student's -test on the sample intensities, with an
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equal number of samples

taken from each region. In this chapter, we use a data model

that makes the following assumptions:
I.

intensities of voxels containing the features of interest

and background

are jointly Gaussian distributed random variables that are correlated within each
region and independent between regions (i.e.
and

, respectively, where

random effect on the -th region and

is a Gaussian

is a Gaussian random effect on the -th

voxel in the -th region);
II.
III.

the interregion variances are equal for regions
when the regions

and

and regions

(i.e.

);

are not aligned, due to registration error, the

proportions of samples that fall within

(termed the fractional overlap

hereafter; see Figure 2.1c) are independently and identically distributed from a
distribution
IV.

the regions

, and independent from the intensities;
and

registration error,

are surrounded by background tissue, such that when there is
may contain a region of background tissue (denoted

), but

the sampling region for background still contains only background. Intensities of
voxels in regions
or
V.

are correlated within

, but uncorrelated with voxels in any

;

the number of regions

is large enough that the distribution of the mean of the

pooled samples approximates a Gaussian distribution; and
VI.

the number of samples, , from each region is constant and is large enough that
can be approximated as an integer.
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2.2.2 Derivation of the statistical power formulae incorporating registration
error
When there is no registration error, the test statistic

2.1

which is used when the variance and intraclass correlation are unknown, has a distribution with
and

and

degrees of freedom, where

and

are the sample means

are the region means of the -th regions. Using the terminology

introduced above in Eq. 2.1 and letting

be the minimum detectable

difference for a two-sample -test, we have

2.2

where

is a statistical threshold

, where

and

are two- and one-tailed critical values taken from the inverse cumulative
distribution function of the -distribution with
type I error to

degrees of freedom, constraining

and type II error to . This formula holds for cases where the samples

are from Gaussian distributions and there is equal variance and equal correlation within
each class. The first two of the assumptions in our model are derived from this. First, to
match the distributions from the classical formula, our model assumes correlated
Gaussian intensity distributions, although in practice, image intensities may have varying
distributions and may be truncated by the imaging systems. Second, the classical formula
assumes equal intra- and interregion variances; however, in the presence of correlation
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the sensitivity to unequal intraregion variances is lower than the sensitivity to unequal
interregion variances [14]. Based on these observations, only the equality of the
interregion variances was assumed in our model. Equation 2.2 accounts for the widening
of the standard error of the mean in the presence of correlation between the samples in
each class. An illustrative example of such correlation is an image whose resolution is
much lower than the voxel spacing. While the variance of a randomly selected voxel
from a randomly selected tumor from such images would be

(i.e.

),

estimating the variance using multiple measurements within a smaller number of tumor
regions would yield an artificially low variance, and using this variance estimate in the
calculation of the standard error of the mean

would underestimate the standard

error of the mean. The design factor [15] corrects for this, such that the true standard
error of the mean is represented in the power calculation.
For the purpose of the derivation, we rearrange this classical power formula as

2.3

to isolate

, the expression for the variance of the mean of

randomized samples from the

regions. Note that

is the minimum detectable

difference between the means of the populations being compared (
When there is misregistration of the -th region,
background region
voxels sampled from

that surrounds

and

).

may overlap with the

(illustrated in Figure 2.1a) such that the pool of

contains samples from

differ, then samples from

cluster-

. If the intensity distributions

and

do not represent the same population as samples from

, and Equation 2.3 does not correctly describe the statistical tests being performed. At a

70

high level, to derive the statistical relationships accounting for registration error, we first
characterize the population of samples from
samples from

, then model the statistical comparison of

and , and finally relate this model back to the population parameters of

the original data model. This is described in detail as follows.
The population of samples from
from

is a mixture of samples from

and samples

, as illustrated in Figure 2.1b. The proportion of samples that contain the feature

of interest can be quantified as the fractional overlap
Figure 2.1c). Ignoring partial volumes,
samples from

(illustrated in

will have

samples from

. Each of the samples is a Gaussian random variable

with a distribution that depends on whether the sample is from

or from

Noting that Equation 2.3 incorporates expressions for the mean of
variance of the mean of

and

cluster-randomized samples from

parameters for the population of samples from

. Because

component distributions, the mean of the population

.
and the

, we derive these same
is a mixture of two

is a weighted mean of the means

of the component distributions weighted by the number of samples from each component.
Since the number of samples depends on the fractional overlap, we marginalize this
weighted mean over the distribution of fractional overlap:
2.4
The variance of the mean of

cluster-randomized samples from

can be expressed as

2.5
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where

,

and

. The derivation of this

expression is given in Appendix A.
To model the statistical comparison of samples from regions
incorporate

and

, and substituting
from regions

, we

into the classical formula in Equation 2.3, by substituting
(the variance of the mean of

) for

samples from regions

and

(the variance of the mean of

for

cluster-randomized samples
cluster-randomized

). Although the classical formula in Equation 2.3 is an exact

statistical model, the formula resulting from these substitutions describes an approximate
relationship, as the population of samples from

is not, in general, Gaussian, and so the

distribution of the test statistic is not, in general, a -distribution.
This relationship can be related to the population parameters of
noting that

is a function of the difference in population means

expression can be solved for

, , and

and

by
. This

, as given in the power calculation formulae in

equations 2.6, 2.7 and 2.8, respectively:

2.6

2.7

2.8
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Note that the right-hand side of Equation 2.7 is a function of , because
. This equation must be solved approximately by numerical
methods.

2.3 Simulations
We performed Monte Carlo simulations to assess the accuracy of the derived
statistical model, and the sensitivity of the model to assumption violations. In each
iteration of a simulation, we modeled an experiment comparing the sample means of
voxels from

regions

and

population mean intensities

regions
and

under the alternative hypothesis that the

differed by

, with two-sample -tests of the null

hypothesis that the population mean intensities were equal. By running multiple
simulation iterations, a 95% confidence interval on the power of this experiment was
estimated. Each sampled region

was modeled by sampling a fractional overlap

a specified distribution, and sampling
distribution of intensities of regions

intensity samples from
, and

the distribution of intensities of regions
sampling

intensity samples from

set to be the

from

, the

intensity samples from

. Each sampled region

,

was modeled by

. The difference in the means of

and

was

predicted by the model, so that if the model were perfect, the probability

of a negative -test result from the simulation would match the model's type II error
parameter . In each simulation, 4,000,000 simulation iterations were run so that the
width of the 95% confidence interval on the power of the simulated study was 0.001 (e.g.
[0.7995,0.8005]). For each simulation, the model was evaluated by (1) comparing the
simulation's power to the power predicted by the model (with all other parameters
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matching the simulation), (2) comparing the simulation's number of subjects
underlying population difference

to the number of subjects and

and

predicted by

the model for the observed power (with all other parameters matching the simulation). To
measure each different aspect of the model, a set of multiple simulations with controlled
variation of an underlying parameter (henceforth referred to as a simulation set) was run.
Simulation sets were run with controlled variation of , of the population distributions of
,

, and

, and of the experimental design parameters ,

and . Note that the

population distributions for these experiments were not necessarily constrained by the
model assumptions, in order to allow the testing of violations of these assumptions.

2.3.1 Model accuracy under the specified assumptions
To test the model accuracy under the assumptions specified in Section 2.2.1, we
ran simulation sets using the data model specified in the derivation and parameters that
did not violate any specified assumptions. Voxel intensity distributions were drawn from
2.9
2.10
and the model parameters

,

,

, and

were varied. A variety of distributions

of fractional overlap were tested by using the Pearson family of distributions. These
distributions facilitate the independent manipulation of mean
and kurtosis

, variance

, skew

, and include the normal distribution, giving a well-understood reference

point when varying distribution parameters. Because fractional overlap is a proportion,
the Pearson distributions were truncated to [0,1] and the mean and variance of fractional
overlap did not in general match the specified
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and

. The

and

used in the

model were estimated based on 1,000,000 samples from the distributions.

and

were

varied over a range of values high enough to satisfy assumptions 5 and 6. Error rate
control parameters

and

were also varied. Each of the parameters was varied

independently in one set of simulations, with the other parameters held constant with
values listed in Table 2.1. The ranges of the parameters varied in these simulation sets are
described in Table 2.2.
Table 2.1: Values of power simulation parameters in simulations where these parameters
were held constant.

0.05

0.2

0.5

1

1

30 30

{0.5,0.7,0.9}

0.2

Table 2.2: Varied data model parameters for simulation sets, denoted as

0.01 to 0.2 0.1 to 0.3

0.1 to 2

0

3

to

.

0.1 to 2 0.1 to 2 30 to 80 30 to 80 0.1 to 1 0 to 1 -1 to 1 1.5 to 10

2.3.2 Model sensitivity to violations of the assumptions
To test the sensitivity of the derived model to violations of the assumptions in
Section 2.2.1, we constructed a more general data model, and ran sets of simulations
varying parameters independently, with ranges of values including extremes where the
model assumptions were violated.
2.3.2.1 Generalized data model
The more general data model included a separate intensity distribution
voxels from background regions

surrounding

intensity distribution models.
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, and used more flexible voxel

for

In practice, imaging intensity distributions in normal and abnormal regions may
vary based on the anatomy, the pathology, the imaging modality, and the digitization
processes (such as truncation of the intensity ranges stored in the images), and would not
in general be distributed as a Gaussian. Due to the intractable number of possible
intensity distributions, these effects were not explored directly; instead, the sensitivity of
the power formulae to the intensity distributions was assessed by replacing the Gaussian
distributions with the more general Pearson distributions, a flexible class of distributions
that can model skew and kurtosis and encompasses many common distributions including
unbounded distributions such as the Gaussian distribution, the -distribution and the
gamma distribution, as well as bounded distributions such as the uniform distribution and
the beta distribution. The generalized data model is characterized by the following
intensity distributions:
2.11
2.12
2.13
where

and

denote Pearson distributed random variables sampled

once per region and once per voxel, respectively, with standard deviation , skew
kurtosis , and

,

,

variances

,

, and

distributions

,

and

and

and

were zero-mean Gaussian random variables with
, respectively. Note that distributions

and

(and

) share the same population parameters as they both represent

background tissue; however, for a given and , separate independent samples were taken
from these two distributions.

was sampled once per pair of regions

added to both, to introduce correlated (matched) pairs.
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and

and

and

were sampled once

per simulation iteration and added to all

and

, respectively, introducing correlation

within region types (or, effectively, variability in
was sampled once per region
region

and

and added to

from iteration to iteration).

and the surrounding background

, introducing correlation between regions and their surroundings.

2.3.2.2 Simulation sets
Two types of simulation sets were run to assess the sensitivity of the model to
violations of the assumptions. First, parameters from the original data model were varied
to violate the assumptions of the derivation. The parameters

and

were independently

varied through a range (2–30) that potentially violated the assumptions that these values
were sufficiently large. The ratio

was varied from 0.25 to 4 to violate the

assumption of equality of interregion variances. Because the sensitivity of the -test to
non-Gaussian populations is known to increase with lower

[16], the variations

described in Table 2.2 (apart from ) were repeated with

and

. Second,

the additional parameters introduced in the generalized data model representing skew
,

,

and

) and kurtosis (

,

,

distributions and correlations between regions (

and
,

) of voxel intensity
,

, and

) were varied.

Skew parameters were varied from -1 to 1, and set to 0 when not being varied. Kurtosis
parameters were varied from 1.5 to 10, and set to 3 (the kurtosis of the normal
distribution) when not being varied. Correlation variances were varied from 0.1 to 2, and
set to 0 when not being varied. Other parameters were set according to Table 2.1. As
above, the variations were repeated with

and
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2.3.2.3 Statistical analysis
Statistical analysis was performed in SPSS 21 (IBM SPSS, 2010, Chicago, IL).
For the simulation sets following the assumptions of the derivation, the accuracy of the
model was assessed based on the maximum relative error in the model's prediction of the
simulated number of subjects and MDD, and the maximum absolute error in power
across all the levels of the varied parameter in the simulation set. The sensitivity of the
model to variation of model parameters was assessed using a linear regression with the
power as the dependent variable and the varied parameter as the independent variable,
averaged over the three levels of

(except in the case of varying

, where there was no

averaging). For the regression assessing sensitivity to the parameter , the null
hypothesis was that the linear coefficient of
should be

was -1, as the power of an ideal model

. For the other regressions, the null hypothesis, corresponding to no

sensitivity to parameter variation, was that the linear coefficient of the varied parameter
was 0. For the simulations violating the assumptions of the derivation, the sensitivity of
the model to these violations was assessed by (1) using separate linear regression for
,

, and

, with the power as the dependent variable and the varied

parameter as the independent variable, averaged over three levels of

, and (2)

identifying the ranges of each parameter where the model predicted the number of
subjects and MDD to within 1% relative error and the power to within 0.01 absolute
error. The simulation set varying

was assessed using a single linear regression.
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2.4 Results
2.4.1 Simulation sets following assumptions
The simulations were run for all simulation sets that followed the assumptions of
the derivation. Table 2.3 shows the linear sensitivities of the model's predicted power to
the varied parameter for the simulation sets described in Table 2.2 that met two criteria:
(1) regression detected a significant effect (
was

) and (2) the magnitude of the effect

. For the remaining parameters, (

,

,

, , ,

), the test failed to detect a significant effect or detected an effect

,

, and
. Under the

assumptions of the derivation, the model predicted the power to within 0.003 of the
simulation power, predicted the number of subjects to within 0.8% relative error from the
simulation number of subjects, and predicted the MDD to within 0.5% relative error from
the simulation MDD for all parameter levels for all simulations sets.

2.4.2 Simulation sets violating assumptions
Simulations were run for all the simulation sets that violated the assumptions of
the derivation. Table 2.4 shows the linear sensitivities of the model's predicted power to
the varied parameter for the simulation sets violating the model assumptions that met two
criteria for any of the three levels of : (1) regression detected a significant effect
(

) and (2) the magnitude of the effect was

parameters, (

,

,

,

,

,

,

, , ,

. For the remaining
,

,

failed to detect a significant effect or detected an effect

,

, and

), the test

. Simulation sets for

parameters where the model erred in the prediction of the number of subjects by more
than 1% for any of the parameter levels with any
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or any

are shown in Figure 2.2 for

the original data model, and shown in Figure 2.3 for the generalized data model. In these
figures, the -axes indicate the relative percentage difference between the number of
subjects predicted by the model and the simulations. A value of 0% indicates that the
model exactly predicted the simulation results. Values of

and

indicate that the

model under- and overestimated the number of subjects, respectively. Parameter ranges
where the model predicted the simulated power to within 0.01 absolute error and the
simulated number of subjects and MDD to within 1% relative error are given in Table
2.5.
Table 2.3: Sensitivity of the power prediction error to variation in model parameters,
under the assumptions of the derivation. The linear coefficients of the varied parameter
are shown only for simulation sets that met two criteria: (1) regression detected a
significant effect (
) and (2) the magnitude of the effect was
.
Parameters
,
,
, , , , , and , where the test failed to find a
significant effect or the magnitude of the effect was
, were omitted from the
table. An ideal model would yield a linear coefficient of 0, except for the simulation set
varying , which should yield a linear coefficient of -1.

Linear coefficient (1/unit of parameter variation)

0.015

-0.999 0.003

Table 2.4: Sensitivity of the power prediction error to variation in model parameters, for
simulation sets violating the assumptions of the derivation. The linear coefficients and the
intercepts are shown only for simulation sets that met two criteria for any level of : (1)
regression detected a significant effect (
) and (2) the magnitude of the effect was
. Parameters
,
,
,
,
,
,
, , , ,
,
,
, and
,
where the test failed to find a significant effect or the magnitude of the effect was
for all levels of , were omitted from the table. An ideal model would yield a
linear coefficient of 0, except for the simulation set varying , which should yield a linear
coefficient of -1. Simulation sets that yielded effects
are denoted with a *.

Linear
coefficient

30
20
10

0.015 -0.999
0.027 -0.993
0.054 -0.987

0.001
0.002
0.003

0.006 -0.015 * 0.003 *
*
0.008 -0.019 0.001 0.004 * -0.001
0.01 -0.026 0.001 * 0.001 -0.001
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Table 2.5: Parameter ranges where the model predicted the simulated power to within
0.01 absolute error and the simulated number of subjects and MDD to within 1% relative
error. Ranges are denoted
to
if the whole range of rested parameter values fit
these criteria. Otherwise,
and/or
were replaced with the identified lower and/or
upper bound that did fit the criteria. Parameters where errors were below these thresholds
throughout the tested range were omitted (
,
,
,
,
,
,
, , ,
,
,
,
).

30
20
10

to
to
to

As

to
to
to

to
to
to

to

to
to

to
to

to

to

to

to

to

to

to

to

to

to

to

to

to

was decreased, for the simulation sets that otherwise followed the

assumptions, the model error increased for all simulation sets. For

, the model

predicted the power to within 0.008 of the simulation power, predicted the number of
subjects to within 2% relative error from the number of subjects in the simulation, and
predicted the minimum detectable difference to within 1.1% relative error from the
simulation minimum detectable difference for all parameter levels for all simulation sets.
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Figure 2.2: Simulation sets testing model accuracy under the original data model, for
parameters that yielded >1% relative error in the number of subjects at any level of
or
. The remaining parameters ( ,
, , ,
, and ) showed <1% error in the predicted number of subjects for all
simulation sets. Each curve represents the relative error in the predicted number of
subjects for a particular and
for varying parameter levels. An ideal model would
yield a horizontal line at 0% for all levels of and . Multiple lines with different
slopes, or different shapes suggest that there is an interaction between the sensitivity to
the parameter being varied and or . Negative relative errors mean the model
underestimated the number of subjects, potentially leading to an underpowered study.
Positive relative errors mean the model overestimated the number of subjects, resulting in
potentially inefficient use of resources.
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Figure 2.3: Simulation sets testing model accuracy under the generalized data model, for
parameters that yielded >1% relative error in the predicted number of subjects at any
level of
or
. The remaining parameters ( , ,
,
,
,
,
,
,
,
,
,
, , , , and ) showed <1% error in the
predicted number of subjects for all simulation sets. Each curve represents the relative
error in the predicted number of subjects for a particular and
for varying parameter
levels. An ideal model would yield a horizontal line at 0% for all levels of and .
Multiple lines with different slopes, or different shapes suggest that there is an interaction
between the sensitivity to the parameter being varied and or . Negative relative
errors mean the model underestimated the number of subjects, potentially leading to an
underpowered study. Positive relative errors mean the model overestimated the number
of subjects, resulting in potentially inefficient use of resources.
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2.5 Discussion
In this work, we derived a set of novel statistical power formulae that directly
model registration error for a statistical test of the difference in signal intensity between
foreground and background regions, accounting for correlation within these regions.
This work provides a derivation of a statistical power calculation incorporating
image registration uncertainty and addressing three central questions in the design of
imaging validation studies. (1) Eq. 2.6: What is the maximum acceptable registration
error? (2) Eq. 2.7: How many subjects are needed? (3) Eq. 2.8: What is the MDD
between normal and pathologic image regions? Specifically, we derived an approximate
relationship between an arbitrary distribution of fractional overlap and the statistics of a
study design, elucidating a relationship between registration error, number of subjects
and statistical power, yielding a set of three equations that are central to the design of
imaging validation studies.
These relationships could be used in several applications. During study design,
Eq. 2.7 or 2.8 could be used to evaluate or control the power, after estimating imaging
properties and registration errors, while Eq. 2.6 could be used to guide the selection of
registration algorithms under the constraints of a study design. During algorithm
development, Eq. 2.6 could be used to assess whether an algorithm has sufficient
accuracy for a particular application.

2.5.1 Simulations
We ran Monte Carlo simulations to test the fidelity of our model both when our
assumptions were met and when some of them were violated. When the assumptions of
the derivation were met, the model predicted the number of subjects and MDD to within
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1% error of the simulation and the power to within 0.01 absolute error of the simulation
for all of the simulation sets. When the assumptions of the derivation were met, the
source of the residual error is the deviation of the distribution of voxel intensities in the
sampling region from the Gaussian distribution assumed by the classical power
calculation. The simulations suggest that this source of error is negligible over the range
of parameters simulated.
When the assumptions were violated, the model still predicted the number of
subjects, MDD and power of the simulation to within 11% over all tested parameter
values. The model was most sensitive to the combination of a skewed distribution of
regional mean intensities and low . The parameter ranges shown in Table 2.5 and
Figures 2.2 and 2.3 may suggest study parameter ranges for which this model is
appropriate. For example, the model's accuracy decreases as the number of samples
decreases below 6 and as the number of subjects

decreases below 4, suggesting that the

model may not be appropriate for studies where the pathological regions occupy fewer
than 6 voxels, or the study includes fewer than 4 subjects. In addition to serving to
evaluate the statistical model, Figure 2.3 may also serve as a guideline for compensating
for known deviations from the assumed model. For example, if it is known that the
distribution of the background voxels has a positive skew of 1, a conservative study
design could recommend an additional 4% beyond the number of subjects predicted by
the model.

2.5.2 Fractional overlap relates registration error to study outcome
The post-registration misalignment of many homologous landmarks not used to
define the registration (often quantified as the TRE) is considered to be the ideal general
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metric for measuring registration error [4, 5]. In the study design addressed in this work,
where image signals averaged within foreground and background regions are compared,
the test statistic, and thus the study outcome, is invariant to some types of registration
error. Specifically, two different registrations that map a point on the study image to
different points that are both within the region

will yield the same test statistic.

Because of this invariance, the statistical power of such a study is more directly tied to a
surrogate measure for registration error that shares this invariance. Furthermore, as
fractional overlap for a sampling region is linearly related to the average signal inside the
sampling region, it is readily integrated into the derivation, which is a desirable feature
for a surrogate measure.

2.5.3 Estimating fractional overlap
The presented power formulae depend on estimates of two population parameters
of the distribution of fractional overlap for the registration methods and data used in a
study. The statistical properties of fractional overlap have not yet been well characterized
in the general case, and methods for estimating its population parameters have not yet
been standardized. Thus, the practical use of the formulae requires careful consideration
to be made in selecting an approach to this parameter estimation that is appropriate to the
problem at hand. One possible approach [11] would estimate

and

from a quantified

target registration error [3], under assumptions of having translational registration errors
distributed as a 3D Gaussian, and having spherical regions of known volumes. Depending
on the study, these assumptions may be overly strong. An alternative approach to
estimating the mean fractional overlap that avoids the assumption of spherical regions
with known volumes would be to (1) characterize the distribution of tumor shapes (e.g.,
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as a sample of tumor shapes taken from pilot data), (2) characterize the distribution of
registration errors (e.g., as a distribution of per-region translations modeled as a 3D
Gaussian distribution whose covariance is defined based on a quantified TRE), (3)
repeatedly sample from these distributions and measure the fractional overlap for each
sample, and (4) estimate the population mean and standard deviation of fractional overlap
as the sample mean and standard deviation. The characterization of the statistical
properties of these approaches, and the development of generalized approaches to
estimating fractional overlap, would support the application of the power calculation
formulae.

2.5.4 Case study
The application of these power calculations can be illustrated through a sample
size calculation for a case study, modeled closely after a prostate cancer imaging
validation study currently taking place at our institution. In this study, patients scheduled
for radical prostatectomy (surgical removal of the prostate) undergo in vivo imaging
before surgery using multi-parametric magnetic resonance (MR) imaging (structural,
diffusion weighted and dynamic contrast-enhanced (DCE) sequences). These images
could be processed to yield derived images (T2 maps from structural imaging, the
average diffusion coefficient (ADC) from diffusion weighted MRI, and both the contrast
transfer coefficient

and the contrast leakage

from DCE MRI). Following

surgery, the prostate specimens are processed for whole-mount histology [17] and are
digitized, annotated by a pathologist to identify cancer of different grades [18], and
reconstructed and registered to the in vivo images. The contemporary per-patient cost for
this study underway in our center is approximately $10,000 USD, so correctly estimating
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the required number of subjects is important. Although these data can be applied to
answer many questions, in this illustration we calculate the number of subjects for a
hypothesis testing whether these modalities show significant signal differences between
cancer and benign regions in the prostatic peripheral zone, known to harbor the majority
of prostate cancer [19].
To predict the required number of subjects for such a study, we can use
Equation 2.7. In order to use this equation, we need to specify three study design
parameters: (1) , the acceptable false positive error rate (chosen as 0.05, in our case
study); , the acceptable false negative error rate (chosen as 0.2 in our case study); and
, the minimum magnitude of signal difference we need to distinguish with these error
rates. For our case study, we estimated the differences in mean intensities from the
literature: Langer et al. [20] reported medians and ranges (from which means and
variances can be estimated [21]) for the intensity in tumor and benign tissue in the
prostatic peripheral zone for T2, ADC,

and

images. We also need to estimate 6

model parameters:
I.

, the average number of samples per tumor, which can be calculated as the
average tumor volume divided by the volume of an image voxel. For this case
study, we assume an even distribution of tumors with 0.5 cc, 1 cc and 2 cc
volumes.

II.

, the variance of tumor voxel intensities. For this case study, we used the
variance estimated from statistics reported by Langer et al. [20] for tumor
peripheral zone tissue for T2, ADC,

and
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.

III.

, the variance of background voxels. For this case study, we used the variance
estimated from statistics reported by Langer et al. [20] for benign peripheral zone
tissue for T2, ADC,

IV.

and

.

, the interclass correlation coefficient relating the relative contributions of intraand interregion variances to the total variance of voxel intensities. This parameter
is typically assumed to be equal for both classes, and so can represent
or

. This can be estimated from the literature, or calculated

from pilot data as
tumor regions and

, where

is the variance of the mean intensities of

is the variance of tumor voxels after subtracting the mean

intensity for each tumor. For this case study, without pilot data or information from
the literature specifying , we used a conservative estimate of
V.

.

, the mean fractional overlap of our tumor sampling regions with the underlying
tumor for our registration algorithm. For this case study, we estimated
first approach described in Section 2.5.3, i.e., estimating

using the

from a TRE estimate

under the assumptions of spherical tumors and 3D Gaussian translational error, and
using the same tumor volumes as used for estimating . For this case study, we
explored multiple levels of TRE.
VI.

, the variance of fractional overlap of our registration algorithm. For the case
study, this was also estimated using the first approach described in Section 2.5.3.
From these parameters, we can calculate 4 derived parameters: (1)
, (2)

, (3)

, and (4)

. The number of subjects can be calculated by substituting these
parameters and

into Equation 2.7 and solving numerically
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for the fixed point of

[22]. For the case study, this was performed by expressing the

right hand side of Equation 2.7 as
an iterative solver implemented as

and finding the zero-crossing of

using

in Matlab R2011b (The Mathworks Inc.,

Natick, MA).
Because it may be necessary to estimate
values, an intuitive understanding of

in the absence of pilot data or reported

is important. The effect of

can be understood by

comparing the variance of the mean of cluster-randomized samples in the absence of
correlation

, and in the presence of correlation,
.

has an effect equivalent to changing the number of independent samples

that can be collected from each region. Since the power depends on the total number of
independent samples, the number of subjects needed is inversely proportional to the
number of independent samples per region. Assuming

(i.e. effectively 1 sample

per region) would yield a conservative estimate of the necessary number of subjects. As
initial data is collected during the study and better estimates for
may reassess the required number of subjects. For example,

can be made, the study
(i.e. effectively ~2

samples per region) would halve the required number of subjects.
If we had an ideal zero-error registration, we could apply the classical power
calculation in Equation 2.2 by solving for , substituting in this study's parameter
estimates for , , ,

,

and , and numerically solving for the fixed point of . This

would yield an estimated number of subjects for each modality: 28 for T2, 13 for ADC,
188 for

, and 772 for

. In practice, since histology-in vivo MR image

registrations have error, Equation 2.7 predicts the functional relationship between number
of subjects and registration error using this study's parameter estimates (shown in Figure
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2.4). In this relationship, the -axis is target registration error, from which we calculated
the mean and variance of fractional overlap [11]. For a target registration error of 1 mm,
we would predict a required number of subjects of 36 for T2, 15 for ADC, 208 for
, and 889 for

. For a target registration error of 2.5 mm, we would predict a

required number of subjects of 48 for T2, 19 for ADC, 243 for

, and 1090 for

,

in which case, the classical power calculation underestimated the number of subjects by
as much as 40%.

Figure 2.4: Relationship between estimated required number of subjects and target
registration error (TRE) for 4 imaging modalities (note the differing -axis scales
illustrating the variable sensitivity of the required number of subjects to TRE for the
different modalities). An estimate of the required number of subjects using the classical
power formula (marked with circles) will underestimate the required number of subjects
when there is registration error. This relationship also illustrates the high potential impact
for improving registration error in the context of imaging validation studies. Based on
contemporary per-patient cost for a study underway in our center, the per-patient cost is
more than $10,000 USD, so reducing the required number of subjects can have a
substantial impact on the overall study cost.
In practice, several methods have been proposed for reconstruction of prostate
histology to in vivo MR imaging. The required number of subjects (and thus the study
cost) varies as a function of the registration error. Figure 2.4 shows this relationship,
demonstrating the value in improving registration accuracy.
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2.5.5 Limitations
The novel power calculations derived in this work should be considered in the
context of two key limitations. First, the classical power calculation on which this work
builds assumes that the samples being compared are drawn from a Gaussian distribution.
In the presence of registration error, one sample may no longer be Gaussian, causing the
distribution of the statistic to deviate from a -distribution. Thus, this work relies on the
robustness of the -test to non-Gaussian distributions. Second, the derivations in this
work are exact under strong assumptions. Because statistical power calculations
inherently depend on the particular statistical analysis being performed, the derived
power calculations can be directly applied only in the context of the described statistical
design. The approach used in this derivation, however, may facilitate derivations of
power calculations suitable for other statistical designs. The specific data models
assumed in the derivation may not perfectly describe data for a given problem; however,
the analysis of sensitivity to violations of these assumptions should allow users to assess
whether the model is appropriate for a given experiment. Third, due to the assumptions of
the classical power formula from which the novel power calculation formulae were
derived, our model assumes that the interregion variances

and

are equal.

Depending on the study, this assumption may be violated if, for example, the variability
of the pathology from subject to subject results in more variable appearance between
pathological regions than between benign regions. Prediction errors due to such
violations are shown in Figure 2.3. Fourth, the power calculation formulae depend on the
estimation of the mean and standard deviation of fractional overlap, which are required
for the application of the formulae. The statistics of fractional overlap, and their
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dependence on registration method and data, are not as well characterized as those of
other registration metrics such as TRE. The two approaches to this estimation discussed
in the case study, one using strong assumptions about region shapes and the distribution
of TRE, and one incorporating region shape information from pilot data, may warrant
further investigation.

2.6 Conclusions
In this work, we derived novel power calculations relating registration error to the
minimum detectable difference and the number of subjects. These power calculation
formulae enable imaging researchers to answer three central questions in the design of
certain imaging validation studies: (1) What is the maximum acceptable registration
error? (2) How many subjects are needed? (3) What is the minimum detectable difference
between normal and pathologic image regions? These formulae were accurate to within
1% error when the model's assumptions were followed, and the sensitivity of the model
to violations of the assumptions was characterized. The case study presented in this work
highlighted the importance of adjusting the number of subjects to account for registration
error, showing that the classical power calculation underestimated the required number of
subjects by as much as 40% for a study design modeled closely after an ongoing imaging
validation project in our center.
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Chapter 3.
3D prostate histology image reconstruction: quantifying
the impact of tissue deformation and histology section
location †

3.1 Introduction
Determining the 3D spatial relationship between corresponding histology and in
vivo images, for the purpose of evaluating prostate cancer imaging. is often performed in
two steps: (1) a reconstruction of histology images to a 3D ex vivo spatial context, and (2)
an alignment of reconstructed histology to in vivo images.
The challenges in 3D histology reconstruction can be illustrated in the context of
the process of collecting histology from radical prostatectomy specimens, which typically
proceeds as follows (shown in the first row of Figure 3.1). After surgery, the prostate is
fixed in a formalin solution and then cut into 3–5-mm-thick tissue slices at the pathology
bench. These tissue slices proceed through a series of chemical baths to replace water in
the tissue with paraffin, and the slices are embedded in a block of translucent paraffin.
This block is mounted to a microtome by hand, aligned by eye to square the tissue face
(as seen through the translucent paraffin) with the microtome blade, and tissue is cut until
a full cross-section can be collected. Once a sufficient depth has been reached, the
† A version of this chapter has been published: E. Gibson, M. Gaed, J. A. Gómez, M. Moussa, S. Pautler, J.
L. Chin, C. Crukley, G. S. Bauman, A. Fenster, A. D. Ward, “3D prostate histology image reconstruction:
Quantifying the impact of tissue deformation and histology section location.” J Pathol Inform 4:31 (2013).
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operator cuts a 4 μm histological section, allows it to expand on a water bath to flatten the
section, and mounts it on a glass slide.
Slicing
Specimen
processing

Paraffin
embedding

Microtoming
Paraffin block
Histology section
orientation & trimming cutting & slide mounting

Tissue slices

Paraffin blocks

Histology sections
Histology
digitization

Paraffin
photography

Slice MR
imaging
Imaging

Slice MR images

Paraffin images

Identifying front face on MR images
Front face plane
Analysis

Landmarking histology, paraffin and MR images

Histology plane

Depth ( ,
,)&
,,
orientation (𝜃 ) measurement

Histology images

Homologous landmarks
←ℎ

←ℎ
Deformation (
,
,
measurement

←

)

Questions 1 & 2: Tissue deformation and spatial misalignment of sections

TRE & FRE measurement
Question 3: Impact of reconstruction model on reconstruction error

Figure 3.1: Overview of specimen processing, imaging and analysis.
The 3D reconstruction of histology consists of retroactively determining the
positions of the cutting and the deformation of the tissue to determine the original 3D
spatial relationships of histological tissue, a process that remains an active area of
research [1-4]. 2D to 3D deformable reconstructions for clinical prostate specimens have
many degrees of freedom and sparse out-of-plane information content. A common
approach to mitigate these challenges is to make simplifying assumptions about the
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spatial relationship of histological tissue to the corresponding tissue in the specimen.
Some assumptions made in existing approaches for 3D histology reconstruction are
enumerated below. The focus of this chapter is on testing the strength of the first two
assumptions in this list.


The deformation of the histological tissue after coarse slicing fits a specified
constrained deformation model, such as the rigid [1], rigid + isotropic scaling
(referred to as similarity throughout this chapter) [5, 6], affine [2, 7], or thin-platespline (TPS) [8, 9] deformation models. This is referred to as the deformation
model assumption throughout this chapter.



Each histological section corresponds to the front face of the 3–5-mm-thick tissue
slice from which it was taken [3, 5-7, 9-11]. This is referred to as the front face
assumption throughout this chapter.



Each histological section corresponds to a planar surface in the specimen [1-3, 7,
10, 11].



Each histological section corresponds to a surface in the specimen defined
prospectively by carefully controlling the position and orientation of the cuts
made during specimen slicing [3, 10, 12, 13].



The histological sections correspond to parallel, evenly spaced surfaces in the
specimen (typically justified based on controlled cutting of tissue slices) which
are determined retrospectively using additional imaging (typically photographs of
the faces of tissue slices) during or after the slicing of specimens into thick tissue
slices [5, 7, 9, 11].
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By constraining the allowable spatial relationship between each histology section
and the tissue from which it was cut, these assumptions may simplify the registration
problem by decreasing the degrees of freedom but may also impact the accuracy of 3D
reconstruction methods. In the context of imaging validation studies that evaluate
imaging modalities by comparison to a 3D reconstructed histological reference,
reconstruction accuracy affects the statistical power (i.e. the probability of a study finding
an existing statistically significant effect) of studies that apply the reconstruction
methods [14, 15]. Because of this relationship, 3D histology image reconstructions with
greater error create a requirement for more patients to be enrolled in the study, which can
have a substantial impact on the cost of the study (see discussion for an illustrative case
study) or run the risk of improperly evaluating the imaging modality if the study is
underpowered for the error inherent in the technique. Thus, it is important to consider
these simplifying assumptions, and their impact on reconstruction error, in the
development and/or selection of reconstruction methods for such studies.
The strengths of these assumptions depend on their fidelity to the processes the
tissue undergo throughout the preparation of histological sections. For example, the
correspondence of the histological sections to the front faces of tissue slices depends in
part on the skill and experience of the microtome operator determining the paraffin block
face orientation and cutting depth. This task is complicated by the fact that the tissue face
is hidden behind a translucent layer of paraffin, challenging the assessment of tissue face
orientation until the tissue has already been exposed by the microtome blade and thus
sectioned. The strengths of these assumptions, and their impact on the reconstruction
error, have not, to the best of our knowledge, been quantified in the literature. This
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complicates the selection of appropriate assumptions for reconstruction method
developers, and also complicates the selection of reconstruction methods (that may
incorporate such assumptions) for study designers.
In this work, our objective was to quantify the spatial relationships between
histological sections, paraffin-embedded blocks, and the corresponding tissue slices from
which the sections were taken to answer three questions, referred to according to the
following enumeration throughout this chapter.


Question 1: How does prostate tissue deform during histology processing?
Specifically, with what accuracy can rigid, similarity, affine or TPS deformation
models align homologous landmarks on histology sections (Figure 3.2f, labeled
ℎ ), on the cut paraffin-embedded tissue blocks (Figure 3.2e, labeled
MR images of formalin-fixed tissue slices (Figure 3.2c-d, labeled

) and on
). This

question constitutes a test of the strength of the deformation model assumption.


Question 2: What spatial misalignment of the tissue sections is induced by
microtome cutting? Specifically, relative to the front faces of the tissue slices,
from what depth (Figure 3.2c, labeled

) and at what orientation (Figure 3.2c,

labeled 𝜃 ) are histology sections taken? This question constitutes a test of the
strength of the front face assumption.


Question 3: How does the choice of reconstruction model affect the accuracy of
histology reconstructions? A reconstruction model is defined in this chapter by a
choice of one of four deformation models (rigid, affine, similarity, TPS), and a
choice of whether or not to make the front face assumption. This question
resolves to the following two more specific questions: for all possible
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reconstruction models as defined above, (1) what are the target registration errors
(TRE) and (2) the fiducial registration errors (FRE) of least-squares best-fit
landmark-based reconstructions?
These questions constitute an evaluation of the impact on registration error of
making the deformation model assumption and the front face assumption. The answers to
these questions were quantified using homologous landmarks manually identified on
histology images, paraffin block face images, and MR images of the tissue slices, and the
resulting errors were evaluated in the context of a type of imaging validation study that
relies on histology image reconstruction.

3.2 Materials and methods
3.2.1 Materials and imaging
As part of an ongoing prospective imaging validation study, we obtained prostate
specimens from 6 subjects after radical prostatectomy with the following inclusion
criteria: (1) male, (2) age 18 years or older, and (3) clinical prostate cancer stage T1 or T2
with histological confirmation from biopsy. The exclusion criteria were: (1) prior therapy
for prostate cancer, (2) use of 5-alpha reductase inhibitors within 6 months of the study
start, (3) inability to comply with preoperative imaging, (4) allergy to contrast agents, (5)
sickle cell or other anemias, (6) hip prosthesis, (7) sources of artifact within the pelvis,
and (8) contraindications to MRI. This research was approved by our institutional human
subjects research ethics board, and informed consent was obtained from each subject.
An overview of the processing, imaging and measurement of these data is shown
in Figure 3.1. After resection, fixation (10% buffered formalin for 48 hours), and marking
with fiducial strands [3], the prostatic apex was removed and the mid-gland was gross101

sectioned into 4.4-mm-thick tissue slices (3–5 per specimen, 21 total). MR images of
these tissue slices were acquired using a Discovery MR750 (GE Healthcare, Waukesha,
WI, USA) at 3 T using an endorectal coil (Prostate eCoil, Medrad, Inc., Warrendale, PA,
USA). Tissue slices were immobilized in tissue processing and embedding cassettes and
immersed in Christo-Lube (Lubrication Technology Inc., Franklin Furnace, OH, USA) to
provide a black background and minimize boundary artifacts on imaging. Imaging used a
T1-weighted protocol (3D SPGR, TR 6.5 ms, TE 2.5 ms, bandwidth ±31.25 kHz, 8
averages, FOV 14×14×6.2 cm, slice thickness 0.4 mm, 256×192 matrix, 312 slices, flip
angle 15°, 25 min) and a T2-weighted protocol (3D FSE, TR 2000 ms, TE 151.5 ms,
bandwidth ±125 kHz, 3 averages, FOV 14×14×6.2 cm, slice thickness 0.4 mm, 320×192
matrix, 312 slices, 25 min). These images are referred to as tissue slice MR images
throughout this chapter.
Following MR imaging, formalin-fixed tissue slices were decalcified in a
hydrochloric acid/chelating agent solution (Cal-Ex Decalcifier, Fisher Chemical, Ottawa,
Canada) overnight and then dehydrated and embedded in paraffin using a series of
chemical baths of formalin, ethanol, xylene and paraplast under our hospital's standard
clinical pathology laboratory protocol for large blocks (wherein the duration of ethanol,
xylene and paraplast are lengthened). The full processing schedule is given in Appendix
B.
The embedded blocks were sectioned by one of fifteen clinical histotechnologists
in our hospital’s clinical pathology laboratory. Each block was mounted by hand on the
chuck of a microtome (RM2245 or RM2255, Leica Biosystems, Nussloch, Germany),
and the operator attempted to align the front face of the tissue, as seen through the semi-
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transparent paraffin covering, with the cutting axis by manually adjusting mechanical
control knobs on the microtome. Sections were repeatedly cut until a full cross-section of
the tissue block was reached. A final 4 μm section was cut from the block, floated on a
hot water bath to remove distortion and mounted on a positively-charged glass slide. All
sections were stained with hematoxylin and eosin.
After the clinical pathology assessment was complete, stained histology sections
were digitized on a ScanScope GL (Aperio Technologies, Vista, CA, USA) bright field
slide scanning system with a 0.5 μm pixel size. These images are referred to as histology
images throughout this chapter.
Photographs of the exposed face of paraffin-embedded tissue blocks were
acquired using a Pentax K200D with an SMC Pentax D FA 100 mm F2.8 macro lens
(Pentax Imaging Company, Denver, CO, USA). The camera was attached to the cameramount column of the photography table to ensure the optical axis was perpendicular to
the tissue blocks. Labels containing a 4 mm long scale marker were affixed to the cut
surfaces, and used to calibrate the pixel size of the images. These images are referred to
as paraffin images throughout.
Three sections were excluded from our analysis, because we identified an
insufficient number of homologous landmarks on the three imaging modalities
(histology, paraffin, and tissue slice MR images). Five sets of homologous landmarks
were necessary for our evaluation; see discussion for details.

3.2.2 Methods
Our method is illustrated in the “Analysis” portion of Figure 3.1, and is
summarized at a high level as follows. To characterize prostate tissue deformation due to

103

histology processing (Question 1), we determined the class of deformation that best
mapped tissue on histology sections to the homologous tissue on the paraffin block faces
and on the formalin-fixed tissue slices. Specifically, we assessed which of the four
evaluated classes of transformation (rigid, similarity, affine or TPS) best mapped
homologous landmarks on histology images (Figure 3.2f, labeled
images (Figure 3.2e, labeled

), on paraffin

) and on tissue slice MR images (Figure 3.2c-d, labeled

). To measure the spatial misalignment of tissue sections induced by microtome
cutting (Question 2), we characterized the locations from which histology sections were
taken from within tissue slices, by estimating the depth (Figure 3.2c, labeled

) and the

orientation (Figure 3.2c, labeled 𝜃 ) relative to the front face of the tissue slice from
which the histology sections were taken. To assess the impact of the choice
reconstruction model (i.e. choice of deformation model, plus choice of whether or not to
make the front face assumption) on 3D reconstruction error (Question 3), we estimated
two reconstruction error measures, the TRE and the FRE, using different reconstruction
models. The impact of these assumptions will depend, in part, on the reconstruction
algorithm that is used. We used least-squares best-fit alignment of manually identified
homologous intrinsic fiducials for these measurements. This approach is parameter-free,
has an analytic solution for each considered reconstruction model and has an accuracy
that depends only on the number and placement of fiducials and not on image properties.
In the four subsections that follow, we describe the details of the selection of these
landmarks, as well as the details of the methods used to address each of the three central
questions of this work.
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Tissue slice
Tissue section indicated in blue is cut from paraffin block with the microtome
(a)
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Figure 3.2: Schematic representations of tissue, landmarks and measurements, including
(a) a surface rendering of a tissue slice MR image; (b) a schematic rendering of the tissue
slice with front face fiducials , and the best-fit front face plane ; (c) a projected side
view of the tissue slice as oriented over the microtome blade with front face fiducials ,
the best fit front face plane , histology-visible landmarks
, the best-fit histology
section plane , the orientation 𝜃 and the depth measurement ; (d) a schematic
rendering of the tissue slice with histology-visible landmarks and best-fit histology
section plane ; (e) a schematic rendering of the paraffin block face after histological
sectioning showing homologous landmarks
and (f) a schematic rendering of the
corresponding histology section with homologous landmarks ℎ .

3.2.3 Identification of landmarks and tissue slice faces
All of these measurements rely on identifying homologous landmarks in histology
images, paraffin images and tissue slice MR images. For each tissue slice, we identified
7–15 distinct landmarks (162 in total), comprising the centers of atrophic ducts, cysts and
corpora amylaceae with diameters less than 1 mm. Illustrative examples of these images
and identified homologous landmarks are shown in Figure 3.3. The positions of the
landmarks (2D for histology and paraffin images, 3D for tissue slice MR images) on
these modalities are denoted

,

, and

, respectively, for -th landmark on the -

th tissue slice. Landmarks were interactively localized using 3D Slicer (Surgical Planning
Lab, Harvard Medical School, Boston, USA), which required that the histology images
be loaded into random-access memory; as the full resolution images typically occupy 15–
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20 GB, we downsampled them to a 30 × 30 µm voxel size for landmark identification,
yielding images 10–40 MB in size.
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T1w slice MRI

Paraffin

Histology

Figure 3.3: Illustrative examples of the T1-weighted tissue slice MR (left), paraffin
(middle) and histology (right) images transformed by a best-fit affine transformation
aligning manually identified landmarks. The three highlighted regions in row 1 are shown
magnified in rows 2, 3 and 4, with corresponding landmarks denoted by arrows.
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We estimated the front face of the -th tissue slice by first manually identifying
seven 3D points 𝒇

evenly distributed across the face of the -th tissue slice

on the tissue slice MR image (approximately in the configuration shown in Figure 3.2b),
and then computing the least-squares best-fit plane

to these points.

Because variability in landmark localization introduces uncertainty into spatial
relationships measured in this work, the fiducial localization error (FLE) was estimated
on histology (

), paraffin (

) and tissue slice MR (

images. Based on

previous measurements using these histology images and MR images of intact prostate
specimens using the same protocols [16],

and

were taken to be 0.05 mm and

0.16 mm respectively. These measurements quantified FLE as an unbiased estimator of
the standard deviation of repeated localizations of landmarks.
0.05 mm, the same as

was estimated to be

, because the types of fiducials and the pixel sizes were

similar (30 µm for histology images, 18 µm for paraffin images).

3.2.4 Tissue deformation due to histology processing (Question 1)
To assess the fidelity of the different deformation models, we quantified
deformation between formalin-fixed tissue slices, paraffin blocks and histology sections
under each of the models. Thus, we assessed the deformation due to three histology
processes: (1) paraffin processing and embedding (denoted with superscript
corresponding to the transformation

←

← ,

from the paraffin images [ ] to the tissue slice

MR images [ ]), (2) histological sectioning and mounting (denoted with superscript
← ℎ, corresponding to the transformation

←

from the histology images [ℎ] to the

paraffin images [ ]), and (3) the combination of both processes (denoted with superscript
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←

← ℎ, corresponding to the transformation

from the histology images [ℎ] to the

tissue slice MR images [ ]).
Deformation models were compared using the mean TRE of homologous
landmark pairs identified on images before and after each process after landmark-based
registrations constrained by 4 deformation models of increasing flexibility: rigid,
similarity (rigid + isotropic scaling), affine (rigid + scaling + skewing), and non-linear
TPS [17]. The mean TRE was estimated as the misalignment between homologous
landmarks after transformation by a least-squares best-fit transformation constrained by
the deformation model, and was calculated using a leave-one-out cross-validation:
←

←

where

←

3.1

is the transformation of type

that

best maps the vector of image landmarks
slice on the source modality

ℎ

from the -th

to the vector of image landmarks

from the -th slice on the target modality
slices, and

denotes which landmark is left out. For example,

,
←

tissue

is the best-fit

rigid transformation for the second tissue slice that maps from histology to tissue slice
MR image coordinates that is fit to all but the third identified fiducial.
The sensitivity of these measurements to FLE depends on the spatial
configuration and number of landmarks identified for each tissue slice. For example, the
best-fit transformation, and hence the leave-one-out TRE, of a section with few
landmarks centrally clustered near the urethra and one landmark near the prostate
boundary could be more sensitive to a misplaced landmark than that of a section with
many widely-spaced landmarks. Although relationships between TRE and FLE with
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respect to spatial distribution of the landmarks have been characterized for rigid
transformations [18], to the best of our knowledge there is no closed form solution for
calculating this sensitivity for a leave-one-out TRE for all four deformation models.
Thus, we assessed this sensitivity instead by Monte Carlo simulation. For each tissue
slice, landmarks on histology, paraffin, and tissue MR images were modeled as
,

, and

, respectively, where

variable sampled for each landmark with
and

and

is a 2D Gaussian random

components distributed as

is a 3D Gaussian random variable sampled for each landmark with ,

components distributed as

,
and

. For each tissue slice, the TRE measurements were

calculated for 5,000 sets of perturbed landmarks, and the standard deviation of these
measurements was calculated. The sensitivity of the TRE measurements to FLE was
quantified as the average of these standard deviations across all tissue slices. The number
of samples was chosen such that the standard error of the standard deviation would be 1%
of the standard deviation itself.

3.2.5 Spatial misalignment of tissue sections induced by microtome cutting
(Question 2)
To assess the strength of the front face assumption, we quantified the depth and
orientation of histology sections relative to the front face of the tissue slices from which
they were cut. The depth and orientation of each histology section were both estimated
based on the spatial relationship between two planes: the best-fit plane

through the

points identified on the front face of the tissue slice in the tissue slice MR image and the
plane

, an estimate of the tissue from which histology section was cut, computed as the
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best-fit plane through the landmark points

in the tissue slice MR image

corresponding to homologous landmarks visible on the histology image. The orientation
𝜃 of the -th histology section within the corresponding tissue slice was measured as the
angle between the normal of plane
where

and plane

: specifically, 𝜃

is the 3D unit normal of plane . The depth

of the -th histology

section from within the tissue slice was measured as the minimum, average and
maximum distances from the tissue points

(the intersection of plane

identified on tissue slice MR) to the front face plane
,
where

with tissue

: specifically,

and

is the distance from 3D point

,

to the plane . Tissue points on the tissue

slice MR image were identified by a threshold-based segmentation of the T1-weighted
tissue slice MR image using a manually selected threshold, followed by manual editing.
The sensitivity of these measurements to FLE also depends on the spatial
configuration and number of landmarks identified for each tissue slice. For example, the
estimated orientation of a section with few landmarks centrally clustered near the urethra
could be more sensitive to a misplaced landmark than that of a section with many widelyspaced landmarks. Because, to the best of our knowledge, there is no closed form
solution for calculating this sensitivity with respect to spatial distribution of the
landmarks, we assessed it instead by Monte Carlo simulation. For each tissue slice,
histology-visible landmarks on tissue slice MR images were modeled as
front face landmarks were modeled as 𝒇

, and

. As was done for Question 1, the

sensitivity of the depth and orientation measurements to FLE was measured as the mean,
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across all tissue slices, of the standard deviation of each measure across 5,000 sets of
perturbed landmarks.

3.2.6 Impact of reconstruction model on 3D reconstruction error (Question
3)
For a reconstruction algorithm that uses a particular reconstruction model (i.e. a
specified deformation model with or without the front face assumption), reconstruction
accuracy may decrease if the true spatial relationships between histology sections and the
tissue slices from which they were cut are different from the assumed constraints. While
the impact will depend on the 3D reconstruction methods used, it can be explored by
examining reconstructions based on the least-squares best-fit transformation of identified
homologous intrinsic landmarks under various reconstruction models. This reconstruction
approach was chosen because the reconstructions are parameter-free, they can be solved
analytically avoiding reconstruction errors due to local optima, and their accuracy
depends only on the number and placement of the fiducials and not on image properties.
The impact of the reconstruction model was quantified using the TRE (calculated
in a leave-one-out manner). This is analogous to the TRE described in Equation 3.1, but
with an expanded set of transformation types

that includes the deformation types

both with and without an additional constraint
imposed by the front face assumption. Because the TPS transformation is an interpolating
spline (i.e. source fiducials used to define the transformation are mapped exactly to target
fiducials) and target fiducials may lie at a non-zero depth from the front face, the front
face assumption cannot be directly applied. However, a transformation that does satisfy
the front face assumption can be realized by first projecting the target fiducials used to
111

define the transformation onto the front face, and then defining a TPS transformation
from source fiducials to the projected target fiducials. For rigid, similarity and affine
transformations, the constrained least-squares fitting (constrained by the front face
assumption) of transformed source fiducials to target fiducials is mathematically
equivalent to the unconstrained least-squares fitting of transformed source fiducials to the
projected the target fiducials. Thus, for the reconstructions where the front face
assumption was made, the target fiducials were projected onto the front face for all four
deformation models. The sensitivity of TRE to FLE was quantified as for the TRE in
Question 1.
In addition to quantifying the reconstruction error for these particular
reconstructions, we can also calculate the lower bound on reconstruction error as
measured by the identified landmarks for any possible reconstruction algorithm
constrained by a particular reconstruction model. This lower bound is quantified as the
FRE,
←

←

where

←

is the transformation of type

3.2

(the expanded set of transformation types

described in the previous paragraph) that best maps the vector of image landmarks
from the -th slice on the source modality
of image landmarks
and

ℎ

to the vector

from the -th slice on the target modality
tissue slices. Note that unlike the TRE, the FRE includes all

fiducials when fitting the transformation

←

, and represents a lower bound on the

TRE as measured using the identified intrinsic landmarks. Because the TPS
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transformation is an interpolating spline (i.e. source fiducials used to define the
transformation are mapped exactly to target fiducials) the FRE of an unconstrained TPS
transformation is 0, by construction, for any configuration of fiducials. The sensitivity of
FRE to FLE was quantified as for the TRE in Question 1.

3.2.7 Statistical analysis
Statistical analyses were performed in SPSS 20 (IBM, Chicago, USA). The depth
and orientation measurements were characterized with descriptive statistics (mean and
standard deviation) and 95% confidence intervals (CI) on the means were computed.
Correlations of the depth measurements with the orientation were assessed using pairwise
Spearman correlations.
The TRE measurements quantifying deformation during paraffin processing and
embedding, histological sectioning and mounting, and the combination of both processes
were characterized with descriptive statistics. We assessed differences in mean TRE
between the deformation models using separate 1-way repeated-measures analysis of
variance (ANOVA) tests with Greenhouse–Geisser correction for asphericity with the
deformation model as the factor. Pairwise post hoc analysis of adjacent levels (i.e. rigid
vs. similarity, similarity vs. affine and affine vs. TPS deformation models) was performed
by constructing 95% CI on the differences in mean TRE.
To assess the impact of reconstruction assumptions, we assessed the differences in
mean TRE using a 2-way repeated-measures ANOVA with a Greenhouse–Geisser
correction for asphericity, with the two assumptions (the deformation model assumption
and the front face assumption) as factors. Pairwise post hoc analysis was performed by
constructing 95% CI on the difference in FRE and TRE due to the front face assumption
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under each deformation model, and on the pairwise differences due to the deformation
model between adjacent levels with and without the front face assumption. Note that the
FRE of a reconstruction under stricter assumptions is mathematically guaranteed to be
equal to or higher than the FRE under relaxed assumption. For example, the rigid
deformation assumption is stricter than the affine deformation assumption, and the front
face assumption is stricter than eliminating that assumption.

3.3 Results
3.3.1 Tissue deformation due to histology processing (Question 1)
The key finding regarding tissue deformation was that modeling isotropic scaling
as in the similarity deformation model improved the mean TRE by 0.8–1.0 mm, while
modeling skew or thin-plate-spline deformation improved the mean TRE by less than 0.1
mm (bolded intervals in the first row of Table 3.1). The mean and standard deviation of
TRE for the three histology processes under the four deformation models are shown in
Table 3.2. For the combined deformation from tissue slice to histology section (shown in
the first row of Tables 3.1 and 3.2 and as a box plot in Figure 3.4), the similarity model
had a significantly lower mean TRE than the rigid model and the affine model has a
significantly lower mean TRE than the similarity model (by 0.9 mm and 0.06 mm
differences respectively), but post hoc analyses failed to show a statistically significant
difference between the affine and TPS deformation models (0.005 mm difference).
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Table 3.1: Post hoc analyses comparing mean TRE under varying deformation models:
95% CI of TRE for model A – model B. Key findings are shown in bold.
Deformation model A
Deformation model B
Tissue slice MR to histology images
Tissue slice MR to paraffin images
Paraffin to histology images

Rigid
Similarity
[0.78,0.98]
[1.07,1.31]
[0.12,0.20]

Similarity
Affine
[0.03,0.10]
[-0.04,0.01]
[0.02,0.07]

Affine
Thin-plate spline
[-0.02,0.02]
[-0.03,0.01]
[-0.01,0.02]

Table 3.2: Mean±SD TRE (mm) for four models of deformation during histological
processing stages. Statistical comparisons (performed between adjacent columns) where
the statistical tests failed to detect a significant difference are connected by lines.

Target registration error (mm)

First image Second image Rigid
Tissue slice MR Histology 1.44±0.73
1.71±0.82
Tissue slice MR Paraffin
Paraffin
Histology 0.42±0.27

Similarity
0.56±0.31
0.52±0.26
0.26±0.18

Affine Thin-plate spline
0.50±0.27
0.50±0.28
0.54±0.26
0.54±0.28
0.22±0.14
0.21±0.14

4
3
2
1
0
Rigid

Similarity Affine

TPS

Figure 3.4: Box plot showing the target registration errors of homologous landmarks
under four deformation models for the tissue deformation due to histological processing
and cutting. These results correspond to the descriptive statistics shown in the first row of
Table 3.1.
For the intermediate deformation due to paraffin embedding (second row of
Tables 3.1 and 3.2), the rigid model had a significantly higher mean TRE than the
similarity model (by a 1.2 mm difference), but post hoc analyses failed to show a
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statistically significant difference between the other models (differences < 0.03 mm). For
the intermediate deformation due to histological sectioning (third row of Tables 3.1 and
3.2), the affine model had a significantly lower mean TRE (by 0.05 mm) than the
similarity model and the similarity model had a significantly lower mean TRE (by 0.2
mm) than the rigid model. Post hoc analyses failed to show a statistically significant
difference between the affine and TPS deformation models (0.009 mm difference). The
sensitivities of the TRE to the observed FLE ranged from 0.05 to 0.13 mm.

3.3.2 Spatial misalignment of tissue sections induced by microtome cutting
(Question 2)
The key finding regarding the spatial misalignment of tissue sections was that the
95% confidence interval on the mean of orientation was 1.1 to 1.9° and the 95%
confidence interval on the mean of mean depth was 0.9 to 1.3 mm (bolded intervals in the
second column of Table 3.3). The distributions of depth and orientation measurements
are shown in Figure 3.5, and the correlation plots of orientation with the minimum
(Spearman r = -0.4), mean (Spearman r = 0.4) and maximum (Spearman r = 0.75) section
depth measures are shown in Figure 3.6. A subset of the tissue slices, chosen to illustrate
the range of depths and orientations, are shown in Figure 3.7 with the front face
the best fit plane to

and

superimposed. The standard deviation, 95% CI on the mean, and

sensitivity to FLE for the orientation, minimum section depth, mean section depth, and
maximum section depth are shown in Table 3.3.
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Figure 3.6: Correlation of minimum, mean and maximum histology section depths with
orientations. Tissue slices corresponding to sections marked with circles are shown in
Figure 3.7.
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Figure 3.7: Renderings of the spatial relationships between tissue slices, histology-visible
landmarks, front face plane and histology section planes for 10 tissue slices, ordered by
increasing mean depth from left to right. Each tissue slice is shown as a silhouette
projected along
, the cross-product of the front face and histology section
plane normals. With this projection, the front face plane and histology section plane
can be represented as solid and dashed lines respectively. The projected histology-visible
landmarks
are shown as circles.
Table 3.3: Descriptive statistics for the orientation, minimum depth, mean depth and
maximum depth of histology sections relative to the tissue blocks from which they were
cut. Sensitivity to FLE was quantified as the mean of the standard deviation of
measurements in a Monte Carlo simulation with perturbed landmark positions. Key
findings are shown in bold.

Orientation (°)
Minimum depth (mm)
Mean depth (mm)
Maximum depth (mm)

Standard deviation 95% CI on mean Sensitivity to FLE
0.9
0.30
[1.1,1.9]
0.4
[0.4,0.7]
0.12
0.4
0.05
[0.9,1.3]
0.6
[1.4,1.9]
0.13
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3.3.3 Impact of reconstruction model on 3D reconstruction error (Question
3)
The two key findings regarding the impact of the reconstruction model on 3D
reconstruction error were as follows. (1) Modeling isotropic scaling (as in the similarity
deformation model) improved the mean TRE by 0.5 to 0.7 mm if the front face
assumption was made and by 0.8 to 1.0 mm if the front face assumption was not made,
but modeling skew or thin-plate-spline deformation improved mean TRE by less than 0.1
mm (bolded intervals in Table 3.4). (2) Under a similarity deformation model, the front
face assumption increased the mean TRE by 0.6 mm to 0.8 mm (bolded interval in Table
3.5). The mean and standard deviation of TRE and FRE for the intrinsic landmark-based
reconstructions are shown in Tables 3.6 and 3.7, respectively. The 95% CI for the
difference in TRE and FRE due to deformation model and due to the front face
assumption are shown in Tables 3.4 and 3.5, respectively. The sensitivities of the TRE to
the observed FLE ranged from 0.10 to 0.13 mm. The sensitivities of the FLE to the
observed FLE were 0 mm (by construction) for the reconstruction model comprising the
thin-plate-spline deformation model without the front face assumption and 0.07 to 0.09
mm for the remaining reconstruction models.
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Table 3.4: Post hoc analyses comparing TRE/FRE after intrinsic landmark reconstruction
under varying deformation models: 95% CI of TRE/FRE for model A – model B.
Key findings are shown in bold.
Deformation model A

Rigid

Similarity

Deformation model B

Similarity

Affine

95% CI of mean TRE (mm) with front
face assumption
95% CI of mean TRE (mm) without
front face assumption
95% CI of mean FRE (mm) with front
face assumption
95% CI of mean FRE (mm) without
front face assumption

Affine
Thin plate
spline

[0.54,0.70] [0.01,0.06]

[-0.01,0.01]

[0.78,0.98] [0.03,0.10]

[-0.02,0.02]

[0.47,0.62] [0.03,0.06]

[0.04,0.07]

[0.75,0.94] [0.07,0.13]

[0.29,0.35] †

†. The FRE after an unconstrained thin-plate-spline transformation is 0 mm by construction.

Table 3.5: Post hoc analyses comparing TRE/FRE after intrinsic landmark reconstruction
under varying deformation models: 95% CI for of the difference between reconstruction
with and without the front face assumption.
Thin-plate spline
Rigid
Similarity
Affine
[0.62,0.77]
95% CI of mean TRE (mm) [0.36,0.46] [0.60,0.75] [0.63,0.77]
[1.00,1.15] †
95% CI of mean FRE (mm) [0.40,0.51] [0.68,0.83] [0.74,0.89]
†. The FRE after an unconstrained thin-plate-spline transformation is 0 mm by construction.

Table 3.6: Mean±SD TRE after intrinsic landmark reconstruction under varying
constraints. Statistical comparisons (performed between adjacent columns and rows)
where the statistical tests failed to detect a significant difference are connected by lines.
Rigid
With front face assumption 1.85±0.71
Without front face assumption 1.44±0.73

Similarity
1.23±0.48
0.56±0.31

Affine Thin-plate spline
1.20±0.47
1.20±0.47
0.50±0.27
0.50±0.28

Table 3.7: Mean±SD FRE after intrinsic landmark reconstruction under varying
constraints. All statistical comparisons (performed between adjacent columns and rows)
showed significant differences.
Rigid
With front face assumption 1.72±0.66
Without front face assumption 1.27±0.66

Similarity
1.18±0.48
0.42±0.25

Affine Thin-plate spline
1.13±0.48
1.08±0.50
0.32±0.19
0±0 †

†. The FRE after an unconstrained thin plate spline transformation is 0 by construction.
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3.4 Discussion
In vivo prostate imaging is increasingly being validated against 3D reconstructed
histology images [19-22]. Many algorithms for 3D reconstruction limit the degrees of
freedom by making simplifying assumptions about the cutting of histology sections from
the prostate gland which may affect the accuracy of reconstruction. This work explored
two such assumptions: the deformation model assumption that histology sections have
been deformed under a specified deformation model relative to the fixed tissue, and the
front face assumption that histology sections correspond to the front face of the tissue
slice from which it was cut. Operator variability in sectioning could lead to histology
sections that are not taken coincident with or parallel to the front face of the tissue slice,
and the cumulative deformation of the histology section due to dehydration, cutting,
water-bath expansion and slide-mounting processes may not be accurately modeled by
the chosen transformation. In this work, we quantified the spatial relationship between
histology images and the formalin-fixed tissue slices from which they were taken and
evaluated the impact of the reconstruction model assumptions on 3D reconstruction error.

3.4.1 Tissue deformation due to histology processing (Question 1)
Modeling the deformation due to paraffin processing and histological sectioning
as affine deformation yielded the lowest mean TRE (0.5 mm), although the difference
between the affine and similarity models was 0.06 mm, and our analysis failed to show a
statistically significant difference between the affine and TPS models. The 0.5 mm TRE
under the affine and TPS deformation model is larger than the 0.2 mm FLE, suggesting
that there is some submillimeter-scale non-affine deformation that occurs, but that is not
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well-captured by the interpolation of the TPS deformation model with the landmark
configurations identified in this work.
The analysis of deformation from tissue block MR to paraffin images suggests
that most of the deformation during the paraffin processing is characterized by isotropic
scaling, which is consistent with the dehydration that occurs during this process. The
analysis of deformation from paraffin to histology images suggests that some further
affine deformation occurs during histological sectioning, which is consistent with
anisotropic cutting forces that are applied during sectioning. The larger mean TRE across
all deformation models and the larger change in TRE with isotropic scaling for the
paraffin processing compared to the microtome sectioning suggests that paraffin
processing is the source of most of the observed deformation. Notably, the mean TRE of
the combined processes under the rigid deformation model is less than that of the paraffin
processing alone, which is consistent with expansion on the water bath partially
cancelling out contraction due to dehydration during paraffin processing.
To perform these analyses, at least five sets of homologous landmarks were
required; in particular, four sets of landmarks are required for a 2D−3D TPS
transformation to define a non-affine transformation and a fifth is needed to enable the
leave-one-out evaluation. Three histology sections were omitted from the analysis
because fewer than five sets of landmarks were identifiable.

3.4.2 Spatial misalignment of tissue sections induced by microtome cutting
(Question 2)
The histology sections were taken at a mean depth of 1.1 mm, and were taken at
an average angle of 1.5° relative to the front face. To illustrate these values, a histology
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section cut with the mean depth and the mean orientation from a hypothetical tissue slice
30 mm in diameter (typical for our sample of tissue slices), would be 0.7 mm from the
front face at the closest point and 1.5 mm from the front face at the furthest point.
The standard deviations of the orientation (0.9°) and depth measurements (0.4
mm) are greater than would be expected due to the 0.16 mm FLE alone, suggesting that
there is operator variability in the alignment of the tissue block face with the microtome
blade and in the depth of cutting. The variability in the minimum section depth suggests
that the variability in depth is not directly caused by variability in tissue block alignment;
if the variability in depth of cutting were the result of variability in tissue block alignment
followed by consistently cutting until a full cross-section of tissue were barely reached,
we would expect the minimum depth to have low variability. We speculate that the
continued cutting beyond the best-fit front face plane could be due to concavity of the
tissue front face that can be introduced during paraffin embedding, which would require a
deeper cut to achieve a full face. This continued cutting could also be due to the practice
of removing the paraffin block from the microtome to cool the cutting surface with ice,
leading to variability in the orientation when the block is replaced.
The impact of the observed variability in depth and orientation on the relative
spatial relationship of histology sections in a 3D reconstruction can be seen in Figure 3.8,
where the tissue slices were sliced to be parallel at an even spacing (by embedding the
specimen in an agar gel and cutting it on a rotary slicer), but after an alignment of tissue
slice MR images (and accompanying registered histology sections) with an MR image of
the intact ex vivo specimen with a 0.5 mm TRE, the non-parallel and uneven spacing of
the three midgland histology images can be seen.
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Figure 3.8: 3D reconstruction of three histology sections aligned (with a mean TRE of
0.5 mm) to an anterior view of 3D surface rendering of the corresponding intact ex vivo
prostate gland with seminal vesicles, illustrating the potential for non-parallel, nonevenly-spaced histological tissue sections.

3.4.3 Impact of reconstruction model on 3D reconstruction error (Question
3)
If a reconstruction algorithm used a reconstruction model wherein histology
sections corresponded to the front faces of tissue slices, the lower bound of the
achievable mean TRE for any of the tested deformation models would be 1.1 mm (for the
affine and TPS deformation models), suggesting that to achieve submillimeter
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reconstruction error, the front face assumption should not be made. For a reconstruction
model unconstrained by the front face assumption using an affine deformation model, the
lower bound of the mean TRE is 0.3 mm (the corresponding lower bound of the mean
TRE for the TPS model is 0 mm by construction and therefore does not provide for an
informative comparison). The improvement in TRE for modeling isotropic scaling (from
rigid to similarity deformation models) was 0.78 to 0.98 mm when the front face
assumption was not made, but the improvement from the similarity deformation model to
the more flexible affine and TPS deformation models was less than 0.1 mm, suggesting
that a similarity transformation may be sufficient. Note that this reconstruction error is
only a component of the overall registration error from the histology images to in vivo
images; Groenendaal et al. [5] and Orczyk et al. [23] presented two methods for the
registration of reconstructed ex vivo images to in vivo images with reported errors of 2.1
mm and 1.6 mm, which would, under the assumption that these errors are independent, be
added in quadrature with reconstruction error.
It is important to interpret these reconstruction errors in the context of the
application in which the reconstructions could be used. A recent model (described in
Chapter 2) quantifying the impact of registration error on the statistical power (and thus
the required sample size) of imaging validation studies [14, 15] can be used to relate the
differences in reconstruction error in these experiments to an appropriate application.
This can be illustrated through the scenario of an imaging validation study testing for
differences between the mean imaging signal of tumors and normal tissue regions, under
the assumptions that the tumors are spherical foci of the smallest clinically significant
volume (0.2 cm3) [24] and that reconstruction error can be modeled as an isotropic
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Gaussian. For this scenario, our reconstruction is combined with a registration of
reconstructed histology to in vivo images with mean TRE 2.1 mm (as reported by
Groenendaal et al. [5]). In this scenario, we can compare the required sample sizes for the
imaging validation study over a range of reconstruction errors as compared to an
arbitrarily chosen baseline. In this illustration, we use landmark-based reconstruction
under the similarity deformation model and the front face assumption with a mean TRE
of 1.23 mm as the baseline. The relative required sample sizes for reconstruction errors
ranging from 0.3 – 2.0 mm mean TRE are shown in Figure 3.9, with each of the assessed
combinations of assumptions marked. Between the worst and best performing sets of
assumptions, there is a 1.5-fold difference in required sample size. Based on per-patient
costs of $10,000, from an ongoing imaging validation study in our centre with 66
subjects, a 1.5-fold reduction in sample size could yield savings of $220,000 for the same
statistical power.
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Figure 3.9: Sample sizes, relative to an arbitrarily chosen baseline, for imaging
validation studies of image signal differences between cancerous and background tissue
for 0.2 cm3 cancer foci, under assumptions that foci are spherical and reconstruction error
can be modeled as a translation error distributed as a 3D Gaussian and is combined in
quadrature with a 2.1 mm TRE due to registration to in vivo imaging. Reconstructions
under differing deformation assumptions, and with or without the front face assumption
are indicated, with the reconstruction using a similarity transform and the front face
assumption arbitrarily chosen as the 100% baseline reference.

3.4.4 Limitations of cutting measurement
The conclusions of this work should be considered in the context of the
limitations of the performed experiments. This study had four notable limitations. First,
the process of sectioning tissue for histological examination varies between laboratories
and many aspects of the processing can affect the sectioning distortion, and possibly the
amount of trimming before a full cross-section is successfully cut. Examples include
tissue type, embedding medium, water-bath duration and temperature [21], knife quality
and angle [25], and possibly operator skill. It is also unclear how these results would
generalize when prostate tissue slices are cut into quarters before paraffin processing, an
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approach adopted in many clinical laboratories. While this study used histological
sections sectioned by multiple histotechnologists, the use of a consistent processing
protocol in a single clinical laboratory prevented us from assessing the impact of these
other factors on the identified spatial relationships. A second limitation of the study is
that the fidelity of the TPS deformation to the true underlying deformation is limited in
part by the number of homologous landmarks identifiable on tissue slice MR, histology
and paraffin block face images. It is not clear if the 7–15 landmarks identified per section
are sufficient to characterize the unknown underlying deformation. If 7–15 landmarks are
too few, then the TPS model may not capture the underlying deformation (resulting in a
higher reported TRE) even if the deformation could be well-described by a TPS model. A
third limitation of the study is that only one non-linear deformation model was assessed
in this study, although there are an infinite number of such models. This work does,
however, suggest an upper bound of less than 0.5 mm for the possible improvement that
could be derived from better non-linear deformation models. Fourth, our assessment of
the impact of the reconstruction errors on the statistical power of imaging validation
studies examines the histology image reconstruction in isolation; if the reconstruction
were followed by additional processing, such as 3D image registration, the impact of the
reconstruction errors would be challenging to isolate, and was not assessed by this study.
In conclusion, this work addressed three questions, as follows. (1) How does
prostate tissue deform during histology processing? (2) What spatial misalignment of the
tissue sections is induced by microtome cutting? (3) How does the choice of
reconstruction model affect the accuracy of histology reconstructions? The key
conclusions from these investigations are that for accurate 3D reconstruction of whole-

128

mount histology, the reconstruction model should not assume that histology corresponds
to the front face of the tissue slices from which it was cut as such an assumption yields a
higher mean TRE by 0.6 to 0.8 mm, and should use a similarity deformation model as the
mean TRE under this model is 0.5 to 0.7 mm lower than that of a rigid deformation
model and within 0.1 mm of the affine and thin-plate-spline deformation models with
more degrees of freedom. The mean TRE of 0.56 mm was measured for the least-squares
best-fit fiducial-based reconstruction using a similarity deformation model without the
front face assumption. Additionally, our characterization of the misalignment of histology
sections revealed a mean section depth of 1.1 mm (with maximum depths as high as 2.8
mm) and a mean section orientation of 1.5° (with orientations as high as 4.2°), which
may support commensurate heuristics in 3D reconstruction. Finally, in the context of
imaging validation studies testing for imaging signal differences between cancerous and
background tissue for the smallest clinically significant prostate cancer foci by
correlation with reconstructed histology images, the range of reconstruction errors seen in
this work would result in a 1.5-fold difference in the required sample size for such a
study under our modeling assumptions, potentially translating to a difference of hundreds
of thousands of dollars.
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Chapter 4.
Registration of prostate histology images to ex vivo MR
images via strand-shaped fiducials †

4.1 Introduction
The registration of histology to in vivo images faces several challenges. First, it is
a multi-modality registration (e.g. from histology to MRI). Second, deformations induced
by the imaging (e.g. due to the MRI endorectal receive coil), resection, and fixation
processes are best modeled by non-rigid transformations. Finally, each section is taken
from a variable position and orientation within a separate 3−5-mm-thick tissue block, so
adjacent histology images are sparsely and irregularly spaced, and non-parallel. The
variability and sparseness of histology image spacing introduces substantial challenges to
the reconstruction of a 3D histology image for 3D registration. Differences in image
content and scale, and substantial non-linear deformations introduce challenges to direct
2D to 3D registration.
Acquiring ex vivo prostate 3D images can address these challenges. In vivo to ex
vivo image registration can compensate for tissue distortion due to surgical resection and
fixation. Histology to ex vivo image registration can then compensate for slicing
variability and the reduced distortion due to tissue shrinkage and sectioning during
† A version of this chapter has been published: E. Gibson, C. Crukley, M. Gaed, J. A. Gómez, M. Moussa,
J. L. Chin, G. S. Bauman, A. Fenster, A. D. Ward, “Registration of prostate histology images to ex vivo MR
images via strand-shape fiducials.” J Magn Reson Imaging 36:6 (2012).
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histoprocessing. Many previous methods (described in detail in Section 1.2.3.3) approach
histology to ex vivo image registration by guiding the slicing of the ex vivo specimen, in
order to approximately constrain the positions and orientations of the tissue slices from
which each section was cut, or by retrospectively registering histology-ex vivo MR
images using manual or automated image-based registration methods (with additional
images optionally acquired during specimen preparation). None of the existing work
meets the criteria for histology-imaging registration discussed earlier in Section 1.2.2.3:
(1) permitting specimen slicing and sectioning according to normal clinical pathology
protocols, (2) providing registrations whose accuracies are robust to varying appearance
of the prostate on imaging and pathology, (3) providing a quantitative evaluation of the
registration error using a 3D target registration error (TRE), and supporting wide
implementation by avoiding the use of specialized equipment.
In this study, we present and evaluate a method for registration of histology to ex
vivo prostate MR images, developed in our laboratory, that takes steps towards meeting
these criteria. The method utilizes strand-shaped fiducial markers that allow the
determination of the location and orientation of each section without constraining the
slicing of the specimen. Using non-anatomical fiducials provides robustness to variations
in the appearance of the prostate on MR and histology images. Our registration method
was evaluated using intrinsic anatomical landmarks and compared to previous methods.
We also demonstrated that a proposed local registration optimization can be used to
improve registrations provided by previous methods.
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4.2 Materials and methods
This study was conducted with the approval of the Human Subjects Research
Ethics Board of our institution and the informed consent of all subjects.

4.2.1 Materials
We obtained nine prostate specimens after radical prostatectomy with the
following inclusion criteria: age 18 years or older, and histologically confirmed clinical
prostate cancer stage T1 or T2. The exclusion criteria were: prior therapy for prostate
cancer, use of 5-alpha reductase inhibitors within 6 months of the study start, inability to
comply with preoperative imaging, allergy to contrast agents, sickle cell or other
anemias, hip prosthesis, sources of artifact within the pelvis, and contraindications to
MRI.

4.2.2 Ex vivo MR imaging
MR images were acquired for all specimens using a Discovery MR750 (GE
Healthcare, Waukesha, WI, USA) at 3 T. After resection, formalin fixation (10%
buffered formalin for 48 hours), and marking with fiducial strands [1], specimens were
immobilized in a syringe filled with Christo-Lube (Lubrication Technology Inc., Franklin
Furnace, OH, USA) to provide a black background and minimize boundary artifacts.
Using an endorectal coil (Prostate eCoil, Medrad, Inc., Warrendale, PA, USA) placed
flush with the syringe, specimens were imaged using a T1-weighted (3D SPGR, TR 6.5
ms, TE 2.5 ms, bandwidth ±31.25 kHz, 8 averages, FOV 140×140×62 mm, slice
thickness 0.4 mm, slice spacing 0.2 mm, 256×192 matrix, 312 slices, flip angle 15°, 25
min) protocol used in the registration and validation and a T2-weighted (3D FSE, TR
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2000 ms, TE 151.5 ms, bandwidth ±125 kHz, 3 averages, FOV 140×140×62 mm, slice
thickness 0.4 mm, slice spacing 0.2 mm, 320×192 matrix, 312 slices, 25 min) used only
in the validation. Each specimen was then coarsely sliced into whole-mount tissue blocks
4.4 mm thick, as required by clinical protocol. As part of another study from which our
specimens were obtained, each specimen was sliced using image guidance to yield cuts
coincident with in vivo MR imaging planes [1]. For each specimen, all tissue blocks were
separated and immobilized in tissue processing cassettes, immersed in Christo-Lube, and
imaged using the same coils. MR protocols were as above but with a larger FOV to cover
the separated tissue blocks. These images are referred to as block MR images hereafter.

4.2.3 Digital histology imaging
After standard whole-mount paraffin embedding, a 4-μm-thick section was cut
from each midgland tissue block and stained with hematoxylin and eosin. The resulting
34 slides were digitized on a ScanScope GL (Aperio Technologies, Vista, CA, USA)
bright field slide scanning system with a 0.5 μm resolution, and downsampled to a 30 μm
resolution.

4.3 Methods
The overall process of our method is outlined in Figure 4.1.
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Figure 4.1: Specimen processing overview.

4.3.1 Fiducial marking
Two sets of strand-shaped fiducials visible on T1-weighted MR and histology
images (details in [1]) were added to all specimens, running from apex to base: 7 surfacemounted fiducials and 3 internal fiducials. External fiducials consisted of cylindrical
strands of lamb kidney cortex (16-gauge biopsy, 31±6 mm mean±standard deviation (SD)
length) infused with a 1:40 solution of Magnevist (Bayer AG, Germany) gadolinium
contrast and 10% buffered formalin. They were rigidly affixed to the surface of the
specimen with Loctite 411 toughened, heat-resistant, ethyl cyanoacrylate adhesive
(Henkel Inc., Germany) along the entire length of the fiducial. Internal fiducials consisted
of cotton thread infused with a 1:40 solution of Magnevist and blue Tissue Marking Dye
(Triangle Biomedical Sciences Inc., Durham, NC, USA). Internal fiducials were inserted
by (1) introducing an 18-gauge cannula and stylet with a Quincke-type point (BD
Medical Inc, Franklin Lakes, NJ, USA), which is designed for clean tissue separation
without damage, (2) removing the stylet, (3) inserting the thread through the cannula and
(4) removing the cannula leaving the thread in place. The resiliency to deformation of
formalin-fixed prostate tissue and the flexibility of the cotton thread minimize the
potential for distortion of the prostate during the insertion of the internal fiducial.
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Given two potential planes in the MR image, each fiducial would intersect the two
planes at two different points in the planes. Thus, the intersections of all fiducials on any
given plane form a set of points with a particular configuration. The layout of fiducials
was designed to maximize the difference in the configurations of points for the possible
cutting planes. This facilitates the registration of each histology image to the correct
plane in the MR image by matching the configuration of fiducial cross-sections. The
layout of the fiducials is illustrated in Figure 4.2. Neighboring pairs of surface-mounted
fiducials were placed at approximate 45° angles to each other, with 4 roughly inferiorsuperior (

) and 3 oblique (

) fiducials. This makes the

configuration of fiducial cross-sections on an intersecting plane sensitive to the inferiorsuperior position and orientation of the plane.
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Figure 4.2: Fiducial configuration showing prostate surface (a and b) and a cross-section
along the dotted line (c). These fiducial markers are visible on histology images (d).
Insets (e and f) show enlarged views of h10 and h1 respectively.
The centerlines of fiducial tracks were manually localized on the T1-weighted
MR images at ~1 mm intervals, using 3D Slicer (Surgical Planning Lab, Harvard Medical
School, Boston, USA), and interpolated to ~0.2 mm intervals using cubic splines.
Fiducials, shown in Figures 4.2e-f and 4.3c-d, were readily identifiable on histology and
MR images. In some histology images, some fiducial cross-sections were absent due to
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f

the section not intersecting the fiducial or due to detachment during processing. These
sections were registered using only the remaining fiducial cross-sections.

d

c

a

b

Figure 4.3: Co-registered T1-weighted MR images of the whole specimen (a) and a
tissue block (b). Barely visible (e.g. large arrows) or invisible (e.g. small arrows) ducts on
the whole specimen image are visible on the tissue block image due to Christo-Lube
contrast. Labeled arrows show the appearance of surface-mounted (c) and internal (d)
fiducials, respectively, on the T1W MR image.

4.3.2 2D−3D histology to MR image registration algorithm
4.3.2.1 Definitions of algorithm terms
On MR images, the -th fiducial track forms a 3D parametric curve
, as illustrated on

in Figure 4.2b. On the histology image, the cross-section of

the -th fiducial gives a 2D point

(Figure 4.2d), which corresponds to some 3D point

along the corresponding fiducial track. For the 10 fiducial cross-section points in each
histology image, any possible correspondence can be encoded as a 10D vector
. For example,

denotes that the

first fiducial cross-section on the histology image corresponds to the point 40% along the
length of the first fiducial track on the MR image, measured from the apex, and all other
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cross-sections correspond to the midpoints of their respective tracks. Each
least-squares best-fit 2D−3D affine transformation

determines a

mapping fiducial cross-sections on

the histology image to their corresponding points on the MR image.

4.3.2.2 Algorithm step 1: identify an initial plane on MR image
corresponding to each histology image
Finding the MR image plane corresponding to a histology image involves finding
the correspondence vector , defined as
4.1
yielding the smallest squared residual error after the affine transformation

which

transforms the histology image to its corresponding MR image plane.
An exhaustive search of the 10D correspondence space to find this vector would
be computationally prohibitive, and a greedy minimization may tend to find local minima
far from the global minimum. For an efficient, broad search of the space of
correspondences, we manually selected a triplet of fiducials

corresponding to

three dimensions of , defining a 3D correspondence vector
unique 2D−3D affine transformation

, and the

that maps

to

. We performed an exhaustive search of this reduced space
of 3D correspondence vectors. This yielded a 3D correspondence vector with the
minimal residual computed from all 10 fiducials,
4.2
where

is the closest point to

on parametric curve
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.

The fiducial triplets were manually selected to include widely spaced fiducials,
including at least one diagonal fiducial. When all fiducials were present, the triplet
(i.e.,

,

, and

points

in Figure 4.2(a-b)) was used. The plane defined by the
was taken to be the MR image plane corresponding to the

histology image.

4.3.2.3 Algorithm step 2: compute an affine transformation mapping each
histology image to its corresponding MR image plane
The next step was to compute a 10D correspondence vector , defining an affine
transformation

(which utilizes the spatial information provided by all 10 fiducial

markers) mapping the histology image onto the MR image.
We construct
section

based on the plane defined in step 1, such that each fiducial cross-

corresponds to the closest point on

to the defined plane.

is defined as,

4.3

4.3.2.4 Algorithm step 3: refine the fiducial correspondence using local
optimization and compute affine transformation
is intended to yield a near-optimal histology to MR image alignment. To find
the optimal correspondence vector , we used a Nelder-Mead greedy simplex
minimization [2] of the squared residual FRE in the 10D correspondence space (Equation
4.1), initialized with . This yields the correspondence vector at the nearest optimum in
the 10D correspondence space, giving a corresponding affine transformation.
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4.3.3 Validation
TREs for all specimens were used to evaluate the registration [3]. TREs were
calculated as the 3D post-registration misalignments of small anatomical landmarks
identified on histology and MR images.
Identifying homologous landmarks on histology and MR images is
challenging [4] due to a large 3D search space, a lack of 3D context on histology images
and few identifiably homologous structures. We developed a protocol for identifying
such landmarks on histology and whole-gland ex vivo MR images by constraining the
search using an approximate alignment informed by "block MR" images of the sliced
tissue blocks, acquired using the same MR imaging protocol described above. The
smaller search space and higher contrast features (as shown in Figure 4.3) due to
infiltration of Christo-Lube into ducts exposed by specimen slicing facilitate aligning
histology to block MR images; similar image content and 3D context facilitate aligning
block to whole-gland MR images. Landmarks included the centers of atrophic ducts,
cysts and corpora amylaceae (or parts thereof) with diameters less than

, which are

large enough to be resolved on the ex vivo MR images (voxel size 0.27×0.27×0.20 mm).
Homology of these landmarks was evaluated based on spatial relationships with nearby
salient features. Potential landmarks without nearby salient features, or for which the
nearby salient features did not uniquely constrain the correspondence, were not included
as landmarks. Landmarks were identified by one observer under advisement from 2
genitourinary pathologists and 1 radiologist with expertise in prostate imaging.
Measurement of TREs based on localized landmarks incorporates error from the
registration and error in localizing the landmarks. The target localization error (TLE) of
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landmarks on each modality was quantified as an unbiased estimator of the standard
deviation of repeated localizations of the same landmark [3], at least one day apart:

4.4

where

is the -th localization of the -th fiducial,

landmarks, and

repeated localizations of each landmark. The TLE on histology images (

) used

landmarks pre-specified on MR images, while the TLE on MR images (

) used

landmarks pre-specified on histology images. Landmarks for this assessment comprised
all landmarks from 3 blocks from 3 randomly chosen specimens for calculating
and a separate 3 blocks for calculating

,

.

4.3.4 Experiments
We conducted four experiments: (1) to evaluate the proposed method, (2) to
compare the accuracy of the proposed method, where the plane selection and registration
is informed by fiducial correspondence, to a previous approach, where the plane selection
is informed by image-guided slicing, (3) to determine the reduction in TRE provided by
the internal fiducials, and (4) to determine the reduction in TRE provided by the
augmentation of the proposed method to use an additional set of images as an
intermediate registration target.
4.3.4.1 Experiment 1: To evaluate the proposed method
To assess the accuracy of the proposed method, TREs were calculated after steps
2 and 3 of the algorithm. We documented the fiducial cross-sections that were absent on
histology images and correlated the number of remaining fiducials with the mean TRE.
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To assess the anisotropy of the TRE, we analyzed the post-registration misalignment
vector for each landmark pair, denoted

for the -th landmark pair, in the MR image

coordinate space. We computed the 3D principal component analysis (PCA) of these
vectors using MATLAB (The Mathworks Inc., Natick, MA) yielding the directions of
maximum variance, and the variance of error along these directions. An isotropic TRE
would yield 3 equal variances. To examine anisotropy related to the histology images,
which are not all parallel, we also decomposed each

into in-plane and out-of-plane

components, and computed an aggregate in-plane and out-of-plane variance:
4.5
4.6
where

is the unit normal of the corresponding histology plane, and N = 184 fiducials.

For an isotropic TRE, in-plane variance, being the sum of two equal 1-dimensional
variances, would be twice the size of the out-of-plane variance.
4.3.4.2 Experiment 2: To compare the proposed method to a previous method based on
image-guided slicing [1]
The proposed method was compared to a previous method [1] to evaluate which
had a lower mean TRE. Because the specimens used in this study were obtained from
another study where specimens were sliced using image-guided slicing defined in the
previous method, slicing planes from the previous method were known. In the previous
work, these slicing planes were taken to be the MR image plane corresponding to the
histology image. To directly compare the previous method to the proposed method,
algorithm steps 2 and 3 were applied to these slicing planes to yield affine registrations.
This was accomplished by defining

to contain three non-collinear
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points on the slicing plane for algorithm step 2 for the previous method. A TRE was
calculated after step 2, to compare the previous method against the proposed method, and
after step 3, to evaluate the effect of local optimization on the previous method.
4.3.4.3 Experiment 3: To compare the accuracy of the method with and without the use
of internal fiducials
To assess the effect of using only surface-mounted fiducials (to reduce the
processing time required and render the method suitable to pathology environments
prohibiting internal fiducials), we computed a TRE for the proposed algorithm, excluding
the internal fiducials, with and without the local optimization.
4.3.4.4 Experiment 4: To evaluate the effect of incorporating information from block MR
images
Since each section is cut from a tissue block, each histology image corresponds to
the prostate region corresponding to that block. However, in algorithm step 1, the entire
lengths of the fiducial strands, including parts outside of the corresponding block, are
searched. In principle, step 1 could associate a histology image with a plane outside the
block from which it came. To overcome this potential problem, previous approaches [411] have used additional images as intermediate registration targets. Testing this
approach, we replaced algorithm step 1 with a procedure, based on [11], wherein the
plane search described in step 1 was run for each histology image using the
corresponding block MR image taken prior to sectioning. As in [11], least-squares bestfit rigid transformations of the fiducial markers was used to place these planes within the
whole-gland MR image. We subsequently carried out algorithm steps 2 and 3 as above,
computed a TRE, and compared it to that yielded by the proposed method.
146

4.3.5 Statistical analysis
Statistical analyses were performed in Prism 5.04 (Graphpad Software, Inc., San
Diego, USA). To compensate for the positive skew in the measured TREs, data were
transformed using a square-root function. To compare the mean TREs of the different
methods, we used a repeated-measures ANOVA of the transformed TREs from each
method, followed by post hoc analyses with Bonferroni multiple-comparison correction.
After the square-root transformation, the TRE distribution for the proposed method
without internal fiducials remained non-normal (D'Agostino & Pearson omnibus
normality test; p<0.0001). To confirm the findings involving this method, Wilcoxon
matched-pairs signed-rank tests were performed.
To assess relative accuracy, pairwise post hoc analyses tested for a difference in
the mean TRE between the proposed method and three alternative methods: imageguided slicing, tissue block imaging, and the proposed method without internal fiducials.
To evaluate whether the local optimization improved the previous image-guided slicing
method [1], post hoc analysis tested for a difference in the mean TRE of the previous
method with and without local optimization. Confidence intervals on these differences
were estimated using the same analysis on the untransformed data; these intervals must
be interpreted with the non-normality of the underlying data in mind. To assess the
interchangeability of initialization methods, we generated two Bland-Altman plots
comparing the proposed method to the image-guided method with local optimization, and
the tissue block imaging method with local optimization.
Additionally, the accuracy of the proposed method inside and outside the
peripheral zone was compared using an unpaired t-test omitting landmarks with indefinite
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classification, and the accuracy of the proposed method with and without internal
fiducials omitting sections with missing fiducial cross-sections was performed using a
paired t-test. Finally, to assess the robustness of the proposed method to missing fiducial
cross-sections, a Spearman correlation test was performed between the TRE for each
landmark and the number of fiducial cross-sections on the section containing the
landmark.

4.4 Results
The proposed method required ~3 hours per specimen including fiducial
application (90 minutes), imaging (80 minutes), fiducial localization (12 minutes) and
registration computation (59±11 seconds). Our application of previous methods using
block MR images [11] and image-guided slicing [1] required ~5 and ~11 hours per
specimen, respectively, for all processing steps.
The landmark localization protocol yielded 3–7 homologous landmark pairs on
each of 3–5 sections per specimen, totaling 184 landmarks on 34 histology images.
Figure 4.4 shows histology and MR images of 5 homologous landmark pairs and nearby
salient features, confirmed by a genitourinary pathologist (J.A.G.) and a radiologist
specializing in prostate imaging (C.R.). These landmarks were located in the peripheral
zone (75/184), transitional zone (66/184), central zone (8/184) and anterior fibromuscular
stroma (11/184); 24/184 landmarks were not definitively categorized. The spatial
distribution of the landmarks is illustrated in Figure 4.5, showing the landmarks evenly
distributed throughout the posterior midgland. Few landmarks were near the apex and
base, because only midgland sections were included in this analysis, and few landmarks
were near the anterior due to a lack of salient features in the anterior fibromuscular
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stroma. The TLE on histology images was 50 μm, relative to a pixel size of 30×30 μm2.
The TLE on MR images was 0.16 mm, relative to a voxel size of 0.27×0.27×0.2 mm3.
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Figure 4.4: Homologous landmark pairs (large white arrows), used for evaluation of the
registration algorithm, shown on histology images (top) and on the corresponding oblique
slices on T2 (middle) and T1 (bottom) MR images. Small black arrows denote salient
nearby features used to corroborate the established landmark correspondence. Salient
features in these images include corpora amylaceae (labeled *), the urethra (labeled +),
extrinsic fiducials (labeled °) and atrophic ducts (unlabeled).
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1
0.5within the specimen normalized such that the
shown with its AP, LR and IS position
0 from 0 to 1 for each specimen. Each one is
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marked as to the anatomical zone where it is located: peripheral zone (PZ), transition
zone (TZ), central zone (CZ) and anterior fibromuscular stroma (AFS). The 24 landmarks
with indefinite classification were omitted.
Three histology and MR images co-registered using the proposed method are
shown in Figure 4.6. The proposed method yielded a mean TRE of 0.71 ± 0.38 mm. An
unpaired t-test failed to show a significant difference between the mean TRE inside and
outside the peripheral zone (p=0.75, 95% CI,-0.14 to 0.11 mm). This TRE is anisotropic,
with variances of 0.33, 0.13 and 0.09 mm2; the principal direction of variation is [0.45,0.12,-0.88], which is not aligned to the MR image axes. The out-of-plane variance is 0.39
mm2, larger than the largest variance of the 3D PCA. The in-plane variance is 0.24 mm2,
a factor of 3 lower than the 0.78 mm2 that would be expected for an isotropic TRE.
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Figure 4.6: Three histology images registered to ex vivo MR images using the proposed
registration method. Example validation landmarks are shown by arrows.
The proportion of fiducial cross-sections absent on histology images was 20/340,
7 due to the section not passing through the fiducial, and 13 due to detachment during
specimen cutting or processing. As a result, 7/34, 5/34 and 1/34 sections were registered
using 9, 8 and 7 fiducial cross-sections, respectively. The Spearman correlation test failed
to show a correlation between TRE and the number of fiducial cross-sections used
(p=0.25, 95% CI for r: -0.23 to 0.06).
The mean and standard deviation of the TREs before and after local optimization
are shown in Table 4.1 for four registrations: the proposed method, the proposed method
without internal fiducials, the method using tissue block imaging, and the method using
image-guided slicing. The TRE data are shown in Figure 4.7 for the five registrations
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examined in the discussed experiments, and the post hoc analyses are summarized in
Table 4.2.
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Figure 4.7: Box plot of TREs for five registrations with 5–95% whiskers.
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Table 4.1: Mean TREs of the registration methods with and without local optimization.
Proposed
method

Proposed
Image-guided Tissue block
method without
slicing
imaging
internal
method
method
fiducials

Mean±SD TRE (mm)
0.76±0.43
without local optimization
Mean±SD TRE (mm) with
0.71±0.38
local optimization

1.21±0.74

0.86±0.50

0.95±0.84

0.71±0.37

0.70±0.36

0.92±0.82

Table 4.2: Statistical analysis of accuracy of methods. Each row represents a paired t-test
of TREs of landmarks between two methods.
p-value
h0:

95% CI (mm)
of

Method A

Method B

Image-guided slicing

Proposed w/ LO
Image-guided slicing
w/ LO

< 0.0001

[0.38,0.63]

< 0.0001

[0.38,0.62]

Proposed w/ LO

> 0.05

[-0.12,0.13]

Proposed w/ LO

< 0.0001

[0.09,0.34]

Proposed w/ LO

> 0.05

[-0.13,0.11]

Image-guided slicing
Image-guided slicing
w/ LO
Proposed w/ LO w/o
internal
Tissue block imaging
w/ LO

The proposed registration had a lower mean TRE (p<0.0001) than that using
image-guided slicing. Applying local optimization to the method using image-guided
slicing improves the TRE (p<0.0001). The post hoc analysis failed to show a statistically
significant difference between the mean TRE of the proposed registration and the method
using image-guided slicing with local optimization (p>0.05, 95% CI, -0.12 to 0.13 mm).
A Bland-Altman comparison of these methods is shown in Figure 4.8a.

153

1.50

0.2
0.1
0.0
-0.1

0.0

0.5

-0.2

1.0

1.5

Average TRE (mm)

2.0

2.5

TREP-TRE IGSLO (mm)

TREP - TRE TBI (mm)

1.5
1.0
0.5

0.25
0.2
0.1
0.0
-0.1
-0.2

1.0

1.5

2.0

2.5

Average TRE (mm)

-0.25
-1.50

a

0.5

b

Figure 4.8: Bland-Altman plots comparing TREs with local optimization after
initializations using the proposed method (TREP) and (a) the tissue block imaging
(TRETBI) and (b) the image-guided slicing with local refinement (TREIGSLO). Each point
represents one landmark pair.
The mean TRE for the proposed method with internal fiducials was lower than
that without internal fiducials (p<0.0001 using ANOVA post hoc analysis, p=0.0006
using non-parametric confirmation). Notably, for the method without internal fiducials,
all 9 of the outliers seen in Figure 4.7 are from sections with missing fiducial crosssections. Omitting sections with missing fiducial cross-sections, the difference in mean
TRE with (0.67 mm) and without (0.75 mm) internal fiducials was less significant
(p=0.024, 95% CI,0.01 to 0.14 mm using t-test; p=0.15 using non-parametric
confirmation).
Post hoc analysis comparing the proposed method to the method incorporating
block MR images failed to show a statistically significant difference between the mean
TREs (p>0.05, 95% CI,-0.13 to 0.11 mm). A Bland-Altman comparison of these methods
is shown in Figure 4.8b.

4.5 Discussion
In this chapter, we proposed a method for registration of histology to ex vivo MR
images with submillimeter accuracy that reduces the processing time over a previously

154

adopted method. Our registration uses a controlled spatial configuration of nonanatomical fiducials to address the challenges of 2D to 3D multimodality registration. We
register histology to ex vivo MR images acquired using a similar arrangement to that used
in clinical in vivo prostate MRI (3 T magnet, T1- and T2-weighted sequences, endorectal
receive coil). Thus, our method addresses many challenges of the full registration of
histology to in vivo MR images, leaving as the remaining step (outside the scope of the
present work) a single-modality 3D ex vivo-in vivo prostate MR image registration, a task
addressed in previous work [4] using standard methods. Furthermore, the histology to ex
vivo image registration can be used directly in validation studies of ex vivo imaging (e.g.
[12]).
While some disruption of clinical workflow is inevitable when using an
intermediate registration to ex vivo imaging, our method reduces the extra-clinical
processing time required to collect data for registration from 11 hours using a previous
workflow [1] to 3 hours; a reduction of 70%. This 3-hour processing time could be
integrated into existing clinical workflows with no delay to the clinical diagnosis by
scheduling the processing around specimen batch processing schedules, which was not
generally possible with the 11-hour workflow.
The maximum acceptable registration error for registration-based validations
depends on application-specific information regarding (a) the size of the regions of
interest to be registered, (b) the imaging properties of these regions, (c) the type of
analysis and (d) the power of the analysis. Large registration error may constrain the size
of region that can be included in an analysis [13, 14], or may underestimate the
differences between benign and cancerous tissues on imaging [15]. When the registration
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error is unknown, studies must err on the side of caution, excluding more small regions
than necessary, or searching for smaller effects than necessary. The measurement of TRE
is challenging [4] as it requires the identification of homologous landmarks in histology
images and other medical images, and it is therefore frequently omitted in analyses of
these registration techniques [4, 16, 17]. In prostate histology to ex vivo MR image
registration, few efforts have been made to report TRE: Kimm et al. [18] reported a 2D
TRE of 0.86 mm based on 3 sections from a single specimen including non-anatomical
landmarks in their measurement, Zhan et al. [19] and Ou et al. [20] reported TREs of 0.82
mm and 0.79 mm using anatomical landmarks with no further indication of the number or
type of landmarks used, or whether the TRE was 2D or 3D. The proposed landmark
localization framework enabled the localization of 184 landmarks to robustly quantify the
3D TRE of the proposed registration for 34 sections from 9 subjects. The TLE is
sufficiently small that localization variability does not dominate the measurement of TRE
using these landmarks. While these TLEs are large relative to the differences in mean
TRE between methods, the use of repeated-measures ANOVA comparisons and paired
post hoc analyses mitigates the effect of TLE in these comparisons.
The mean±SD TRE for the proposed method was found to be 0.71±0.38 mm,
more accurate than the previously adopted method based on image-guided slicing
1.21±0.74 mm. The size of the smallest clinically relevant cancer focus is a topic of
controversy, with thresholds from 0.2 cc [21] – 0.5 cc [22]. The mean TRE is sufficient to
achieve an

overlap of a hypothetical spherical 0.2 cc tumor. If used as a component

of a histology image to in vivo image registration, the mean error of the combined
registration would be added in quadrature, assuming independent errors. For example, if
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the ex vivo to in vivo registration also had a mean TRE of 0.71 mm, the mean combined
error would yield a 75% overlap of a 0.2 cc tumor, or an 85% overlap of a 0.5 mm tumor.
The anisotropic variance of the TRE, highest in the direction perpendicular to the
histology plane, could have several causes: out-of-plane deformation of the tissue during
slicing or histology processing, poor sensitivity of the configuration of fiducial crosssections to the plane selection, or higher out-of-plane error in locating the landmarks.
This last effect is consistent with the landmark location procedure: the landmarks on MR
images were typically placed at the center of an anatomical feature, and on histology
images, the center of an anatomical feature can only be accurately identified in the
histology image plane.
The proposed local optimization can also be leveraged to improve previous
registration methods to achieve similar accuracy. The difference in mean TRE between
the proposed method and the image-guided slicing registration with local optimization is
less than 0.13 mm, with 95% confidence. The high agreement between landmark TREs
seen in the Bland-Altman plot in Figure 4.8a suggests that this improved image-guided
slicing registration can provide equivalent registration accuracy to the proposed method
in specific research contexts where histology interrogation of particular MR imaging
planes is required. In all other research contexts, the proposed method is applicable and
provides a substantially faster, less clinically disruptive solution. The proposed method
augmented with block MR images also has high agreement between landmark TREs;
however, there is no clear research context where this method would be required,
suggesting the additional complexity and delay is not warranted.
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While the rigid fixation of external fiducial markers to the prostate surface by the
cyanoacrylate adhesive inhibits fiducial markers from moving along the surface, it is
possible for cross-sections of the fiducial markers to detach entirely, which occurred for
4% of fiducial marker cross-sections. An additional 2% of fiducial marker cross-sections
were not visible on histology images due to the sections not intersecting with the fiducial
markers. The proposed method was robust to the absence of 1–3 of the fiducial crosssections on histology images. There is, however, a theoretical limit to this robustness, as
the method will not function with fewer than 4 fiducials as the residual fiducial
registration error being minimized would be uniformly zero.
The proposed registration method can be used with or without internal fiducials,
although we observed a trade-off between method simplification (by eliminating internal
fiducials) and accuracy. Registrations of sections with no absent fiducials were more
accurate, suggesting that the proposed method without internal fiducials is less robust to
loss of fiducials. Elimination of internal fiducials may still be warranted if required by an
institution’s pathology workflow and our reported accuracy is sufficient for the study. In
this case, careful handling to ensure slicing through the fiducials and to avoid the loss of
surface-mounted fiducials may increase the registration accuracy.
An ideal error measurement of an image registration algorithm informs as to the
post-registration misalignment of anatomically homologous points. The most
straightforward approach to obtaining this information is to identify homologous point
landmark pairs in the images to be registered and compute an aggregate of the postregistration Euclidean distances between them (e.g. yielding a mean TRE). The use of
non-point structural landmarks (e.g. via the introduction of additional strand-shaped
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fiducial markers to be used only for validation) complicates the error calculation due to
the need to establish an accurate point correspondence across these more complex
structures, which may be an ill-posed problem. In our application, this would involve the
computation of a correspondence between the points defined by the cross-sections of the
strand-shaped fiducial markers on the histology images and the space curves visible in
the MR images. Because the location of the histological section is unknown, it is
ambiguous which point along the curve on the MR image corresponds to the point on the
histology image. The approach used in our study avoids this ambiguity by identifying
homologous point landmarks in the histology and MR images.
One limitation of the method is that the registration assumes there is an affine
transformation between histology and post-fixation ex vivo images. This assumption is
supported by preliminary work [11] and the work described in Chapter 3 using the same
whole-mount histology processing protocol. However, if this assumption is violated, the
registration could be adapted to incorporate more flexible non-linear transformations. A
second limitation is that all specimens were sliced according to the constraints of the
ongoing study from which specimens were drawn. While this allowed a comparison of
registration accuracy on the same specimens, it prevented a measurement of the range of
acceptable variation in slicing orientations recoverable by the proposed registration and
local optimization. We hypothesize that the method is robust to a wide range of slicing
angles as long as the slicing plane passes through the applied fiducial strands.
In conclusion, the proposed method for histology image – ex vivo MR prostate
image registration yields submillimeter registration error of 0.71 mm while reducing the
processing time by 8 hours (70% reduction) relative to a currently adopted method. It
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does not require guidance of specimen slicing, does not require block face or tissue block
imaging as an intermediate registration target, and does not depend on the stable
appearance of images that may be disrupted by the disease process.
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Chapter 5.
3D prostate histology reconstruction: an evaluation of
image-based and fiducial-based algorithms †

5.1 Introduction
Reconstruction methods based on the registration of 2D digital histology images
to in vivo [1-6] or ex vivo [7-9] 3D images (referred to as registration-based
reconstruction methods throughout this chapter) hold the potential for automated 3D
histology image reconstruction with fewer assumptions about the relative positions of the
histology sections and less disruption of pathologists’ tissue slicing workflows.
Furthermore, the reconstructions generated by these methods result in histology images
that are inherently registered to a volumetric 3D image, further facilitating the coregistration with clinical images. Some such registration algorithms use only intrinsic
image information and allow existing specimen handling processes to be used with
minimal alteration beyond the additional imaging; however, this type of registration
algorithm relies on the presence of intrinsic image features that may vary due to
anatomical variation and, as noted by Ou et al. [7], by the presence of cancer foci, the
very tissue these methods aim to align. To mitigate this dependence, other registration
algorithms use image information derived from extrinsic fiducial markers applied to
† A version of this chapter has been published: E. Gibson, M. Gaed, J. A. Gómez, M. Moussa, C.
Romagnoli, S. Pautler, J. L. Chin, C. Crukley, G. S. Bauman, A. Fenster and A. D. Ward, "3D prostate
histology reconstruction: an evaluation of image-based and fiducial-based algorithms," Medical Physics 40,
093501 (2013).
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specimens before imaging, which increases robustness to image variation, but requires
additional specimen handling.
This work explores this trade-off for registration-based reconstruction methods
between intrinsic information-based and extrinsic fiducial-based registration algorithms
via a direct comparison of the registration errors of four algorithms on the same data set
quantified as a 3D TRE using homologous landmarks. This comparison comprised three
experiments measuring the registration errors of these algorithms, measuring the
sensitivity of the performance of each algorithm to initialization, and identifying the
sources of any substantial registration errors that were observed. This work builds on our
laboratory’s previous image-guided slicing [10] method based on an altered pathology
workflow using image guidance to prospectively control the slicing of the specimen, and
on our subsequent extrinsic-fiducial-registration-based reconstruction method (Chapter
4) [11] that eliminated image-guided slicing to reduce this workflow disruption. In this
work, we investigated an intrinsic image-information-based registration that could further
reduce workflow disruption by eliminating the need for extrinsic fiducial markers and
compared it to our previous extrinsic-fiducial-registration-based reconstruction method.
To the best of our knowledge, this represents the first direct comparison between
intrinsic-image-registration-based and extrinsic-fiducial-registration-based prostate
histology reconstruction methods on the same data set with error quantified as a 3D TRE.

5.2 Materials and methods
5.2.1 Patient selection and imaging
We obtained twelve radical prostatectomy specimens from patients with prostate
cancer being treated by one of three collaborating urologists and surgical oncologists.
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The inclusion criteria were: (1) age 18 or older, (2) having histologically confirmed
clinical prostate cancer of stage T1 or T2 on a previous biopsy, and (3) suitable for and
consenting to radical prostatectomy. The exclusion criteria were: (1) prior therapy for
prostate cancer, (2) use of 5-alpha reductase inhibitors within 6 months of the study start,
(3) inability to comply with preoperative imaging, (4) allergy to contrast agents, (5)
sickle cell or other anemias, (6) sources of artifact within the pelvis such as hip and
penile prostheses, and (7) contraindications to MRI such as electronic implants, metal in
the orbit, cerebral aneurysm clips, claustrophobia and morbid obesity. The subjects' ages
ranged from 47 to 69 years. The specimens had volumes (estimated from transrectal
ultrasound at biopsy) ranging from 19 to 49 cm3 and biopsy Gleason scores of 6 or 7.
This study was approved by the University of Western Ontario Human Subjects Research
Ethics Board, and informed consent was obtained from each subject.
Prostatectomy specimens were formalin fixed in 10% buffered formalin for 48
hours and marked with strand-shaped fiducial markers approximately 1 mm in diameter
on the exterior of the specimen and internal to the specimen (illustrated in Figure 5.1) that
are visible on histology and MR images [11]. After adding fiducial markers, the intact
specimens were imaged ex vivo in a 3 T GE Discovery MR750 (GE Healthcare,
Waukesha, WI, USA) with an endorectal coil (Prostate eCoil, Medrad, Inc., Warrendale,
PA, USA) using a T1-weighted protocol (3D SPGR, TR 6.5 ms, TE 2.5 ms, bandwidth
±31.25 kHz, 8 averages, FOV 140×140×62 mm, image slice thickness 0.4 mm, image
slice spacing 0.2 mm, 256×192 matrix, 312 image slices, flip angle 15°, 25 minutes) and
a T2-weighted protocol (3D FSE, TR 2000 ms, TE 151.5 ms, bandwidth ±125 kHz, 3
averages, FOV 140×140×62 mm, image slice thickness 0.4 mm, image slice spacing 0.2
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mm, 320×192 matrix, 312 image slices, 25 minutes). During MR imaging, specimens
were immobilized in a syringe filled with Christo-Lube (Lubrication Technology Inc.,
Franklin Furnace, OH, USA) to provide low signal in the background and minimize
boundary artifacts.
As part of another study from which our specimens were obtained, removal of the
prostatic apex was performed using image guidance to yield cuts coincident with in vivo
MR imaging planes obtained preoperatively, and the midgland was cut into 4.4±0.2-mmthick tissue slices using a rotary slicer to yield parallel cuts [10]. After gross slicing, the
resulting tissue slices were immobilized in tissue processing cassettes, immersed in
Christo-Lube and imaged using the same imaging protocol. To distinguish these images
from the whole-gland images described above, these images are referred to as tissue slice
MR images hereafter.
After standard whole-mount paraffin embedding, a 4 μm histology section was
cut from each midgland tissue slice and stained with hematoxylin and eosin. After
staining, histology sections were digitized on a ScanScope GL (Aperio Technologies,
Vista, CA, USA) bright field slide scanner, and downsampled to a 30 µm pixel size.
5.2.1.1 3D reconstruction methods
We evaluated four 3D registration-based reconstruction methods corresponding to
four registration algorithms. Specifically, for each histology image independently, each
algorithm computed a 2D–3D affine transformation from each histology image to the
space of the corresponding whole-gland MR image by minimizing a similarity metric
over a constrained search space of linear transformations , yielding a transformation
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5.1
where

is the -th scalar histology image,

corresponding specimen, and

is the whole-gland MR image from the

maps the histology image plane

into a plane

in the whole-gland MR image space. The minimization was performed using a
local iterative Nelder–Mead simplex algorithm implemented in Matlab R2011b (The
Mathworks Inc., Natick, MA) as fminsearch. This minimization was initialized using an
affine transformation, the construction of which differed in different experiments. The
differences between the algorithms were the choice of the similarity metric
information (

) or fiducial registration error (

transformations (

)] and the search space

) or fiducial-constrained affine transformations (

is correspondingly denoted

).

)]. Each algorithm

) and fiducial

measures the negative normalized mutual information [12]

(MI) of a 2D histogram relating image intensities from
through

[affine

.

Two similarity metrics were used: mutual information (
registration error (

[mutual

defined by the plane

and the oblique image slice

, resampled at the coordinates of the transformed

histology image. Three parameters that may affect the performance of the metric were
varied in this work: the number of joint 2D intensity histogram bins, the color channel
used for

, and the choice of MRI sequence. As these parameters are varied in the

experiments, their selection will be described in Section 5.2.3. To avoid using fiducial
information in
calculation.

, voxels containing fiducials were excluded from the histogram
measures the post-transformation misalignment between strand-shaped

fiducial markers identified on

and

. Internal and external fiducial strands were

attached to the specimen before imaging as shown in Figure 5.1. The -th fiducial strand
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on

was semi-automatically localized as a 3D parametric curve

center of the cross-section of the -th fiducial marker on
2D point

.

. The

was manually localized as a

is the sum of squared 3D distances for each fiducial between

and the closest point on

1

to the plane

.
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Figure 5.1: Schematic of strand-shaped fiducial markers (1–10), with parameterized 3D
fiducial space curve m4 indicated with arrows, and histology showing 2D fiducial crosssections (boxed) with h4 and h10 inset.
Two search spaces were used: affine transformations (
constrained affine transformations (

).

) and fiducial-

is the space of 2D–3D affine

transformations, realized by optimizing over the uppermost 9 matrix elements of a 4×3
homogeneous transformation matrix.

is a subspace of

used in previous work [11]

that includes only transformations that can be realized from a best-fit affine mapping of
the vector of 2D fiducial points

to a vector of 3D fiducial points
. This space was realized by optimizing over the
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vector of curve parameters,

. Constraining the search space in this way

is a trade-off between eliminating solutions (and potentially local minima) known to be
non-optimal, and potentially introducing new local minima not present in the initial
search space. This trade-off is illustrated in Figure 5.2.

1

0

0.5

1

0.5

0
(a)

(b)

Figure 5.2: Constraining the search space in an optimization reduces the number of
possible solutions to be considered, but may introduce local minima. On this illustrative
metric in a 2D search space (surface view (a) and 2D view (b), with darker intensity
representing lower values), the red curves show two monotonically decreasing paths an
unconstrained optimizer might take, one ending at the global optimum (red circle) and
one ending at a local minimum (red x). If it is known a priori that the optimal solution for
the metric lies on the cyan dashed line, an optimization could search just these solutions,
avoiding solutions and local minima known to be suboptimal (off the cyan dashed line);
however, this constrained space may have local optima (e.g. the cyan x) not present in the
unconstrained space.

5.2.2 Metrics for algorithm evaluation
5.2.2.1 Target registration error
We quantified the registration error of each algorithm using the mean TRE [13], i.e. the
mean post-registration 3D Euclidean distance between corresponding pairs of
homologous landmarks on the whole-gland MR images and on the reconstructed
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histological images, averaged over 232 landmarks from 37 sections taken from 10
specimens.
These point landmarks (3–16 landmarks per section) were interactively identified
using 3D Slicer by one observer under advisement from 2 genitourinary pathologists
(J.A.G. and M.M.) and 1 radiologist (C.R.) with expertise in prostate imaging.
Landmarks included the centers of atrophic ducts, cysts, and corpora amylaceae, and
were selected based on salient shape characteristics and the presence of nearby salient
features that uniquely constrained the correspondence. Illustrative examples of these
landmarks are shown in Figure 5.3.
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Figure 5.3: Homologous landmark pairs (large white arrows), used for evaluation of the
registration algorithms, shown on histology images (top) and on the corresponding
oblique image slices on T2 (middle) and T1 (bottom) MR images. Small black arrows
denote salient nearby features used to corroborate the established landmark
correspondence, but not used as landmarks themselves. Salient features in these images
include corpora amylaceae (labeled *), the urethra (labeled +), extrinsic fiducials
(labeled °) and atrophic ducts (unlabeled). Figure reproduced here with permission from
the Journal of Magnetic Resonance Imaging [11].
5.2.2.2 Sensitivity to initialization
The sensitivity of the algorithms' mean TRE to initialization error was evaluated
by initializing the algorithms at sets of different transformations, including the “ideal”
section-specific least squares best-fit 2D–3D affine transformation aligning homologous
landmarks on histology and MR images
deviated from

, and also at four sets of transformations that

by controlled rotations, translations and scaling factors.

as,
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is computed

5.2

where

is the -th landmark in the -th histology image,

landmark in the corresponding whole-gland MR image, and

is the homologous
is the number of

landmarks identified in the -th histology image. Sensitivity was quantified as the linear
coefficient of a general linear model relating post-registration TRE to the absolute
rotation, translation or scaling change of the initialization from
of

. Because identification

is sensitive to error in the placement of the landmarks, sections with fewer than 5

identified landmarks were excluded from this calculation; thus, a total of 28 sections,
taken from 10 specimens, were used.
5.2.2.3 Quantifying contribution of the sources of post-registration TRE
The landmark localization error (LLE) (measuring the repeatability of the
landmark placement) was quantified as an unbiased estimator of the standard deviation of
seven repeated localizations (at least one day apart) of 16 landmarks identified on MR
and histology [11]. This metric was measured independently for histology and MR
images.
The landmark registration error (LRE) (measuring the combined effect of error in
localizing landmarks and the distance from the correct homology to the closest point in
the search space) was quantified as the mean residual misalignment of homologous
landmarks after applying the best-fit transformation from the search space,

5.3
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where

is the number of sections. To mitigate under-estimation of LRE due to

overfitting, sections with fewer than 5 identified landmarks were excluded from this
calculation; in total,

landmarks from

sections were used.

We explored the relative impacts of two other sources of error (the similarity
metric not having a globally optimal value at the best transformation in the search space,
and the optimizer not converging to the globally optimal value) by examining the
similarity metric values after minimization. Ideally, the similarity metric value at
would be the global minimum of the similarity metric function (i.e.
and the minimization would converge to this
transformation (

); in this case, the difference in metric values
. If

global minimum of the similarity metric function. If
the similarity function was not at

, the optimizer did not find the
, the global minimum of

. We quantified the relative contributions of these

sources of error as the proportion of minimizations that resulted in
that resulted in

to those

.

5.2.3 Experimental design
We conducted three experiments in this work. In the first experiment (Section
5.2.3.1), the registration errors of four algorithms for the registration of 2D prostate
histology images to 3D ex vivo MR images were compared by measuring the postregistration TRE of intrinsic homologous point landmarks when initialized with a
straightforward initialization involving aligning the histology images in 2D, stacking
them at even intervals and aligning the stack to the ex vivo MR image. The algorithms
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differed in the optimized similarity metric (mutual information or fiducial registration
error) and the search space examined (affine transformations or a subset of affine
transformations constrained by the spatial configuration of fiducial markers). In the
second experiment (Section 5.2.3.2), the sensitivities of TRE to initializations that
deviated from the best-fit transformation for these four algorithms were compared by
varying the initialization and recording the resulting TREs. In the third experiment
(Section 5.2.3.3), the causes of substantial registration errors were explored by
quantifying contributions to error from five possible sources: (1) the selection of
parameters of the similarity metric, (2) the incorrect localization of the homologous
landmarks, (3) the correct transformation not being part of the search space, (4) the
similarity metric not having a globally optimal value at the best transformation in the
search space, and (5) the optimizer not converging to the globally optimal value.
The first two experiments required the selection of a single configuration of the
three MI parameters described in Section 5.2.1.1. Rather than resorting to ad hoc
parameter selection, we used the nine histology images from two randomly selected
specimens from our data set to guide the selection of the MI parameters. For these nine
histology images,

at the best-fit affine registration (identified using homologous

intrinsic landmarks) was minimized over all parameter combinations (histopathology
image color channel chosen from red, green, blue, and the mean of all three; MRI
sequence chosen from the T1-weighted and T2 weighted sequences; and number

of

joint intensity histogram bins chosen from {6, 16, 32, 64, 128}). This procedure yielded
one set of parameters giving the lowest
T1-weighted MRI sequence and

(the blue channel of the histology image, the
); this set is henceforth referred to as the selected
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MI parameter set. The two specimens used to determine the selected MI parameter set
were not used in any of our experiments; thus, for all three experiments, our results were
calculated based only on the remaining 10 specimens in our data set.
5.2.3.1 Algorithm performance with practical initialization
To assess the algorithm performance in practical applications, we initialized each
algorithm using a transformation that can be practically achieved by researchers able to
control, and collect data during the coarse slicing of the specimen. With this initialization,
we executed each algorithm, and computed the post-registration TRE. To define the
initialization, extrinsic fiducials were stacked into a 3D volume by (1) identifying the
vector 𝒇

𝒇

𝒇

of 2D points of extrinsic fiducial cross-sections on the front

face of the -th tissue slice in a standard 2D coordinate system, (2) stacking these vectors
at 4.4 mm intervals (i.e. the quantified gross slicing thickness [10]) to yield a 3D point
set, (3) computing a rigid transform
curves

mapping the 3D point set to the fiducial marker

in the whole-gland MR image using the iterative closest

points algorithm [14], and (4) computing the best-fit affine initialization transformation
mapping

to

work, the vector 𝒇

𝒇

𝒇

𝒇

𝒇

𝒇

for each section . In this

was determined by interactively identifying the

inferior-most point of each fiducial on tissue slice MR images that were manually
registered to whole-gland MR images, and projecting these points onto the plane at the
front face of the superior-most tissue slice; however, an analogous vector
𝒇

𝒇

𝒇

could also be identified by photography of the specimen in a common

coordinate system after each cut during gross sectioning, as performed by Breen et
al. [15]. For this experiment,

used the selected MI parameter set.
175

5.2.3.2 Sensitivity of algorithm accuracy to initialization variation
Due to the variability in imaging data sets and initialization methods, initialization
errors may deviate from those in the experiment described above. Accordingly, the
sensitivity of the algorithms' registration error to initialization error was assessed. Each
algorithm was initialized with the best-fit affine transformation
of transformations that deviated from

and also with four sets

by controlled rotations, translations or scaling

factors, and the post-registration TRE was calculated. The first and second sets of
transformations varied the initialization by rotations about the AP axis and about the LR
axis, respectively, with rotations in both sets ranging from -15° to 15° in 3° increments.
The AP and LR axes were determined by manually aligning the whole-gland MR images
in 3D Slicer. The third set of transformations varied the initialization by translations in
the inferior direction normal to the plane

ranging from -10 mm to 10 mm of

translation in 1 mm increments. The fourth set of transformations varied the initialization
by scaling factors from -10% to 10% in 2.5% increments. For each type of deviation from
, a linear coefficient of sensitivity was calculated as described in Section 5.2.2.2. For
this experiment,

used the selected MI parameter set.

5.2.3.3 Sources of error for mutual information
Based on preliminary observations of the results of these experiments, we were
motivated to explore the relative contributions of four causes of error to the observed
TRE. To quantify variability in landmark localization, we computed the LLE for
histology and MR images. To quantify error caused by the combined effect of landmark
localization and search space we computed the LRE for

. To quantify the relative

prevalence of errors in the optimizer and in the similarity metric, we computed the

176

difference between the similarity metric value at the post-optimization transformation and
at the landmark-based best fit transformation (

) as discussed in Section 5.2.2.3.

To explore the impact of parameter selection on the observed errors, the accuracy and
sensitivity to initialization experiments (described in Sections 5.2.3.1 and 5.2.3.2) were
run for

with all combinations of the

parameters described in Section

5.2.3. (i.e. different histology color channels, MRI sequences and histogram sizes).

5.2.4 Statistical analysis
Statistical analyses were performed in SPSS 19 (SPSS, Inc., Chicago, USA).
ANOVA tests used repeated measures ANOVA with Greenhouse–Geisser corrections for
asphericity, and used a threshold of

for significance. For experiment 1, the

improvement in mean TRE from the pre-registration initialization to the post-registration
transformation was assessed using a 1-way ANOVA and pairwise post hoc analyses
between the TRE at initialization compared to the TRE after each of the algorithms.
Differences in the mean TRE due to the search space (
(

or

or

) and the similarity metric

) were assessed using a 2-way ANOVA and pairwise post hoc analyses. For

experiment 2, the sensitivities of the algorithms to the four types of initialization errors
(rotational about AP and LR axes, translational, and scaling) were assessed using four
separate 2-way ANOVAs. In each ANOVA, the factors were the choice of algorithm and
the rotational, translational or scaling deviations of the initialization from . In post hoc
analyses for each algorithm, we modeled sensitivity as a general linear model relating
post-registration TRE to the absolute rotation, translation or scale of the initialization
from

, estimating the linear coefficient as a measure of sensitivity. The sensitivity of

the mean TRE of algorithms using

to the choice of MRI sequence, histology image
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channel and number of histogram bins was assessed using a 3-way ANOVA and post hoc
analyses. The relative contributions of sources of error were estimated with point
estimates for the LLE, LRE, and the proportion of

above and below zero for

the practical initializations and each set of perturbed initializations for each set of
parameters.

5.3 Results
5.3.1 Algorithm performance with practical initialization
The key finding of this experiment was that the choice of similarity metric
affected the mean TRE, with the landmark-based similarity metric outperforming the
intensity-based similarity metric: algorithms using

had a mean TRE of 0.7±0.4

mm, an improvement of 0.5–0.7 mm from the initialization (with mean TRE 1.3±0.6
mm), whereas algorithms using

had a mean TRE of 1.2±0.7 mm, an improvement of

0.1–0.2 mm from the initialization.
Results for individual algorithms, and computational times are shown in Table
5.1. An illustrative registration from the practical initializations is shown in Figure 5.4a.
All algorithms showed a statistically significant improvement in mean TRE over
initialization. The 2-way ANOVA of TRE showed a significant difference due to choice
of metric but failed to find a difference due to the choice of search space and failed to
find an interaction between the two factors. Pairwise post hoc analyses (shown in Table
5.2) showed that (1) algorithms using

yielded a lower mean TRE than those using

for algorithms using both search spaces, and (2) the difference in mean TREs due to
the choice of search space was less than 0.12 mm with 95% confidence.
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Figure 5.4: Illustrative registrations from (a) the practical initialization experiment and
(b) the initialization offset by 5 mm translational error from the sensitivity experiment,
showing a posterior view of a surface rendering of the prostate with sections (represented
by colored planes) reconstructed via 4 different transformations: the initialization (red),
the transformation given by
(yellow), the transformation given by
(blue), and the best-fit transformation (green). Corresponding oblique image slices of the
T1-weighted MR image are shown in the “Init”, “MI”, “FRE”, and “Opt” panels,
respectively. The H&E-stained histology image is shown in the “Hist” panel.
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Table 5.1: Comparison of the algorithms after practical initialization: mean ± standard
deviation of TRE, 95% confidence interval (CI) on the improvement over the
initialization (i.e.,
, and mean computational time per section of the
four registration algorithms, (columns 2 to 5).
;
TRE (mm)

;

;

;

0.7 ± 0.4
1.2 ± 0.7
0.7 ± 0.4
1.2 ± 0.7
[0.55,0.70] [0.05,0.22] [0.53,0.69] [0.06,0.23]

(mm)
Computation time (s)

2

32

9

1.3 ± 0.6

38

Table 5.2: 95% CI on mean TRE difference for similarity metrics and search spaces
across initialization algorithms.
Factor held constant
Pairwise difference analyzed
95% CI on mean TRE
difference

[-0.03,0.00]

[-0.10,0.12]

[0.40,0.57]

[0.38,0.55]

5.3.2 Sensitivity of algorithm accuracy to initialization variation
The key finding from this experiment was that the landmark-based algorithm
using an affine transformation (

showed negligible sensitivity to initialization

error, while the other three algorithms showed greater sensitivity.
95% CI on the sensitivity coefficients for each type of initialization error for each
algorithm are shown in Table 5.3, and the graphical relationships are shown in Figure 5.5.
An illustrative registration from the sensitivity experiment is shown in Figure 5.4b. The
ANOVA showed significant effects of sensitivity to initialization. The

;

algorithm shows an asymmetry in the sensitivity to translational offset; the distributions
of TRE for translational offsets (Figure 5.6a) are bimodal for extreme inferior
translational offsets, and this variation was correlated (
in the inferior direction normal to the plane
(Figure 5.6b).
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) with the extent of tissue

of the best-fit histological section

Table 5.3: Sensitivity of mean TRE to initialization error quantified as 95% CI on the
sensitivity coefficients of general linear models.
Perturbation
AP rotation (mm/° rotation AP)
LR rotation (mm/° rotation LR)
Translation (mm/mm translation)
Scaling (mm/% scale)

;
[0.00,0.01]
[0.00,0.01]
[0.00,0.00]
[0.00,0.00]

;
[0.15,0.17]
[0.10,0.12]
[0.57,0.61]
[0.06,0.08]

;
[0.00,0.00]
[0.00,0.01]
[0.22,0.26]
[0.00,0.00]

(a)

(b)

(c)

(d)

;
[0.06,0.07]
[0.05,0.06]
[0.70,0.74]
[0.00,0.00]

Figure 5.5: Sensitivity of mean TRE to four types of initialization error: rotation about
the (a) AP and (b) LR axes, (c) translation, and (d) scaling.
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(a)

(b)

Figure 5.6: (a) Violin plot showing the distribution of TRE for the {T A; MMI } algorithm
for translational initialization error; (b) scatter plot of TRE vs. the extent of tissue in the
inferior direction normal to the plane
of the best-fit transformation.

5.3.3 Sources of error for mutual information
The key findings for this experiment were (1) the observed mutual informationbased registration errors were not fully explained by landmark localization and landmark
registration errors, and (2) in more than 80% of cases, the mutual information metric
value at the ideal registration was not the globally optimal value, suggesting that the
mutual information metric may not be ideally suited to these cases. More specifically, (1)
the landmark localization error values were 0.05 mm and 0.16 mm on histology and MR
images, respectively, and the landmark registration error was 0.29 mm, insufficient to
account for the observed registration errors with mutual information, and (2) across the
40 sets of mutual information parameters tested, the proportion of optimizations that
resulted in metric values less than those at the best fit transformation (

,

showing evidence of errors due to the similarity metric) ranged from 81% to 98%.
Figure 5.7 shows the distribution of
perturbed initialization for
perturbed initializations, with the

over all histology sections for each

using the selected MI parameter set. For the
parameters used in experiments 1 and 2, we
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observed that 18% of the optimizations in our sample resulted in
resulted in

. Of the optimizations that resulted in

and 82%
, the

majority (10% of all optimizations) resulted from initializations that were translated from
by

mm.
The lowest mean TRE for all of the parameter combinations was 1.2±0.7 mm,

using the selected MI parameter set. Mean TRE was sensitive to MRI sequence selection,
histology channel selection and number of histogram bins, and there were significant
interactions between the factors. Sensitivity to MRI sequence selection was the most
significant effect where all algorithms using the T2-weighted MRI sequence had higher
mean TRE than all those using the T1-weighted MRI sequence (95% CI on the difference
of estimated marginal means: [0.78,0.97] mm). Within the algorithms using the T1weighted MRI sequence, a post hoc 2-way ANOVA showed that mean TRE was
sensitive to the number of histogram bins, but failed to detect sensitivity to the choice of
histology channel or interaction between the factors. Among the algorithms using the T1weighted MRI sequence, the 95% CI on the difference between the parameter
combination with the lowest mean TRE (the selected MI parameter set using the blue
histology channel, the T1-weighted MRI sequence and

) and the highest mean TRE

(using the blue histology channel, the T1-weighted MRI sequence and

) was

[0.07,0.22] mm. On our sample of 10 specimens, no MI parameter combination yielded a
lower mean TRE than the selected MI parameter set that was used in experiments 1 and
2.
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(a)

(b)

(c)

(d)

Figure 5.7: Violin plots showing the distribution of DMI for four types of initialization
error: rotation about the AP (a) and LR (b) axes, translation (c), and scaling (d). Each
data point represents one run of the
algorithm;
(above the blue
line) shows that the optimizer did not find the global minimum, while
(below the blue line) shows that the similarity metric had values lower than that of the
best-fit transformation.

5.4 Discussion
In this chapter, we have performed a comparison of accuracy and sensitivity to
initialization for four registration-based 3D histology reconstruction algorithms on the
same data set, comparing registration algorithms that use intrinsic image information with
algorithms that use extrinsic fiducial information. Specifically, we explored the effects of
using

, a similarity metric based on the mutual information of intrinsic image

information, compared to using

, a similarity metric introduced in previous

work [11] based on the fiducial registration error of extrinsic fiducials. We also explored
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the impact of using the transformation spaces
affine transforms, compared to using

, comprising the unconstrained set of

, a transformation space used in previous

work [11] comprising a subset of affine transforms constrained to align extrinsic
fiducials.

5.4.1 Evaluating histology reconstruction methods
Two criteria that are important in the evaluation of methods for the 3D
reconstruction of histology from clinical specimens are the disruption to the clinical
workflow and the accuracy of the reconstruction.
5.4.1.1 Disruption to the clinical workflow
Because the specimens are used clinically, care must be taken to minimize
unnecessary disruption to the clinical use of the data for the sake of research. The clinical
workflow can be disrupted in several ways, including altering which tissue is cut for
histological examination, altering the appearance of histology sections or altering the
timeline of processing by introducing additional processing steps.
Several existing reconstruction methods control which tissue is cut for
histological examination by constraining the slicing of the specimen into 3–5-mm-thick
tissue slices, so that histology is taken from tissue that approximately corresponds to in
vivo imaging planes [10, 16-18]. The spatial relationships of these histology sections may
differ from those normally used for diagnosis by a pathologist.
Retrospective methods, including registration-based reconstruction methods that
use registration algorithms based on extrinsic fiducial information [11, 19, 20] or intrinsic
image information (as described in this work and elsewhere [4-9]), as well as other
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retrospective methods [21, 22], avoid the disruption of controlling which tissue is cut for
histological examination by retrospectively determining the spatial relationships between
histology sections regardless of how they were cut, enabling the slicing of histology
according to the pathologists’ workflow. Many approaches achieve this by adding
extrinsic fiducials to the prostate specimen; however, care must be taken to avoid
disrupting the appearance of the histology by adding features that would not typically
appear on histology or removing/moving tissue when fiducials are introduced within the
prostate. By using intrinsic image information, the mutual information-based registration
algorithm described in this work and other such methods [2-9, 23] avoid this challenge.
The use of additional ex vivo imaging for registration, as seen in the methods
presented in this work and other existing work, may disrupt the processing timeline of the
pathology laboratory, which some methods [21] avoid by relying on known geometrical
properties of their extrinsic fiducials.
5.4.1.2 Accuracy of the reconstruction
The accuracy of the reconstruction (and the accuracy of the following registration
to in vivo imaging) may constrain the types of questions that can be asked of the data and
may impact the power of some statistical analyses of the data (Chapter 2) [24]. A
comparison of the accuracy of reconstruction methods is challenging, due to the variety
of methods for quantifying accuracy.
Some methods do not report reconstruction errors as point-to-point distances,
instead using surrogates such as overlap of the prostate gland [8, 25], prostate boundary
distances [2, 22], qualitative assessment of tumor alignment [6, 18], post-optimization
similarity metric values [6], or image intensity properties [9].
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Even reconstruction errors reported as distance must be interpreted carefully,
considering the modalities involved in the reconstruction, the method of measurement,
the dimensionality of the measurement and the errors that may be omitted from the
measurement. Previous work in our laboratory using a guided-slicing approach measured
reconstruction error from histology to in vivo images comprising a 2D in-plane mean
error of 1.1±0.7 mm based on intrinsic landmarks and a root-mean-square error in the
position of the slicing plane of 0.9 mm based on physical measurements. However, these
measurements were made under an assumption that histology corresponded to the front
faces of the thick tissue slices (referred to as the front face assumption hereafter), and as
the mean distance of whole-mount prostate histology sections from the front face has
been estimated to be ~1 mm (Chapter 3) [26] these errors may underestimate the total
error accordingly. Park et al. measured reconstruction errors of 3.74 and 2.26 mm based
on a distance between medial axes of foci contoured on histology and in vivo images.
Direct comparison with these errors is challenging, as they represent reconstruction to
align with in vivo images, where there is more deformation.
Groenendaal et al. reported an error of 2.2±0.5 mm from histology to in vivo
images, but broke the error down into a histology—fixed tissue image TRE component of
0.7±0.3 mm based on extrinsic landmarks which similarly held the front face assumption,
and a fixed tissue to in vivo image error component of 2.1±0.5 mm. Orczyk et al. broke
the error into a histology-fresh tissue slice image FRE (where the landmarks used for
error calculation were also used to compute the transformation, typically underestimating
the TRE) component of 0.9±0.3 mm measured using intrinsic anatomical landmarks that
did not measure out-of-plane error due to the 3D reconstruction and held the front face
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assumption, and a reconstructed specimen—in vivo image FRE of 1.6±0.3 mm. Kimm et
al. reported 2D displacements (interpretable as a surrogate for a distance-based
reconstruction error) from histology to fixed tissue of 1.2±0.6 mm and 0.9±0.4 mm for
two methods measured using the misalignment of intrinsic landmarks using a metric that
is invariant to rotational and translational error and that may underestimate error relative
to a 2D TRE, and that held the front face assumption. Nir et al. reported a mean±SD 2D
TRE of 1.5±0.9 mm using intrinsic fiducials. Prabu et al. reported a mean 2D TRE of 1.4
mm using intrinsic landmarks. Two pieces of related work by Zhan et al. and Ou et al.
used intrinsic landmarks to measure TREs of 0.8 mm and 0.6–1.0±0.43–0.79 mm (range
is for landmarks chosen by 2 observers), respectively. The identity and number of the
intrinsic landmarks are not specified, and it is not clear if the calculated TREs are 2D or
3D. Recent work by Hughes et al. reported a 2D TRE of 0.6±0.5 mm using one extrinsic
landmark per section and a 3-fiducial FRE of 0.1±0.1 mm on a beef liver surrogate and a
3-fiducial FRE of 0.2±0.1 mm on prostate specimens.
To the best of our knowledge, no existing publications have directly compared the
accuracy of intrinsic image registration-based algorithms to extrinsic fiducial registrationbased reconstruction algorithms on the same data set and measured the error as a 3D TRE
based on homologous landmarks localized in 3D on the 3D images (to avoid
underestimation due to the front face assumption). Our work addresses this gap in
knowledge by comparing our previously developed fiducial-based algorithm to an
intrinsic image-based algorithm using mutual information, measuring the 3D TRE using
232 homologous intrinsic point landmarks localized in 3D on the ex vivo MR images.
The fiducial-based reconstructions yielded a 3D TRE of 0.7±0.4 mm, among the highest
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accuracies of current fiducial-based methods. The methods based on mutual information
of image intensities yielded a 3D TRE of 1.2±0.7 mm, suggesting that more complex
intensity-based methods, such as those of Zhan et al. and Ou et al, may be necessary to
eliminate the use of fiducial markers while achieving accuracies as low as the most
accurate fiducial-based methods.
There is no TRE value that is universally accepted as necessary and sufficient for
all applications of 3D prostate histology reconstruction. The necessary TRE depends
principally on the central question of the research study served by the 3D histology
reconstruction algorithm. More specifically, as it has recently been shown that TRE can
affect the statistical power and the number of subjects needed to answer a research
question (Chapter 2) [24], answering one particular research question (e.g. localization of
small, high-grade prostate cancer on imaging) could require a 3D histology algorithm
with a submillimeter TRE, whereas a different question (e.g. coarse identification of
larger prostate tumors) could be answerable using an algorithm with a multi-millimeter
TRE. Determination of the necessary and sufficient TRE can be done in detail in the
context of a typical application of 3D histology reconstruction methods: studies
evaluating imaging modalities by correspondence with a histological reference standard.
In such studies, error in the alignment of ground truth information to the images being
validated introduces uncertainty that prohibits certain analyses or reduces the statistical
power. The recent introduction of a sample size calculation that incorporates quantified
registration error (Chapter 2) [24] provides an avenue to quantify the impact of the
algorithms' mean TRE in imaging validation studies, assuming reconstruction error
dominates registration error. The sample size calculation addresses imaging validation
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studies to detect a difference in the mean signal intensity between regions of interest
(ROI) on images from a modality under study based on ROI defined on registered images
from a reference standard modality. It augments the classical power calculation formulae
by modeling the impact of the mean and variance of registration accuracy on the study
power (and thus the required sample size), showing that higher registration accuracy
leads to higher study power or a lower required sample size. Because it also provides a
mapping from TRE to the registration error parameters used in the calculation (under the
assumption of spherical regions of interest of specified volume, and 3D Gaussiandistributed target registration error), we can use this relationship to assess the impact of
mean TRE from different algorithms.
The potential impact of small improvements in TRE can be elucidated by
applying this sample size calculation in the context of a simplified case study. For a
hypothetical imaging validation study of signal differences between tumor and benign
tissue for the smallest clinically significant prostate cancer focus (0.2 cc [27]), the sample
size calculation predicts (assuming equal image intensity variance of tumor and benign
tissue) that an algorithm with a mean TRE of 1.2 mm (

) would need 7% fewer

subjects than would be needed with a mean TRE of 1.3 mm (pre-optimization), while an
algorithm with a mean TRE of 0.7 mm (

) would need 27% fewer subjects.

Considering the high per-subject cost of imaging validation studies (e.g. a contemporary
cost of more than $10,000 USD per subject for the study on which this chapter is based),
we observe that using a more accurate reconstruction can have a substantial impact on the
overall cost of a study. For example, in the ongoing imaging validation study of 66
subjects at our center, the above sample size reduction of 7% resulting from a 0.1 mm
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improvement in TRE could translate to a need for 4 fewer subjects, resulting in a savings
of approximately $40,000 USD.

5.4.2 Algorithm performance with practical initialization
When initialized with the described practical initialization (with a TRE of 1.3
mm), all algorithms significantly improved the mean TRE. Since the choice of practical
initialization was inspired by several existing histology reconstruction methods that
identify the front faces of tissue slices via guided sectioning or tissue slice imaging, these
results suggest that the accuracy of existing reconstruction methods could be improved by
applying these algorithms. Although

showed a small improvement over

initialization without the use of fiducial markers, the size of the difference (95% CI: 0.05
to 0.22 mm) should be considered when assessing its value for refining an image-guidedslicing reconstruction method.
Our experiments failed to detect a significant difference in mean TRE between
algorithms due to the choice of search space used. As the difference in mean TRE was
less than 0.12 mm, and the mean computational times of all four algorithms was less than
40 seconds per section, constraining the search space to the fiducials may not warrant the
added complexity.

5.4.3 Sensitivity of algorithm accuracy to initialization variation
The sensitivity of algorithms using
of algorithms using

.

to initialization error was lower than that

showed no material change in mean TRE across the

range of initializations tested. This suggests that this algorithm can be used without the
need for accurate initialization. The algorithms using
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were more sensitive to

rotational, translational and, in the case of

, scaling initialization, suggesting

that algorithms using

should be initialized close to the correct transformation. The

algorithm using

was less sensitive to translation in the inferior direction,

particularly for the more inferior sections. The initial translation in the inferior direction
combined with the narrowing of the apical region resulted in initializations with poor
overlap of tissue. We speculate that superior translation (compensating for the
initialization error) could rapidly improve the overlap (and the metric value), thus
directing the optimizer in that direction. This effect would be less pronounced for more
superior sections and for initialization errors in the superior direction because the crosssection of the tissue in the midgland and base would not change as quickly with
superior/inferior translation. As in the previous experiment, constraining the search space
to the fiducial markers does not appear to improve the sensitivity of algorithms using
either similarity metric.
The range of initializations was chosen to model realistic use cases. The range of
rotational offsets tested reflects variation seen in unguided specimen slicing [28]. The
broad range of translational offsets was chosen because the variation of this property in
the usual clinical setting was unknown. The range of scaling factors was chosen by
dividing a reported scaling factor between in vivo tissue and fixed tissue (0.96) by
reported scaling factors between in vivo and histology (0.87 to 0.96) [29], yielding a
scaling factor from histology to fixed tissue (1.00 to 1.10). The tested range was extended
to be from 0.90 to 1.10 for symmetry. The use of ranges that span realistic use cases
suggests that these results may be generalizable to practical use cases.
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5.4.4 Sources of error for mutual information
The high sensitivity of the mean TRE of the

algorithm to initialization

error, and the marginal improvement over the initialization motivated a deeper
exploration of the causes of these errors for this algorithm.
The four sources of post-registration TRE described in Section 5.2.2.3 are
interrelated, and cannot be measured directly without knowledge of the true image
homology (for error due to landmark placement and erroneous search space) and the
complex interactions between the search space, the similarity metric, the data and the
optimizer (for errors due to the similarity metric and the optimizer). However,
quantifying aspects of these errors may elucidate their relative contributions. The upper
bound for the sum of the LRE (reflecting variability in landmark placement) and LLE
(reflecting manual landmark alignment that cannot be accounted for by affine
deformation), which occurs when they are perfectly correlated, was only 0.48 mm,
suggesting the majority of the residual error after registration with
other sources. Measurements of

is due to

show that errors due to the optimizer

converging to a local minimum, as well as errors due to the optimizer converging to a
global or local minimum whose metric value is less than that at the best-fit
transformation, are present. Thus, it appears that both the image similarity metric and the
optimizer may be sources of error contributing to our measured TRE. We observe from
Figure 5.7 that for optimizations initialized close to the best-fit transformation, the image
similarity metric seems to be the dominant contributing factor to the TRE, whereas for
initializations far from the best-fit transformation, we observe more frequently that the
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optimizer converges to a local optimum. This brings into question the suitability of using
the mutual information of these modalities for this task.
The variation of MI parameters suggests that these results were not disrupted by
error due to a suboptimal selection of parameters. While the TRE was sensitive to
parameter variation, and in particular to the choice of MRI sequence used, the reported
TRE values in our experiment measuring registration accuracy after practical
initialization were the lowest for any tested combination of MI parameters, and the
evidence of errors due to the similarity metric was present for all tested parameters.

5.4.5 Limitations
The conclusions of this work should be considered in the context of the scope of
our experiments. Our experiments tested a single image-based similarity metric, mutual
information, against a single fiducial-based similarity metric. Mutual information was
tested as it is a commonly chosen metric for intermodality registrations; however, the
poor performance of mutual information in this application cannot be generalized to other
intensity-based metrics. This work tested a range of values for several parameters of
mutual information; however, mutual information has other tunable parameters that were
not varied, including spacing of histogram bins and sampling patterns. An exhaustive
search of the parameter space of

was beyond the scope of this work. It should also

be noted that while sensitivities to rotational, translational and scaling initialization error
were assessed independently, the interactions between these sensitivities and the
sensitivities to anisotropic scaling were not investigated. Finally, the specimens, drawn
from another study, were cut into tissue slices following an image-guided slicing
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approach; thus, the variability of histology section orientations relative to the prostate
gland may be less than seen in typical clinical workflows.

5.4.6 Conclusion
This work compares the accuracy and sensitivity to initialization of 3D prostate
histology registration-based reconstruction algorithms. Minimizing a mutual informationbased image similarity metric over affine transformations yielded a mean TRE of 1.2 mm
when initialized using a practical initialization (pre-optimization mean TRE 1.3 mm), and
was sensitive to the initialization error. Errors due to both the optimizer and the mutual
information-based similarity metric contributed to the residual error, with the latter more
common when optimizations were initialized close to the best-fit transformation. In
contrast, minimizing a fiducial registration error-based metric over affine transformations
yielded a mean TRE of 0.7 mm, with no material change in mean TRE across
initializations representing the full range of clinical use cases. Thus, for registrationbased reconstruction methods, we recommend the use of the extrinsic-fiducial-based
registration algorithm using affine transformations. If the application of fiducials is
prohibited and assuming MR imaging sequences equivalent to those used in this study,
the MI-based algorithm could be used to achieve a 0.1 to 0.2 mm improvement in
registration error, with the caveat that accurate initialization may be critical to its
performance. For an imaging validation study to detect a difference in the image intensity
of tumor and benign tissue for the smallest clinically significant prostate cancer focus
(0.2 cc [27]), the mutual information-based algorithm could reduce the number of
subjects needed by 7% compared to an approach based on stacking aligned histology
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images on the front faces of tissue slices at a fixed spacing, while the fiducialregistration-error-based algorithm could reduce the number of subjects needed by 27%.
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Chapter 6.
Prostate cancer assessment and delineation on 3 T
multi-parametric MRI: interobserver and
intersequence agreement †

6.1 Introduction
Accurate delineation of suspected intraprostatic cancer foci on imaging is
important for many aspects of treatment planning for men with localized prostate cancer.
For example, the use of targeted biopsy procedures may enhance the probability of
sampling high-grade foci [1], thus improving the ability to stratify men between
intervention or careful monitoring with active surveillance. Estimations of cancer volume
may have prognostic importance complementary to Gleason grade [2]. For many patients
with intermediate-grade localized prostate cancer, focal therapy may be an appropriate
treatment option with lower risk of morbidity than radical prostatectomy or radiotherapy
[3, 4]. Focal therapies, including cryotherapy [3], focal laser ablation [5] and highintensity focused ultrasound [6], normally aim to treat prostate cancer under image
guidance by focusing treatment on cancerous lesions identified and delineated on pre-

† A version of this chapter is in preparation for submission: E. Gibson, C. Romagnoli, M. Bastian-Jordan,
D. W. Cool, Z. Kassam, M. Gaed, M. Moussa, J. A. Gómez, S. Pautler, J. L. Chin, C. Crukley, G. S.
Bauman, A. Fenster, A. D. Ward, “Prostate cancer assessment and delineation on 3 T multi-parametric
MRI: interobserver and intersequence agreement” Radiology (in preparation).

200

treatment images. Accurate and precise delineation of these lesions on imaging is of
critical importance because untreated aggressive prostate cancer increases the risk of
recurrence, while treatment of healthy tissue and surrounding organs at risk increases the
risk of morbidity. Furthermore, for men with more advanced cancers, treatment
intensification using focal radiotherapy boosts to intraprostatic gross tumor volumes has
been proposed as a strategy to improve outcomes [7, 8].
mpMRI has shown promise for detection [9, 10], staging [11] and sextant
localization [12-14] of prostate cancer. mpMRI can include T2W [9, 15], DW [16], DCE
[11, 17] and MR spectroscopy [18, 19] images, as well as parametric maps derived from
these images, such as ADC [20, 21] maps. The European Society of Urogenital
Radiology has recently published clinical guidelines [10] for prostate mpMRI, including
a structured reporting scoring system (PI-RADS) which includes, for each lesion, scores
for each sequence and a score for likelihood of cancer. Such guidelines are aimed at
scoring lesions and localizing them to standardized prostate regions. However, the use of
mpMRI for delineation (identifying the boundaries of suspicious regions on imaging) of
prostate cancer lesions has not yet been widely studied [22, 23].
In this study, we investigated the variability of prostate cancer scoring and
delineation on images from three 3 T mpMRI sequences: T2W, ADC and DCE images.
Specifically, for lesions scored to be equivocal, likely cancerous or highly likely
cancerous (PI-RADS likelihood scores 3 – 5), we addressed the following four questions.
(1) What is the agreement in PI-RADS likelihood and sequence-specific scores (referred
to hereafter as interobserver score agreement)? (2) What is the average agreement in
delineated suspicious regions (measured using the Dice overlap coefficient, the mean
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absolute distance between boundaries, and the absolute volume difference) between
observers on images from each of these sequences (referred to hereafter as interobserver
contour agreement)? (3) What is the average agreement in delineated suspicious regions
between images from the different sequences (referred to hereafter as intersequence
contour agreement)? (4) What are the interactions of interobserver score agreement,
interobserver contour agreement and intersequence contour agreement with the
histological grade, anatomical location and volume of the lesions?

6.2 Materials and methods
6.2.1 Participants
The study was approved by the human subjects research ethics board of our
institution, and written informed consent was obtained from all subjects prior to
enrollment. 107 patients were screened for this study between March 2010 and December
2011, selected from patients being treated for prostate cancer by three collaborating
urologists and surgical oncologists (including S.P. and J.L.C., with 13 and 30 years of
experience, respectively). The inclusion criteria were: (1) age 18 or older, (2) clinical
stage T1 or T2 prostate cancer histologically confirmed on previous biopsy, and (3)
suitability for and willingness to undergo radical prostatectomy. The exclusion criteria
(with the numbers excluded in parentheses) were: (1) prior therapy for prostate cancer
(n=8); (2) use of 5-alpha reductase inhibitors within 6 months of the study start (n=6); (3)
inability to comply with preoperative imaging (n=1); (4) allergy to contrast agents (n=0);
(5) sickle cell or other anemias (n=0); (6) insufficient renal function (n=1); (7) sources of
artifact within the pelvis, such as hip and penile prostheses (n=1); (8) contraindications to
MRI such as electronic implants, metal in the orbit, cerebral aneurysm clips,
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claustrophobia and morbid obesity (n=11); and (9) prostate sizes exceeding the
dimensions of 5.1 cm × 7.6 cm (2 inch × 3 inch) whole-mount histology slides (n=15). In
total, 17 subjects were included in this study. The demographics and clinical
characteristics of these subjects are given in Table 6.1.
Table 6.1: Subject demographics and clinical characteristics.
Patient age median, range (y)
PSA level median, range (ng/mL)
Prostate volume estimated from transrectal ultrasound
median, range (cm3)
Pathologic stage (number of subjects)
T2c
T3a
Patient overall Gleason score
(number of subjects)
3+3
3+4
4+3

63, 45–68
4.8, 1.3–11.2
35, 19–49
12
5

5
11
1

6.2.2 Imaging
Subjects were imaged before radical prostatectomy in a 3 T GE Discovery
MR750 (GE Healthcare, Waukesha, WI, USA) with an endorectal coil (Prostate eCoil,
Medrad, Inc., Warrendale, PA, USA). The imaging protocol included T2W 2D fast spin
echo, DCE 3D spoiled gradient-recalled echo, and DW 2D echo-planar sequences, with
parameters shown in Table 6.2. All phases of the DCE images, without computed
pharmacokinetic maps, were available for interpretation during scoring and delineation
tasks. DW images were post-processed on the MRI system console to generate ADC
images, and both were available for interpretation during scoring and delineation tasks.
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Table 6.2: MRI sequence parameters.
Sequence
Repetition time (ms)
Echo time (ms)
Bandwidth (kHz)
Number of excitations
Field of view (cm)
Slice thickness (mm)
Slice spacing (mm)
Matrix
Number of slices
Flip angle (°)
Temporal spacing (s)

T2W
4000–13000
156–164
31.25
2
14
2.2
2.2
320 × 192
40
90
N/A

DCE
5.6–5.9
2.1–2.2
31.25
1–2
14
2.8
1.4
256 × 192
42
15
90

DW
4000
70–77
125.00
3
14
3.3–3.6
3.3–3.6
128 × 256
20–34
90
N/A

6.2.3 Lesion scoring and delineation
Images from each subject were independently read, blinded to histopathological
reports, by four observers who were aware of the inclusion criteria for the study: a
radiology resident (D.W.C.), a radiology fellow (M.B.-J.) and two radiologists (C.R. and
Z.K.) with 4.5, 2, 5.5, and 2 years of experience in prostate MRI assessment,
respectively. For each lesion, observers followed the process illustrated in Figure 6.1, and
described below, for lesion scoring and delineation. Images were assessed following the
PI-RADS guidelines [10] using ClearCanvas Workstation 7.1 (ClearCanvas Inc.,
Toronto, Canada). These guidelines specify recording, for each lesion, the location within
a 27-segment template, a 5-point likelihood score [denoting that clinically significant
cancer is (1) highly unlikely, (2) unlikely, (3) equivocal, (4) likely or (5) highly likely] as
well as separate 5-point sequence-specific scores for each sequence assessed (i.e. three
scores; one for each of the T2W, ADC and DCE sequences in our study) where higher
scores indicate image features associated with cancer. In this study, this record
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(henceforth referred to as a score assignment) was made only for lesions (henceforth
referred to as scored lesions) having a PI-RADS likelihood score of 3 (“equivocal”) or
greater. By a priori agreement, if a scored lesion recorded by at least one observer has no
corresponding score assignment recorded by another observer, a default PI-RADS
likelihood score of 2, denoting “unlikely cancerous”, was assigned for the latter observer.
On each sequence (i.e. T2W, DCE and ADC), each observer delineated a suspicious
region corresponding to each scored lesion that the observer felt could be contoured. In
this chapter, the term composite suspicious region refers to the union of the suspicious
regions (from different sequences) for a scored lesion recorded by an observer.
Delineations of suspicious regions were performed in ITK-SNAP 2.4 (www.itksnap.org)
using either the paintbrush or polygon mode (at the observer’s discretion), yielding a
binary label map depicting each suspicious region. For DCE images, suspicious regions
were delineated on one phase chosen by the observer. If one or more images was
considered by an observer to be non-diagnostic due to imaging artifacts, that observer
could decline to record the corresponding PI-RADS scores and/or to delineate the
corresponding suspicious regions for that image; these missing data were excluded from
the measurements of agreement.
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Identify lesion
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Figure 6.1: Observers' process for generating the PI-RADS scores and suspicious regions
analyzed in this study. Thin arrows denote process flow. Thick arrows denote data
(images, suspicious region contours, and PI-RADS scores).

6.2.4 Interobserver lesion correspondence
To calculate interobserver contour and score agreements, correspondences of
scored lesions between different observers were defined. Between observers, two scored
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lesions were taken to correspond if their composite suspicious regions overlapped. This
correspondence approach was intended to yield aggregate lesions which were spatially
distinct, and therefore each set of corresponding scored lesions is referred to in aggregate
as a distinct lesion in this chapter. For two cases, the overlap of composite suspicious
regions did not yield unambiguous lesion correspondence. In these cases, suspicious
regions were manually corresponded (as described in detail in Appendix B).

6.2.5 Interobserver score agreement
The interobserver score agreement was quantified as the average of the absolute
differences in PI-RADS likelihood and sequence-specific scores between pairs of
observers for corresponding scored lesions. We further quantified agreement in PI-RADS
likelihood scores using Schouten's weighted kappa [24] and using the proportion of
distinct lesions with four-observer consensus on classifying scored lesions with respect to
2 thresholds: <3 (highly unlikely or unlikely cancer) vs. ≥3 (equivocal, likely or highly
likely cancerous) and <4 (unlikely cancer or equivocal) vs. ≥4 (likely or highly likely
cancer). The interactions of PI-RADS scores and interobserver score agreement with
histological grade, anatomical location (i.e. peripheral zone or non-peripheral zone) and
volume were quantified using correlation coefficients.

6.2.6 Interobserver contour agreement
For each of the sequences, the interobserver contour agreement for corresponding
suspicious regions was measured using three pairwise metrics: (1) the Dice overlap
coefficient, (2) the symmetric mean absolute distance (MAD) and (3) the absolute
difference between volumes. When suspicious regions corresponded across more than
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two observers, the agreement was averaged across all pairwise comparisons. The Dice
overlap was computed as the volume of the overlap of two suspicious regions divided by
the average volume of the two suspicious regions. The symmetric MAD was computed
by (a) resampling two suspicious regions onto a 3D isotropic grid with a voxel side
length of 0.25 mm (approximately the smallest voxel dimension in the data set) using
nearest neighbor interpolation; (b) computing the average 3D Euclidean distance from
each voxel on the boundary of the first resampled suspicious region to the nearest voxel
on the boundary of the second resampled suspicious region, and vice versa from the
second resampled suspicious region to the first; and (c) averaging the two average
distances. Correlations of the interobserver contour agreements with the histological
grade, anatomical location, lesion volume as measured on MRI, mean PI-RADS
likelihood score and the mean PI-RADS sequence-specific score (for the same sequence)
were assessed.

6.2.7 Intersequence contour agreement
For each pair of sequences, the intersequence contour agreement for suspicious
regions for the same scored lesion was measured using the same three pairwise metrics as
described in the previous section. When suspicious regions for the same scored lesion
were identified on a pair of sequences by more than one observer, the metrics were
averaged across the observers. To account for different imaging grids for different
sequences, distortion and patient motion, each metric in this analysis was computed by
(1) interactively rigidly registering the MR images to a common reference frame using
3D Slicer 3.6 (Surgical Planning Lab, Harvard Medical School, Boston, USA), (2)
resampling the suspicious regions onto a common 0.25 mm isotropic grid using nearest-
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neighbor interpolation and (3) computing the three pairwise metrics on the resampled
suspicious regions. The mean intersequence target registration error was estimated to be
1 mm using intrinsic landmarks (comprising small atrophic cysts in regions of benign
hyperplasia or in the peripheral zone) on images from 3 subjects (4−6 landmark pairs per
image pair, 41 landmark pairs in total). Correlations of the intersequence contour
agreements with the histological grade, anatomical location, lesion volume as measured
on MRI, and mean likelihood score were assessed.
Score assignment was performed on all sequences together; however, delineation
of suspicious regions was performed on each sequence separately, and each observer
made a subjective judgment of whether or not he/she could adequately delineate on each
sequence a suspicious region corresponding to each scored lesion. For each sequence, we
therefore also calculated the ratio of the number of delineated suspicious regions to the
number of scored lesions. The ideal value of this ratio is 1, where every scored lesion
was also contoured.

6.2.8 Interaction factors
6.2.8.1 Histological grade
To determine the histological grade for each distinct lesion, digitized histology
images from the prostatectomy specimens were examined, and the resulting histological
grades were assigned to distinct lesions based on their corresponding composite
suspicious regions on MR images. Histology images were independently contoured and
graded in ImageScope 10 (Aperio Technologies, Vista, CA, USA) using a pen-enabled
21.5 inch widescreen display (Cintiq 22HD, Wacom Co., Ltd., Otone, Japan) at a 20x
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equivalent scale (illustrative contours are shown in Figure 6.2) by a clinician (M.G., with
2.5 years of experience in contouring prostate cancer contours on digital histology under
the training and supervision of J.A.G. and M.M., genitourinary pathologists with 13 and
22 years of experience, respectively) blinded to mpMRI. These contours and grades were
edited if required and confirmed by a genitourinary pathologist (J.A.G. or M.M.) blinded
to mpMRI. Regions on histological images were delineated as non-cancerous or with a
Gleason score [25] of 3+3, 3+4, 4+3 or 4+4. The interpretation of these scores is as
follows. A score of the form A+A (e.g. 3+3) denotes that only Gleason grade A (e.g. 3)
was present. A score of the form A+B (e.g. 3+4) denotes that Gleason grades A and B
(e.g. 3 and 4) were present and grade A (e.g. 3) tissue occupied more than 50% of the
total area of the region. For scores of the form A+B, the exact proportions of Gleason A
and Gleason B tissue within the region were not recorded due to practical considerations
arising from the fine-scale admixing of tissues of the different grades. Correspondence
establishment between distinct lesions identified on MRI and histological regions was
facilitated by a submillimeter-accurate 3D reconstruction of the mid-gland histology
sections (Chapter 4) [26]. This reconstruction makes explicit the plane-to-plane
correspondence between each 2D histology section and the 3D context of an ex vivo MRI
acquired prior to cutting the specimen and was intended to reduce the impact of observer
variability during the subsequent interactive visual correspondence of the reconstructed
histology with the MR images. Because histological regions were contoured and graded
at a smaller scale than the MR suspicious regions and the relative proportions of tissues
of different grades for histological regions with scores of the form A+B could not
practically be recorded, the proportion of grade 3 and 4 within distinct lesions on MRI
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containing both grades was estimated as an area-weighted average of the grades of
histological regions, assigning 100% of the area when only one grade was present and
assigning 75% of the area to the more prevalent grade and 25% of the area to the less
prevalent grade when more than one grade was present. In this chapter, the terms noncancerous lesions, cancerous lesions, and Gleason 7 lesions refer, respectively, to MRIdefined distinct lesions that did not corresponding to histological cancer, that
corresponded to any histological cancer, and that corresponded to aggregated histological
regions with Gleason score 7.

OL 5.0
4.8
GS
4+3
OL 5.0
4.8
GS
3+4
OL 3.7
4.1
GS
3+4
(a)

5.0

4.3

4.0

4.7

3.7

3.0

(b)

(c)

(d)

Figure 6.2: Illustrative (a) T2W, (b) ADC and (c) DCE mpMRI images for 3 subjects,
showing suspicious regions from 4 observers (yellow, magenta, cyan and red contours).
The Gleason scores (GS) and mean overall likelihood scores (OL) for each lesion are
shown on the left side, and sequence-specific scores are shown with each image. Panel
(d) shows post-prostatectomy histology corresponding to the distinct lesion in the top row
with insets showing the fine-scale contouring of Gleason 3+3 (yellow), 3+4 (cyan), 4+3
(green) and 4+4 (black) regions.
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6.2.8.2 Anatomical location
Because of the differences in mpMRI appearance of tumors in the peripheral zone
from those elsewhere in the prostate [10, 27, 28], the anatomical location of each distinct
lesion was categorized as either peripheral zone or non-peripheral zone for the purpose of
correlation analysis.
6.2.8.3 PI-RADS scores
For the correlation of interobserver contour agreement (on each sequence for all
three metrics) and intersequence contour agreement (on each pair of sequences for all
three metrics) with PI-RADS scores, the scores were averaged over the observers.
6.2.8.4 Tumor volume
Tumor volumes for the analyses in this study were estimated as the average of
volumes of corresponding suspicious regions. For analyzing positive predictive values
(PPVs) of PI-RADS likelihood scores as a function of tumor volume on MRI, volumes
were averaged over all sequences for one observer. For the correlation of interobserver
and intersequence contour agreements with tumor volumes, volumes were averaged over
all observers and all sequences.

6.2.9 Statistical analysis
Statistical analysis was performed using Matlab R2013a (The Mathworks Inc.,
Natick, USA). Reported overall PI-RADS likelihood scores included six non-integer
scores lying between 2 and 3 (two lesions), 3 and 4 (one lesion), and 4 and 5 (three
lesions); these were coded as scores of 2.5 (and excluded from analysis), 3.5 (and
included) and 4.5 (and included), respectively. Similarly, reported sequence-specific PI-
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RADS scores included five non-integer scores lying between 2 and 3 (one lesion) and 4
and 5 (four lesions), which were coded as scores of 2.5 and 4.5 (and included),
respectively. Differences in PPVs for different PI-RADS likelihood scores were assessed
using 95% confidence intervals on differences in proportions (combined Wilson score
without continuity correction [29]). Interobserver score agreements were estimated as a
mean and standard deviation of the score differences, and using Schouten's weighted
kappa [24]. Spearman’s rank correlation test was used to calculate correlations of
interobserver score agreements and PI-RADS scores with histological grade (coded as
ordinals: non-cancerous < Gleason 3+3 < Gleason 3+4 < Gleason 4+3), location (coded
as 0 for non-peripheral zone and 1 for peripheral zone) and volume. Interobserver and
intersequence contour agreements were estimated as the mean and standard deviation for
each metric. For each metric, Wilcoxon signed rank tests were used to compare the
interobserver contour agreement across sequences, corrected for multiple comparisons
using Bonferroni-Holm correction [30]. Spearman’s rank correlation test was used to
calculate correlations of interobserver and intersequence contour agreements with
histological grade (coded as above), location (coded as above), volume, mean PI-RADS
likelihood score and mean PI-RADS sequence-specific scores (for interobserver contour
agreement). We corrected for multiple comparisons using Bonferroni-Holm correction
(separately for the interobserver and intersequence contour agreements).

6.3 Results
Overall, 49 distinct lesions were identified as having a PI-RADS likelihood score
≥3 by at least one of the observers, yielding 104 score assignments (each distinct lesion
could be scored by 1 – 4 observers). 26 distinct lesions (and 68 score assignments)

213

corresponded to histological foci, of which 19 distinct lesions (and 48 score assignments)
had mean contoured volumes ≥0.2 cm3 (the smallest clinically significant cancer
according to [31]) and 9 distinct lesions (and 28 score assignments) had mean contoured
volumes ≥0.5 cm3 (the smallest clinically significant cancer according to [32]). The PPVs
of score assignments with PI-RADS likelihood scores of 3, 4 and 5 for any histological
cancer and for Gleason 7 cancer, are given in Table 6.3. PPVs for PI-RADS likelihood
scores of 5 were higher than those for PI-RADS likelihood scores of 3 or 4; however, we
had insufficient power to statistically distinguish between PPVs for PI-RADS likelihood
scores of 3 vs. 4.
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Table 6.3: Positive predictive values (PPVs) for any histological cancer and for Gleason
7 cancer of score assignments with PI-RADS likelihood scores of 3, 4 and 5,
individually, and scores above thresholds ≥3 and ≥4, broken down by lesion volume on
mpMRI.
Lesion volume on mpMRI PI-RADS likelihood score

Any volume

3
4
5
≥3
≥4

Positive predictive value
Any cancer
Gleason 7
59% (23/39)
46% (18/39)
50% (17/34)
41% (14/34)
89% (24/27)
85% (23/27)
65% (68/104) 57% (59/104)
69% (44/64)
63% (40/64)

> 0.2 cm3

3
4
5
≥3
≥4

52% (12/23)
52% (12/23)
87% (20/23)
66% (48/73)
71% (35/49)

43% (10/23)
43% (10/23)
83% (19/23)
59% (43/73)
65% (32/49)

> 0.5 cm3

3
4
5
≥3
≥4

100% (6/6)
57% (8/14)
93% (13/14)
80% (28/35)
76% (22/29)

83% (5/6)
50% (7/14)
93% (13/14)
74% (26/35)
72% (21/29)

6.3.1 Image assessment
The key findings from this analysis were that (1) the mean PI-RADS likelihood
score was correlated with histological grade and volume, (2) interobserver score
agreement in PI-RADS likelihood scores yielded a kappa value of 0.30, and observers
agreed more frequently on assigning likelihood scores <4 (unlikely cancerous or
equivocal) vs. ≥4 (likely or highly likely cancerous) than on assigning <3 (unlikely
cancerous) vs. ≥3 (equivocal, likely or highly likely cancerous), and (3) the mean
interobserver differences in PI-RADS likelihood and sequence specific scores ranged
from 0.6 to 1.2 points over a 5-point scale.
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The PI-RADS likelihood scores were broken down by histological grade (Figure
6.3) and mean suspicious region volume (Figure 6.4). Analogous graphs for PI-RADS
sequence-specific scores are included in Appendix C. As a basis for interpretation of
these graphs, consider the task of robustly reporting histological foci with Gleason score
3+3 or higher as cancerous lesions. For this task, the ideal breakdown depicted in these
graphs would show no non-cancerous foci recorded (i.e. as PI-RADS 3/“equivocal” or
higher), and all lesions corresponding to cancerous foci recorded and given a PI-RADS
likelihood score ≥4 by all 4 observers. In contrast, Figure 3 shows that 20 score
assignments with PI-RADS likelihood scores of 4 or 5, denoting likely or highly likely
cancerous lesions, were recorded for non-cancerous lesions (demarcated by the dotted
box on Figure 3). Additionally, 16 of 26 cancerous lesions and 9 of 19 Gleason 7 lesions
that were assessed and recorded by at least one observer, were denoted as a PI-RADS
likelihood score of 2 for one or more other observers (recall that by a priori agreement, a
default likelihood score of 2 was assigned for all observers that did not make a score
assignment for a distinct lesion recorded by at least one observer). The Gleason 7 false
negatives are demarcated by the dashed box on Figure 3. Figure 3 does, however, suggest
a positive relationship between PI-RADS likelihood scores and histological grade.
Similarly, Figure 4 shows a positive relationship between PI-RADS likelihood scores and
volume as measured on mpMRI. We identified significant correlations of the mean PIRADS likelihood score with volume (ρ=0.6, p=0.0001) and histological grade (ρ=0.6,
p=0.0001). The correlation between histological grade and volume (ρ=0.3, p=0.051) was
lower, but approached significance (without multiple comparison correction).We also
identified trends of correlation (p<0.05 before multiple comparison correction) relating
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histological grade to the T2W, DCE and ADC PI-RADS scores (ρ=0.3) and relating
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PI-RADS likelihood score

5
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volume to the T2W PI-RADS scores (ρ=0.4).
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Figure 6.3: PI-RADS likelihood scores for lesions broken down by histological grade.
Each vertical solid line corresponds to a distinct lesion, with horizontal dashes at the PIRADS likelihood score for each observer. For each grade, Tukey box plots show the
interquartile range (IQR), median (dotted line), mean (dashed line), and range of data
within 1.5 × IQR of the IQR (whiskers). The dotted box denotes “false positives” where
the PI-RADS likelihood scores denote likely or highly likely cancer for non-cancerous
lesions. The dashed box denotes “higher grade false negatives” where the observer did
not record a PI-RADS score for a Gleason 7 lesion. Note that by a priori agreement, a
default likelihood score of 2 was assigned for all observers that did not make a score
assignment for a distinct lesion recorded by at least one observer.
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Figure 6.4: PI-RADS likelihood scores for lesions broken down by mean suspicious
region volume. Each vertical solid line corresponds to a distinct lesion, with horizontal
dashes at the PI-RADS likelihood score for each observer. For each volume range, Tukey
box plots show the interquartile range (IQR), median (dotted line), mean (dashed line),
and range of data within 1.5 × IQR of the IQR (whiskers). Note that by a priori
agreement, a default likelihood score of 2 was assigned for all observers that did not
make a score assignment for a distinct lesion recorded by at least one observer.
The interobserver score agreement for PI-RADS likelihood scores yielded a
kappa value of 0.30 across all distinct lesions. On the subsets of cancerous lesions and
Gleason 7 lesions, the weighted kappa values were 0.35 and 0.34, respectively.
Interobserver score agreement for assigning likelihood scores <3 vs. ≥3 and <4 vs. ≥4,
for all distinct lesions, for cancerous lesions, for Gleason 7 lesions and for distinct
lesions with volumes ≥0.5 cm3 are shown in Table 6.4, suggesting higher agreement in
distinguishing PI-RADS likelihood scores <4 from ≥4 than in distinguishing scores <3
from ≥3, and slightly higher agreement for more clinically significant lesions (in terms of
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grade and lesion volume as measured on MRI). The mean ± SD interobserver difference
in likelihood, T2W, DCE and ADC PI-RADS scores were 0.8 ± 0.4, 0.6 ± 0.6, 1.2 ± 0.9
and 0.6 ± 0.5 respectively. On Gleason 7 lesions, the differences were 0.9 ± 0.5, 0.7 ±
0.6, 1.3 ± 0.8 and 0.6 ± 0.5, respectively. Our analysis failed to detect correlations
relating interobserver score agreement to histological grade, anatomical location or
volume.
Table 6.4: Interobserver agreement in assigning PI-RADS likelihood scores for two
thresholds.

All scored lesions
Cancerous lesions
Gleason 7 lesions
Scored lesions
with volumes ≥
0.5 cm3

Threshold <3 vs. ≥3
Weighted
Consensus
kappa
proportion
0.17
24% (12/49)
0.26
38% (10/26)
0.23
53% (10/19)
0.24

50% (7/14)

Threshold <4 vs. ≥4
Weighted
Consensus
kappa
proportion
0.38
47% (23/49)
0.44
46% (12/26)
0.43
47% (9/19)
0.45

50% (7/14)

The threshold <3 vs. ≥3 separates unlikely cancerous from equivocal or likely cancerous. The threshold <4
vs. ≥4 separates unlikely cancerous or equivocal from likely cancerous findings.

6.3.2 Interobserver and intersequence contour agreement
The key findings from this analysis were (1) that observers chose to delineate
suspicious regions on T2W (103/104 score assignments) and ADC (96/104) images more
frequently than on DCE (87/104) images; (2) ADC images had marginally superior
interobserver contour agreement (not significant after multiple comparison correction)
for all three measures compared to T2W images and DCE images; and (3) for all pairs of
sequences, intersequence absolute differences in suspicious region volumes were
correlated with PI-RADS likelihood scores and average suspicious region volumes.
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The mean and standard deviation of the interobserver and intersequence contour
agreement measurements are shown in Table 6.5. The mean Dice overlap ranged from
0.3 to 0.5. The mean MAD ranged from 1.5 to 2.4 mm; for comparison, the mean ±
standard deviation of the distinct lesions' longest diameters (averaged over all suspicious
regions corresponding to each distinct lesion) was 15.0 ± 5.0 mm. The mean differences
in absolute volume ranged from 0.2 to 0.5 cm3; for comparison, the mean ± standard
deviation of the distinct lesions' volumes (averaged over all suspicious regions
corresponding to each distinct lesion) was 0.5 ± 0.9 cm3. When including only Gleason 7
lesions, the interobserver and intersequence contour agreement were within 0.05 (Dice
overlap), 0.2 mm (MAD) and 0.1 cm3 (absolute difference in volume) of those for all
distinct lesions reported in Table 6.5. Our analysis failed to detect significant differences
in interobserver contour agreement between the sequences; however, the interobserver
contour agreement on ADC images was marginally superior for all 3 measures in our
data, and the intersequence contour agreement between ADC and T2W was marginally
superior than agreement between other pairs of sequences.
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Table 6.5: Interobserver and intersequence contour agreement, and comparison of
interobserver contour agreement across sequences.

Interobserver
contour
agreement
Intersequence
contour
agreement

T2W
DCE
ADC
T2W – DCE
T2W – ADC
ADC – DCE

Dice
overlap
mean ± SD
0.4 ± 0.2
0.4 ± 0.3
0.5 ± 0.2
0.4 ± 0.2
0.4 ± 0.1
0.3 ± 0.2

MAD
mean ± SD
(mm)
2.4 ± 2.2
2.2 ± 1.6
1.8 ± 1.9
1.6 ± 0.9
1.5 ± 0.8
2.0 ± 1.1

Absolute difference in
volume
mean ± SD (cm3)
0.5 ± 0.6
0.5 ± 0.7
0.5 ± 0.5
0.2 ± 0.3
0.2 ± 0.2
0.2 ± 0.5

SD denotes standard deviation, MAD denotes mean absolute distance between two contour boundaries,
Dice denotes the overlapping volume as a fraction of the average volume of two contours. See Section
6.2.6 for details.

Table 6.6 shows the correlation coefficients between interobserver and
intersequence contour agreement and each of the interaction factors: the volume; the
histological grade; the anatomical location; the PI-RADS likelihood score; and, for
interobserver contour agreement, the corresponding PI-RADS sequence-specific scores.
The intersequence absolute differences in contoured volumes were correlated with tumor
volume (0.7<ρ<0.8) and PI-RADS likelihood score (0.5<ρ<0.6) on all sequences, and the
Dice overlap was correlated with the volume for ADC–DCE images. The interobserver
absolute differences in contoured volumes were correlated with volume as well
(0.5<ρ<0.8), and the interobserver Dice overlaps were correlated with the PI-RADS
likelihood score on DCE. Our analysis failed to detect significant correlation of either the
interobserver or intersequence contour agreements with histological grade, anatomical
location or PI-RADS sequence specific scores.
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Intersequence

Interobserver

Table 6.6: Spearman correlation coefficients* of interobserver and intersequence contour
agreement with interaction factors.

Dice
MAD
T2W
ΔVolume
Dice
MAD
DCE
ΔVolume
Dice
MAD
ADC
ΔVolume
T2W – DCE
Dice
MAD
ΔVolume
T2W – ADC
Dice
MAD
ΔVolume
ADC – DCE
Dice
MAD
ΔVolume

Volume Histological Anatomical PI-RADS PI-RADS
grade
location likelihood sequence–
score
specific
score
0.1
0.0
0.1
0.5
0.5
0.3
0.1
-0.3
-0.1
-0.3
0.4
0.1
0.4
0.8
0.4
0.1
0.3
-0.1
0.7
0.5
0.2
-0.1
0.0
-0.5
-0.5
0.2
0.2
0.2
0.5
0.5
0.0
-0.2
0.2
0.2
0.5
0.4
0.2
0.0
-0.1
-0.5
0.3
-0.1
0.4
0.2
0.6
0.3
0.2
0.0
0.2
N/a
0.3
0.0
0.0
0.2
N/a
0.0
N/a
0.7
0.3
0.6
0.0
-0.1
N/a
0.4
0.3
0.0
0.2
0.1
0.1
N/a
0.3
0.1
N/a
0.7
0.5
0.2
-0.1
N/a
0.5
0.3
-0.2
0.1
0.2
-0.1
N/a
0.3
0.1
N/a
0.8
0.6

*Each value in the table represents the correlation coefficient between an interaction factor (by column; see
Section 6.2.8 for details) and a contour agreement metric (by row; see Section 6.2.6 for details). MAD
denotes mean absolute distance between two suspicious region boundaries, Dice denotes the overlapping
volume as a fraction of the average volume of two suspicious regions, ΔVolume denotes absolute
difference in suspicious region volume. Bolded elements were significant (α=0.05) after multiple
comparison correction. Bold italicized coefficients were significant (α=0.05) before, but not after multiple
comparison correction.
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6.4 Discussion
The accuracy and precision of localizing cancerous lesions is critical to the
evaluation and clinical application of lesion-focused biopsies as well as lesion-focused
therapies, such as cryotherapy, focal-laser ablation, high-intensity focused ultrasound,
and lesion-targeted radiation boost.
This work investigated the variability in prostate cancer scoring and delineation
on mpMRI to address the following four questions. (1) What is the interobserver
agreement in scoring lesions as equivocal, likely cancerous or highly likely cancerous,
following the PI-RADS guidelines? (2) What is the interobserver agreement in regions
delineated on T2W, DCE and ADC images? (3) What is the intersequence agreement in
regions delineated by an observer on these sequences? (4) What are the interactions
between these aspects of agreement with the histological grade, anatomical location, and
volume? In this study, prostate cancer PI-RADS scoring and contouring on T2W, ADC
and DCE 3 T MRI show promise: likelihood scores correlated with Gleason grade and
scores of 5 had an 85% PPV for Gleason 7 cancer, but we observed high interobserver
score and contour variability.
The use of mpMRI for prostate cancer detection and staging has been widely
reported [9-11, 17, 19-21, 33], and consensus guidelines have been proposed, including
the PI-RADS structured reporting system used in this study [10]. In our data set, score
assignments with PI-RADS overall likelihood scores of 5 had an 85% (23/27) PPV for
Gleason 7 cancer, whereas those with likelihood scores of 3 and 4 had substantially lower
PPVs of 46% (18/39) and 41% (14/34), respectively. A similar difference was seen in the
PPVs for any cancer. In the context of clinical guidelines regarding the use of the PI-
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RADS likelihood score to inform the decision to apply focal therapy to the lesion, setting
a threshold criterion for the PI-RADS likelihood scores may be valuable; in our study,
likelihood scores ≥3, ≥4 and =5 had PPVs of 65% (68/104), 69% (44/64) and 89%
(24/27). Although the small number of Gleason 4+3 tumors in our study precludes strong
conclusions, we also observed that 75% (9/12) of the score assignments corresponding to
Gleason 4+3 foci had PI-RADS likelihood scores >4 (including 2 likelihood scores coded
as 4.5). The prevalence of score assignments with PI-RADS likelihood scores denoting
likely (17 score assignments) or highly likely (3 score assignments) cancer that did not
correspond to histological foci suggests that further investigation of image features acting
as confounders [34, 35] in PI-RADS scoring (particularly PI-RADS likelihood scores of
4) could be valuable. Such false positive score assignments were made by all four
observers. There were 26 cancerous lesions identified by the observers, for which there
was the potential for 104 score assignments (26 cancerous lesions × 4 observers = 104
potential sets of PI-RADS scores). Of these potential score assignments, there were 36
false negative instances where the observer did not assign a PI-RADS likelihood score of
3 or higher. For Gleason 6 lesions, the proportion of these false negatives was higher than
for Gleason 7 lesions, which is consistent with previously described challenges in
detecting lower grade cancer on mpMRI [36], and may have marginal clinical
significance [37]. However, there were 17 false negative instances for Gleason 7 lesions,
which potentially have higher clinical significance. All four observers made such false
negative assessments. Note that these data may underestimate the false negative rate, as
they exclude histological foci not recorded by any observer. The performance of mpMRI
seen in this study may reflect, in part, the predominantly lower grade cancers in our study
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population (with patient Gleason scores of G3+3 [n=5], G3+4 [n=11], and G4+3 [n=1],
with no higher grade cancer), compared to previous studies [23]. Such a lower grade
cohort may be more reflective of early stage cancer populations than a typical radical
prostatectomy cohort.
We observed a correlation of ρ=0.6 between histological grade and the PI-RADS
likelihood score, and trends towards correlation for each of the sequence-specific scores.
However, our analysis of interobserver score agreement yielded a weighted kappa value
of 0.30 (consistent with the fair to moderate agreement reported in recent evaluations of
PI-RADS assessments [38, 39]), and there was a 0.6 – 1.2 point average interobserver
difference in the assignment of PI-RADS scores. This interobserver variability may
represent a barrier that needs to be overcome to realize the potential of PI-RADS
assessment. The high variability in PI-RADS DCE scores, in particular, may be related to
the use of a low-temporal-resolution (90 seconds per phase) DCE protocol, or the lack of
pharmacokinetic DCE maps; our investigation of this issue is currently ongoing.
mpMRI assessment has also been shown to support localization of cancer to
prostate sextants [12-14]. This study complements existing studies of regional
localization by directly evaluating the observer delineation of suspicious regions that
could be used to define target volumes for lesion-focused diagnostics and therapies, and
comparing delineations performed on different image sequences. The interobserver
variability measured in this study suggests that there can be substantial disagreement
regarding where the boundaries of such delineations should be. This variability injects
uncertainty into clinical investigations of focal therapy, and may represent a barrier that
needs to be overcome for the clinical implementation of focal therapy using mpMRI. The
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intersequence variability observed in this study suggests that the choice of sequence for
delineation may affect the resulting target volumes, and a marginally improved
interobserver contour agreement for ADC images suggests further investigation of
contouring on ADC images.
The conclusions of this study should be considered in the context of its
limitations. Because each observer performed the scoring and delineation tasks
independently of the other observers, interobserver lesion correspondence was defined a
posteriori based on the overlap of composite suspicious regions, complicating accurate
correspondence. For example, in theory, two partially overlapping suspicious regions
intended by different observers to denote two distinct lesions could have been
corresponded as a single distinct lesion. Alternately, a distinct lesion delineated as one
lesion by one observer and as two separate lesions by another observer might have no
well defined one-to-one correspondence between lesions. Such errors could result in
overestimation of interobserver variability. This was mitigated by visual inspection of all
corresponded regions, and manual correspondence was used in the two cases where it
was deemed necessary. Observers' intersequence lesion correspondence was also
complicated by patient motion between imaging sequences (1 – 13 mm in-plane and 2 –
10 mm out-of-plane), forcing the observers to mentally register the images during the
score assignment on mpMRI. In calculating intersequence contour agreement metrics,
however, rigid image registration with 1 mm mean target registration error was used to
reduce metric error due to misalignment. The sample included in this study was small and
contained only three tumors with Gleason score 4+3, only one subject whose overall
Gleason score was 4+3, and no cancer with Gleason pattern 5. Although interobserver
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score and contour agreement may be different on such a sample than on one including
more advanced cancers, our sample may be more representative a group of patients
suitable for focal therapy. Other limitations include a small number of readers and
variability in experience of the readers. Examination of correlation of the lesion boundary
as delineated by the radiologist against the histological boundary was out of the scope of
this study – this analysis would be necessary to evaluate the accuracy of delineation
strategies on mpMRI (e.g. whether a target should be delineated on a single sequence, or
computed from the overlap or combination of delineations on multiple sequences).
In conclusion, lesion assessments following the PI-RADS guidelines yielded
cancer likelihood scores that correlated with Gleason scores assessed on postprostatectomy histology. Scoring a lesion on mpMRI as having a PI-RADS likelihood
score of 5 had a PPV of 85% for Gleason 7 cancer, with PPV of 93% for such lesions
having volumes of > 0.5 cm3 measured on mpMRI. However, interobserver agreement in
the PI-RADS likelihood score yielded a weighted kappa value of 0.30 and average
interobserver differences in the PI-RADS likelihood and sequence specific scores were
0.6 –1.2 points over a 5 point scale, suggesting variability that may impede interpretation
of PI-RADS assessments. The prevalence of PI-RADS likelihood scores denoting likely
or highly likely cancer for histologically non-cancerous lesions suggests a need for
further investigation of image features that confound PI-RADS assessments. The
delineation of suspicious regions was performed more frequently on T2W and ADC
images than on DCE images. Suspicious regions delineated on ADC images showed a
trend towards superior interobserver agreement compared to T2W and DCE images (with
an average interobserver boundary distance of 1.8 mm for ADC images vs. 2.4 mm and
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2.2 mm for T2W and DCE images, respectively). This suggests further investigation of
contouring on ADC images instead of, or in addition to, contouring on the more
commonly used T2W images and perhaps the inclusion of additional imaging
information (e.g. pharmacokinetic maps computed from DCE).
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Chapter 7.
Toward prostate cancer contouring guidelines on MRI:
dominant lesion gross and clinical target volume
coverage via accurate histology fusion

†

7.1 Introduction
Delineation of prostate cancer target volumes on imaging has the potential to
contribute to the treatment of men with low-intermediate-risk, localized prostate cancer.
Therapies targeted at delineated lesions, including focal laser ablation [1],
cryotherapy [2], and high-intensity focused ultrasound [3], may be suitable curativeintent treatments for many men with low-intermediate-risk cancers, and have lower
morbidity than radical prostatectomy or radiation therapy [2, 4]. For men with more
advanced cancers undergoing radiation therapy, focal boosting of the radiation dose
within a delineated dominant lesion target volume may reduce the rate of recurrence at
the dominant lesion and improve outcomes [5, 6]. Over-contouring the actual extent of
cancer could result in increased damage to prostate tissue and surrounding sensitive

† A preliminary analysis of the data presented in this chapter have been accepted for presentation:
E. Gibson, M. Gaed, J. A. Gómez, M. Moussa, C. Romagnoli, Z. Kassam, M. Bastian-Jordan, D. W. Cool,
S. Pautler, J. L. Chin, C. Crukley, G. S. Bauman, A. Fenster, A. D. Ward. "Toward prostate cancer
contouring guidelines on MRI: dominant lesion gross and clinical target volume coverage via accurate
histology fusion." To be presented at the American Society for Radiation Oncology Annual Meeting; San
Francisco, USA; September 2014. A version of this chapter is in preparation for submission: E. Gibson,
C. Romagnoli, M. Bastian-Jordan, D. W. Cool, Z. Kassam, M. Gaed, M. Moussa, J. A. Gómez, S. Pautler,
J. L. Chin, C. Crukley, G. S. Bauman, A. Fenster, A. D. Ward, “Toward prostate cancer contouring
guidelines on MRI: dominant lesion gross and clinical target volume coverage via accurate histology
fusion” Radiology (in preparation).
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organs, while under-contouring could result in delivering a lower than intended treatment
dose to cancerous tissue.
mpMRI has shown promise for detecting [7, 8] and staging [9] prostate cancer, as
well as approximate localization of cancer to a sextant of the prostate [10-12]. The
suitability and optimal use of mpMRI for accurately and precisely delineating
intraprostatic cancer target volumes, however, has not been well characterized. A recent
evaluation of delineations within single 2D MRI slices [13] suggests that delineations of
the visible cancer (hereafter referred to as gross target volumes or GTVs) do not cover all
histologically identified cancerous tissue for detected cancers, and that adding margins to
GTVs to account for cancer not visible on imaging (creating clinical target volumes or
CTVs) may be a suitable approach to achieve adequate histological coverage (defined as
95% in their analysis). However, a 2D analysis that uses 2D instead of 3D GTVs and that
excludes cancer extending in the inferior-superior direction may underestimate the
necessary margins. There is, therefore, a need to evaluate margins in a 3D context for
CTVs defined in 3D (as would be done in practice).
Selection of appropriate margins is complex and depends on many factors
including predictions of how far cancer typically extends beyond GTVs, the treatmentmodality-specific effects of spatially over- and under-treating the cancer and the
treatment-modality-specific feasibility of treating CTVs with specific shapes and sizes.
For example, focal laser ablation increases temperatures within a defined volume of
tissue surrounding the tip of an inserted optic laser fiber and the number of fiber
applications in a procedure is limited by time and cost; thus, the volume of a CTV is
important to assessing the feasibility of treatment with this modality.
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Accurate registration of prostatectomy histology to mpMRI (and corresponding
GTVs and CTVs) enables the retrospective estimation of the histological cancer covered
by CTVs with specified margins, characterizing the typical extension of cancer beyond
GTVs. Although the extent of histological cancer is not known at treatment, prediction
intervals for histological coverage at specified margins could inform decisions about
appropriate margins for unseen patients.
In this pilot study, we investigated the spatial relationships of GTVs contoured on
different mpMRI sequences and CTVs with isotropic margin expansion from the GTVs
to the prostate volume and to histologically identified cancer. Specifically, we addressed
the following three questions:


Question 1: What margins must be added to delineated GTVs to achieve
adequate coverage of histological cancer? Specifically, for true positive GTVs
detected following PI-RADS guidelines, what margin expansion will yield, with
high likelihood, CTVs that leave 0%, 5% and 10% residual cancer from
corresponding histologically identified cancer foci (Gleason score ≥6) and highgrade cancer foci (Gleason score ≥7)?



Question 2: What are the volumes of CTVs defined using such margins? The
answer to this question illuminates the feasibility of delivering treatment to the
CTVs using different focal therapy modalities.



Question 3: What are the relative volumes of the CTVs defined using such
margins with respect to the corresponding GTVs and the corresponding
histological foci? The answer to this question provides information regarding the
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necessary volumetric expansions of the GTVs, and amount of non-cancerous
parenchyma that would be treated within the GTVs.

7.2 Materials and methods
This study was conducted with the approval of the Human Subjects Research
Ethics Board of our institution and with the informed consent of all subjects.

7.2.1 Participants
Our study population comprised 25 men selected from patients being treated for
prostate cancer by one of three collaborating urologists. The demographics and clinical
characteristics of these subjects are given in Table 7.1. 107 patients were screened for
this study between March 2010 and December 2011. Inclusion criteria included (1) age
18 or older, (2) clinical stage T1 or T2 prostate cancer confirmed on previous biopsy, and
(3) suitability for and willingness to undergo radical prostatectomy. The exclusion criteria
were (1) previous prostate cancer therapy (n=8); (2) use of 5-alpha reductase inhibitors in
the 6 month period prior to enrollment in the study (n=6); (3) inability to undergo
imaging prior to the surgery (n=1); (3) allergies to the contrast agents (n=0); (5) sickle
cell or other anemia (n=0); (6) insufficient renal function (n=1); (7) sources of imaging
artifacts in the pelvis (e.g. hip or penile prostheses) (n=1); (8) contraindications to MRI
such as metal in the orbit, cerebral aneurysm clips, claustrophobia and morbid obesity
(n=11); and (9) prostate sizes exceeding the dimensions of 2 inch by 3 inch whole-mount
histology slides (n=15).
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Table 7.1: Subject demographics and clinical characteristics.
Patient age median, range (y)
PSA level median, range (ng/mL)
Prostate volume estimated from transrectal ultrasound
median, range (cm3)
Pathological stage (number of subjects)
pT2c
pT3a
pT3b
Patient overall Gleason score
(number of subjects)
3+3
3+4
3+4+5
4+3

63, 45–72
4.7, 1.3–18.8
35, 19–49
17
7
1

6
17
1
1

7.2.2 Imaging
We acquired mpMRI of the prostate 19±8 weeks (mean±SD) weeks post-biopsy
and 2±1 (mean±SD) weeks before surgery. mpMRI were acquired on a 3 T GE
Discovery MR750 (GE Healthcare, Waukesha, WI, USA) with an endorectal coil
(Prostate eCoil, Medrad, Inc., Warrendale, PA, USA) using T2-weighted (T2W),
dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) clinical sequences
detailed in Table 7.2. An additional high-resolution T2W image was also acquired to
support registration (also detailed in Table 7.2). DW images were processed on the MRI
console to generate apparent diffusion coefficient (ADC) maps. Images from any
sequence where 3 of the 4 radiologist noted that the images were non-diagnostic or
suffered from artifacts or distortion were excluded from the analysis; four ADC images
were excluded based on this criterion.
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Table 7.2: mpMRI sequence details.
Sequence

Clinical T2W Clinical DCE Clinical DWI

Repetition time (ms) 4000–13000
156–164
Echo time (ms)
31.25
Bandwidth (kHz)
2
Number of excitations
14
Field of view (cm)
2.2
Slice thickness (mm)
2.2
Slice spacing (mm)
320 × 192
Matrix
40
Number of slices
90
Flip angle (°)
N/A
b-value
N/A
Temporal spacing (s)

5.6–5.9
2.1–2.2
31.25
1–2
14
2.8
1.4
256 × 192
42
15
N/A
90

4000
70–77
125.00
3
14
3.3–3.6
3.3–3.6
128 × 256
20–34
90
600–800
N/A

High resolution
T2W
2000
144–177
125
0.5–2
14
1.4
0.7
320 × 192
84–144
90
N/A
N/A

After resection, the prostate gland was fixed for at least 48 hours in 10% buffered
formalin. MRI- and histology-visible fiducials [14] were affixed to the specimen and ex
vivo MR images of the gland were acquired to support histology fusion [15] (described in
Section 7.2.5). The prostatic apex and base were removed for parasagittal histology, and
the midgland was cut into 4.4 mm slices using a rotary cutter and was processed using
our clinical laboratory’s whole-mount histology protocol. Only the midgland histology
was used in the analysis in this study. Histology was stained with hematoxylin and eosin,
and digitized using a ScanScope GL (Aperio Technologies, Vista, CA, USA) bright field
slide scanner at 20x magnification (yielding a 0.5 μm pixel size).

7.2.3 Lesion scoring and delineation
mpMRI images were independently read, blinded to histopathological results, by
four observers, comprising one radiology resident (D.W.C.) and three radiologists (C.R.,
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M.B.-J., and Z.K.) with 5, 6, 2.5 and 2.5 years of experience in prostate MRI assessment,
respectively. Observers identified lesions using all mpMRI sequences together, and
following the PI-RADS guidelines [8] assessed the overall likelihood score. For lesions
judged to be equivocal (PI-RADS likelihood score of 3), likely cancer (4) or highly likely
cancer (5), the observer attempted to delineate the lesions on images from each of the
mpMRI sequences. Images were read using ClearCanvas 7.1 (ClearCanvas Inc., Toronto,
Canada). Lesions were delineated on all image slices using a pen-enabled 21.5 inch
widescreen display (Cintiq 22HD, Wacom Co., Ltd., Otone, Japan) with ITK-SNAP 2.4
software (www.itksnap.org) in polygon or paintbrush mode.

7.2.4 Histological contouring and grading
Histology images were delineated and graded, blinded to MR imaging, by a
clinician (M.G.) with 3 years of experience in contouring prostate cancer on digital
histology images under the supervision of 2 genitourinary pathologists (J.A.G. and M.M.)
with 13 and 22 years of experience, respectively. Each region of homogenous or
intermingled Gleason grade was graded and delineated, as illustrated in Figure 7.1. The
resulting contours were edited, if required, and confirmed by one of the pathologists.
Histology images were delineated and graded using a pen-enabled 21.5 inch widescreen
display (Cintiq 22HD, Wacom Co., Ltd., Otone, Japan) with ImageScope 10 software
(Aperio Technologies, Vista, CA, USA).
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Figure 7.1: Illustrative example of a contoured and graded H&E-stained whole-mount
histology image (A) with magnified insets (B) and (C), showing homogenous Gleason
3+3 (brown), intermingled Gleason 3+4 (dark green), intermingled Gleason 4+3 (purple),
and prostatic intraepithelial neoplasia (light green) contours.

7.2.5 Histology-mpMRI registration
Histology images, and the corresponding contours, were registered to the mpMR
images using a three stage registration. First, the histology images were reconstructed
into the 3D context of ex vivo MR images using a method employing histology- and
MRI-visible strand-shaped fiducial markers (Chapter 4) [15]. This method minimizes the
fiducial registration error, under the space of affine transformations, between crosssections of fiducial markers identified on histology and the corresponding curves of the
strand-shaped fiducial markers on ex vivo MRI. Second, the ex vivo MR images (and
corresponding histology and contours) were transformed into the space of the high
resolution T2W in vivo image using a thin-plate-spline (TPS) deformation [16] computed
from 33–91 control points defined interactively in 3D Slicer 4.2 (Surgical Planning Lab,
Harvard Medical School, Boston, USA). Finally, the images from the three mpMRI
sequences were registered to the high resolution 3D T2W image using a rigid
transformation defined interactively in 3D Slicer. Where residual non-rigid spatial
distortion was observed between in vivo images (which occurred in 6 ADC images), it
was mitigated using an interactively defined TPS deformation.
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The target registration error (TRE) for the histology reconstruction has been
previously reported (Chapter 4) [15]. The TRE for the rigid mpMRI co-registration was
estimated by identifying pairs of homologous landmarks and measuring the posttransformation 3D Euclidean distance between corresponding pairs. The TRE for the TPS
deformations (ex vivo–in vivo registration and in vivo–in vivo distortion correction) was
estimated using a leave-one-control-point-pair-out estimate,
7.1
where

and

are the

-th control point pair (in the moving and fixed image,

respectively) for the -th image pair,
except the

-th control point pair, and

is the TPS deformation defined using all
is the number of control point pairs in the -th

image pair.

7.2.6 Histology fusion
Because the histology was contoured and graded at a fine scale (see Figure 7.1),
histology contours were aggregated into foci. Within each histology image, contours
within 2 mm were considered to be part of the same aggregated histological focus. To
aggregate contours between adjacent histology images, contours were reconstructed into
3D (in the space of the ex vivo image) and projected onto a plane midway between the
reconstructed histology images; any contours that overlapped were considered to be part
of the same aggregated histological focus. Aggregated foci smaller than 0.1 cm3
(estimated using planimetry as the in-plane area times the histological spacing) with a
Gleason score of 3+3 were excluded from analysis. True positive GTVs were identified
by the first author (not involved in mpMRI or histology contouring) using the co-
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registered contoured histology and mpMRI images. Where two observer GTVs
corresponded to a single aggregated focus, the union of the GTVs was considered as a
single GTV.

7.2.7 CTV definition
Single-sequence CTVs were defined by expanding GTVs on images from each
sequence (T2W, DCE and ADC) by 3D isotropic margins from 0–30 mm at 0.5 mm
intervals, with the CTVs constrained to lie within the prostate. Binary masks representing
the isotropic expansion of the GTVs (computed in the delineated image) were
transformed to the high resolution T2W image space using the co-registration
transformations described in Section 7.2.5. Binary masks of the prostate volume,
computed by thresholding an ex vivo MRI of the resected specimen, were also
transformed to the high resolution T2W image space, and used to constrain the CTVs to
the prostate volumes.
In addition to the single-sequence CTVs, composite CTVs were defined by the
union of single-sequence CTVs for each pair of mpMRI sequence (i.e. T2W+DCE,
T2W+ADC and (DCE+ADC) and for the union of all three sequences (i.e.
T2W+DCE+ADC). For true positive findings where an observer declined to contour on
one of the sequences, composite CTVs including that sequence were not defined.

7.2.8 Histological coverage
The coverage of histologically identified cancer in the midgland was estimated for
CTVs corresponding to each true positive GTV. Following a stereological approach [17],
the volumetric proportion of residual cancer was estimated from the proportion by area
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on the histology sections as the ratio between the total area of residual cancer and the
total area of cancer across histology samples. CTVs were sampled along the best-fit
oblique plane to the deformably co-registered histology surface, and histology contours
were projected on this oblique plane. The histology contours and CTVs were discretized
onto a 0.27 mm grid (matching the in-plane spacing of the highest resolution in vivo MR
image). The proportional residual area of cancer for each CTV was computed as the
proportion of discretized histology pixels containing cancer from the corresponding
aggregated focus that were not contained within the CTV. The proportional residual area
of high-grade cancer for each CTV was computed similarly, limiting the analysis to
pixels containing Gleason grades 4 or 5, and excluding aggregated foci containing only
Gleason grade 3. To the best of our knowledge, the prognostic impact of small volumes
of residual cancer post-treatment are not known and may vary with treatment modality,
challenging the definition of adequate histological coverage. To mitigate this uncertainty,
we investigated 3 thresholds for residual cancer area: 0%, 5% (following [13]) and 10%
residual area.
In order to identify the minimum margin with a high likelihood of achieving the
specified residual area for a new patient, considering intertumor variability, we computed
one-sided non-parametric prediction intervals (PIs) for the percentage of residual cancer
area and for the percentage of residual high-grade cancer. PIs were computed for each
observer for each type of CTV (3 single-sequence and 4 composite types) at each margin
size. The confidence level and construction of the PIs are described in Section 7.2.10.
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7.2.9 CTV volumetrics
Since individual sequences may consistently over- or under-estimate the extent of
cancer and different margins could be specified for each CTV type to account for this,
CTV volumetric analyses across CTV types were based on a fixed residual area criterion
instead of fixed margin sizes (see discussion for more details). Specifically, for each
observer and CTV type, the smallest margin that yielded a residual area prediction
interval upper bound <5% was defined as the PI margin. Different CTV types were
compared at their respective PI margins. The 5% residual area criterion corresponds to an
adequate coverage threshold described in previous literature [13].
We computed the absolute volumes of the CTVs with PI margins, in the space of
the high resolution T2W image. We compared these volumes to 2 thresholds: 4.5 cm3,
based on reported volumes for focal laser ablations [18]; and 10 cm3, based on reported
volumes for focal radiation boosting [6]. We also computed the relative sizes of the
CTVs with PI margins with respect to the volumes of the GTVs, in the space of the high
resolution T2W image. The volume ratios between the CTVs and GTVs were expressed
as scaling factors (defined as the cube roots of the volume ratios) representing the
equivalent expansions in each dimension. We computed the relative volumes of the
CTVs with respect to the histologically identified cancers in a manner similar to the
residual area calculation, using planimetrics in the space of the best-fit oblique planes to
the deformably co-registered histology images. The volume ratios between the CTVs and
cancer foci were expressed as scaling factors (defined as the square roots of the
planimetric volume ratios) representing the equivalent expansion in each dimension.
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7.2.10 Statistical analysis
Statistical analyses were performed in SPSS 21 (IBM Corp., Armonk, NY). The
impact of tumor and observer variability (as random effects) and the incremental effect of
contouring on each sequence (as fixed effects) on the minimum margin required to
achieve 95% coverage were tested using a mixed-effects ANOVA (with an observer ×
tumor interaction term and pairwise sequence inclusion interaction terms). Relative
contributions of tumor and observer variability to margin variability were computed as
variance components under the same mixed-effects model. Non-parametric, one-sided
prediction intervals of residual cancer and residual high-grade cancer were calculated
aggregated over the N true positive CTVs for each observer for each CTV type at each
margin size. The confidence levels chosen for these intervals were (N–1)/(N+1), such that
the prediction interval upper bound corresponded to the penultimate order statistic of the
sample [19]. This mitigated the sensitivity to outliers of the highest confidence level
prediction interval (corresponding to the maximum on the sample).

7.3 Results
In our data set, 23/25 subjects had midgland aggregated foci included in the
analysis, yielding 59 aggregated foci. Of the foci larger than 0.1 cm3, 76% (22/29) were
contoured by at least one observer, whereas only 13% (4/30) of the smaller foci were
contoured. The numbers of foci and the subset that were contoured are shown in Table
7.3, broken down by volume and Gleason score. Since each focus could be contoured by
1–4 observers, 72 sets of true positive GTVs were contoured and analyzed. Observers 1–
4 contours 20, 16, 23 and 13 sets of true positive GTVs, respectively. An illustrative set
of true positive GTVs and selected corresponding CTVs are shown in Figure 7.2.
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Inferior
Superior
A) Histology

B) T2W

C) DCE

D) ADC

Figure 7.2: Illustrative set of true positive GTVs for a Gleason 3+4 sparse cancer.
Column A shows 4 sections of midgland histology with regions of Gleason 7 cancer
(green) and Gleason 6 cancer (cyan) highlighted. Columns B–D show corresponding
oblique sections through the T2W, DCE and ADC images respectively, with overlaid
boundaries for the corresponding GTVs (magenta), and CTVs with PI margins for 0%
(solid line), 5% (dashed) and 10% (dotted) residual area for any cancer (green) and for
high-grade cancer (yellow).
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Table 7.3: For each volume range and Gleason score: number of aggregate foci (subset
with at least on true positive GTV).

Gleason score 6
Gleason score 7

<0.1
excluded
30 (4)

Volume (cm3)
0.1–0.2
0.2–0.5
5 (3)
3 (1)
8 (7)
9 (7)

>0.5
1 (1)
3 (3)

The key findings from our analysis were that (1) much of the variance in required
margin size could be attributed to tumor variability, (2) the required margins to achieve
0%, 5% and 10% residual cancer with high probability was smallest (4.5–9.0 mm, 1.5–
7.5 mm and 1.5–4.5, respectively, for residual high-grade cancer, and 6.0–11.0 mm, 5.5–
10.0 mm, and 3.0–9.5 mm, respectively, for any residual cancer) for composite GTVs
defined as the union of T2W, DCE and ADC GTVs; (3) these margins were lower than
the margins for single-sequence GTVs but in many cases not lower than the margins for
at least one 2-sequence GTV; and (4) the lower margins for 2- and 3-sequence composite
GTVs did not result in clear reductions in volumes of the resulting CTVs in cases where
the difference was <2 mm.
The residual areas as a function of margin size for each tumor individually are
included in Appendix D. The per-tumor analysis of required margin to achieve adequate
coverage of histological cancer was conducted for both all cancer and high-grade cancer,
and at three thresholds for residual area (0%, 5% and 10%). The mean required margins
(aggregated over all tumors, CTV types and observers) ranged from 3.5–6.8 mm for all
cancer and from 2.4–5.0 mm for high-grade cancer. The maximum required margins in
these analyses ranged from 15–22 mm for all cancer, and 16.5–21 mm for high-grade
cancer. Details of these analyses are given in Table 7.4. For the 10% residual high-grade
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cancer analysis, one set of GTVs required margins 6–8 standard deviations above the
mean required margins for the remaining data. Table 7.4 shows the details of this analysis
with the corresponding CTVs included and excluded. Excluding this analysis, all three
random effects were significant factors in the required margins: tumor variability
(p<0.001), tumor-observer interaction (p<0.001) and observer variability (p≤0.03). In the
10% residual high-grade cancer analysis with all CTVs included, only the tumor-observer
interaction was significant; however, with the aforementioned GTV excluded, all three
random factors were significant. The factors representing additional delineation of
images from each of the sequences were all significant, with an average reduction in
required margin of 0.8–1.1 mm for contouring DCE GTVs, 0.3–0.7 mm for contouring
T2W GTVs and 0.1–0.6 mm for contouring ADC GTVs. Consistently significant
interaction effects between the addition of T2W and DCE GTVs suggest that their
incremental values depend on the presence or absence of the other GTV. The variance
component analysis suggests that tumor variability is the largest contributor to variability
in required margins; however, tumor-observer interaction and observer effects were also
significant.
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Table 7.4: Per-tumor statistical analysis of the minimum margins required to achieve
specified residual areas. The variance components represent the relative weighting of
different sources of random variability on the per-tumor margin variability. The final 3
rows show estimates of the incremental value of delineating images from an additional
MR sequence, in terms of how much it decreased the margin, on average. The analysis in
the final column (marked with *) excludes one set of GTVs that required margins 6–8
standard deviations higher than the mean of the remaining data.
Residual cancer
Residual high-grade cancer
0%
5%
10%
0%
5%
10%
10%*
Descriptive statistics on minimum margin (mm)
Mean
Minimum
Maximum

6.8
4.7
3.5
5.0
3.3
0
0
0
0
0
22
18
15
21
18
Variance components of minimum margin (%)

2.4
0
16.5

2.2
0
11

VarTumor
71
49
43
48
44
2
23
VarTumor-Observer
10
24
27
18
20
65
23
VarObserver
5
7
8
10
11
7
9
VarUnmodeled
13
20
22
24
25
26
45
Incremental decrease in minimum margin for contouring additional images (mm)
T2W
0.7
0.5
0.4
0.3
0.3
0.4
0.4
DCE
1.0
0.9
0.8
1.1
0.9
0.8
0.8
ADC
0.6
0.5
0.4
0.4
0.3
0.2
0.1

The residual area PI upper bounds for all CTV types for each observer for all
cancer and for high-grade cancer are shown in Figure 7.3, as a function of margin size.
The PI margins (the smallest margin where the PI upper bound was <5% residual cancer)
ranged widely from 5.5–14.0 mm for coverage of all cancer, and from 1.5–11.0 mm for
high-grade cancer. The PI margins for all cancer and for high-grade cancer are
summarized in Figure 7.4 and Figure 7.5, respectively. In general, for all observers, for
all three thresholds on residual area for both all cancer and high-grade cancer, the PI
margins for the three-sequence composite GTVs (defined as the union of T2W, DCE and
ADC GTVs) were lower than the PI margins for single-sequence GTVs, with the
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exception of three cases where the T2W PI margin was the same as the three-sequence
margin for one observer. However, the PI margins for the 3-sequence composite GTVs
were not consistently lower than those for the 2-sequence GTVs. The lowest required
margins for high-grade cancer were 4.5 mm, 1.5 mm and 1.5 mm, for 0%, 5% and 10%
residual area, respectively, for 3-sequence composite CTVs; however, the number of
GTVs considered in this estimate was lower (due to fewer included true positive GTVs),
resulting in a lower confidence level (78%) for these PIs. The 90% confidence PI margins
for this observer/CTV type were 7.5 mm, 3 mm, and 2.5 mm for 0%, 5% and 10%
residual area, respectively.
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Figure 7.3: Upper bound on residual cancer (left) and high-grade cancer (right)
prediction intervals for 4 observers (rows). Legend denotes CTV types by the first initials
of the sequences (T=T2W, D=DCE, A=ADC), with the PI confidence level in
parentheses. The 5% and 10% residual area levels are marked by the horizontal lines.
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Figure 7.4: PI margins for coverage of low- and high-grade cancer for 4 observers
(denoted by symbols) for 0%, 5% and 10% residual area for each CTV type. CTV types
are denoted by the first initials of the sequences (T=T2W, D=DCE, A=ADC)

Figure 7.5: PI margins for coverage of high-grade cancer for 4 observers (denoted by
symbols) for 0%, 5% and 10% residual area for each CTV type. CTV types are denoted
by the first initials of the sequences (T=T2W, D=DCE, A=ADC)
The volumes of CTVs with PI margins for all cancer and for high-grade cancer
are shown in Figure 7.6 and Figure 7.7, respectively. The median volumes of CTVs and
the proportions of CTVs with PI margins smaller than 10 cm3 and smaller than 4.5 cm3
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are given in Table 7.5. Of the 53 and 67 outliers shown in the 24 graphs in Figure 7.6 and
Figure 7.7, respectively, 45/53 and 60/67 correspond to one histological focus, with a 21mm longest diameter on whole-mount histology, substantial Gleason grade 4, and
extraprostatic extension near the bladder neck. The two other foci that led to the
remaining 8/53 and 7/67 outliers were large diffuse cancers, one Gleason score 3+3 with
a largest diameter of 36 mm and extraprostatic extension, and one Gleason score 3+4
with tertiary grade 5, with a largest diameter of 24 mm and extraprostatic extension.
Median CTV volumes for composite CTVs with PI margins were neither consistently
lower nor consistently higher than those for single-sequence CTVs. However, for cases
where the difference between the single-sequence and composite PI margins was < 2 mm,
the median single-sequence-CTV volumes were smaller by 0–4 cm3, while for cases
where the difference was ≥2, the median single-sequence-CTV volumes were larger by
0–16 cm3.
Table 7.5: Volumes of CTVs with PI margins.
Residual cancer Residual high-grade cancer
0% 5% 10%
0%
5%
10%
3
Median volume T2W (cm )
16.3 9.8
6.7
9.2
5.8
4.2
3
Median volume DCE (cm )
16.8 12.0 8.1
10.4
7.0
4.3
3
Median volume ADC (cm )
16.5 13.5 11.3
13.4
8.9
6.7
3
Median volume T2W+DCE (cm )
15.8 10.1 6.7
8.4
6.1
3.7
3
Median volume T2W+ADC (cm )
12.7 10.5 6.8
10.3
6.3
4.7
3
Median volume DCE+ADC (cm )
14.4 11.7 7.0
9.1
5.4
3.2
3
Median volume T2W+DCE+ADC (cm ) 12.4 10.7 6.0
8.3
5.1
3.2
3
Median volume (pooled) (cm )
15.4 11.4 7.7
10.3
6.4
4.4
3
Proportion with volume ≤4.5 cm
0% 3% 22%
9%
32%
51%
3
Proportion with volume 4.5–10.0 cm 20% 39% 41%
40%
35%
28%
3
Proportion with volume >10.0 cm
80% 58% 38%
51%
33%
21%
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The expansion factors of the CTVs relative to their corresponding GTVs are
shown in Figure 7.8 for each observer and level of residual PCa area. There are two key
observations to be made from these plots. First, the CTVs with PI margin were
substantially expanded from the delineated GTVs with median linear expansion factors of
1.3–4.9. Second, the median expansion factors for 3-sequence composite GTVs were
consistently lower than those for single sequence GTVs. Note, however, that 3-sequence
composite GTVs are by construction at least as large, and typically larger, than singlesequence GTVs.
The expansion factors of the CTVs relative to their corresponding histological
foci are shown in Figure 7.9. The key observation to be made from these plots is that
substantial non-cancerous parenchyma is covered by the CTVs with PI margins for 0%,
5% and 10% residual cancer area for all observers, with median linear expansion factors
of 2.7–9.3. Note that these expansion factors incorporate volume due to CTV coverage of
regions with no cancer as well as CTV coverage of stromal regions between diffuse
cancerous gland (not included in histological focus volumes). Scaling factors for
composite CTVs were not consistently larger or smaller than those for single-sequence
CTVs.
The mean±SD TRE for the ex vivo–in vivo MR image TPS registrations was
estimated to be 1.4±0.2 mm aggregated across TRE estimates on 25 MR image pairs.
Each TRE estimate was calculated using 33–90 control point pairs (1482 control point
pairs total across all MR image pairs). The mean±SD TREs for the rigid mpMRI coregistrations to the high resolution T2W images were estimated to be 0.7±0.1 mm for the
clinical T2W images, 1.0±0.5 mm for the DCE images, and 1.0±0.2 mm for the ADC
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images, aggregated across TRE estimates on 3 MR image pairs. Each TRE estimate was
calculated using 4–6 intrinsic landmark pairs (e.g. calcifications and atrophic cysts) per
MR image pair (41 intrinsic landmark pairs total). For the distortion correction
registering the 6 distorted ADC images to their respective high resolution T2W images,
the mean±SD TREs was estimated to be 1.4±0.5 mm aggregated across TRE estimates on
6 MR image pairs. Each TRE estimate was calculated using 32–65 control point pairs
(299 control point pairs total across all 6 MR image pairs). The mean±SD TRE for the
3D histology reconstruction was previously reported to be 0.7±0.4 mm [15] aggregated
across 232 intrinsic landmark pairs (3–16 intrinsic landmark pairs per histology section
for 37 histology sections).
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Figure 7.6: Volume encompassed by CTVs with PI margins for any cancer for 4
observers (rows) for 0%, 5% and 10% residual cancer area (columns). CTV types are
denoted by the first initials of the sequences (T=T2W, D=DCE, A=ADC), with the PI
margin shown above the graph. Box plots show the median, interquartile range (IQR),
whiskers for the closest points within 1.5×IQR from the IQR, and outliers beyond the
whiskers. The horizontal lines mark 4.5 cm3 and 10 cm3, reported treatment volumes for
focal laser ablation and focal radiation boosting, respectively.
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Figure 7.7: Volume encompassed by CTVs with PI margins for high-grade cancer for 4
observers (rows) for 0%, 5% and 10% residual high-grade cancer area (columns). CTV
types are denoted by the first initials of the sequences (T=T2W, D=DCE, A=ADC), with
the PI margin shown above the graph. Box plots show the median, interquartile range
(IQR), whiskers for the closest points within 1.5×IQR from the IQR, and outliers beyond
the whiskers. The horizontal lines mark 4.5 cm3 and 10 cm3, reported treatment volumes
for focal laser ablation and focal radiation boosting, respectively.
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Figure 7.8: Scaling factors of the CTVs with PI margins relative to their corresponding
GTVs for 4 observers (rows) for 0%, 5% and 10% residual cancer area (columns). Y-axis
shows the cube root of the volume ratio (equivalent scaling factor in each dimension).
CTV types are denoted by the first initials of the sequences (T=T2W, D=DCE, A=ADC),
with the PI margin shown above the graph. Box plot shows the median, interquartile
range (IQR), whiskers for the closest points within 1.5×IQR from the IQR, and outliers
beyond the whiskers. A similar set of graphs for high-grade cancer only is shown in
Appendix D.
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Figure 7.9: Scaling factors of the CTVs relative to their corresponding aggregated
foci for 4 observers (rows) for 0%, 5% and 10% residual area (columns). Y-axis shows
the square root of the planimetric volume ratio (equivalent scaling factor in each
dimension). CTV types are denoted by the sequences initials (T=T2W, D=DCE,
A=ADC), with the PI margin shown above the graph. Box plot shows the median,
interquartile range (IQR), whiskers for the closest points within 1.5×IQR from the IQR,
and outliers beyond the whiskers. A similar set of graphs for high-grade cancer only is
shown in Appendix D.
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7.4 Discussion
Delineation of prostate cancer on imaging has the potential to support multiple
stages of the clinical workflow. Although mpMRI has shown promise for prostate cancer
detection, staging and localization, its suitability for delineation is not yet wellcharacterized. In this work, we addressed 3 questions related to the suitability of mpMRI
for delineating target volumes: (1) What margins must be added to delineated GTVs to
achieve adequate coverage of histological cancer? (2) What are the volumes of CTVs
defined using such margins? (3) What are the relative volumes of the CTVs defined using
such margins with respect to the corresponding GTVs and the corresponding histological
foci?
The mean margins required for adequate coverage in our data set were 6.8 mm,
4.7 mm and 3.5 mm for 0%, 5% and 10% residual cancer area, respectively. However,
the margins required for adequate coverage of specific tumors in our data set ranged as
high as 22 mm for 0% residual area, 18 mm for 5% residual area and 15 mm for 10%
residual area. A substantial component of this variability was attributable to tumor
variability. This suggests a strong need to characterize individual lesions during therapy
planning to identify lesions that require larger margins. Imaging characteristics used to
detect cancer, such as the "erased charcoal sign" or "lenticular shape" described in the PIRADS reporting guidelines, could be investigated to assess their correlations with tumors
that need larger margins.
Additional variability in required margin sizes was attributed to observer
variability and tumor-observer interaction. Furthermore, there was considerable
interobserver variability in the identified PI margins for each type of CTV. For CTVs
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derived from GTVs on 1 or 2 sequences, there was interobserver variability not only in
the sizes of the margins, but also in which modality yielded the smallest margins. This
variability might be addressed through training targeted at delineation. Specific training
in target volume contouring on mpMRI with histological feedback, as has been
recommended for reading and reporting mpMRI [20], may play a role in reducing the
observed variability and reducing required margins. Consensus guidelines for how to
delineate target volumes for focal therapy may also reduce variability. If large
interobserver variability remains despite training and guidelines, recommendation of
generally applicable margin guidelines may be challenging. A possible alternative would
be to develop benchmark databases of co-registered mpMRI and histology with tools to
allow clinicians to characterize their own performance and develop individualized
delineation guidelines in terms of optimal sequences and appropriate margins.
The observed variability suggests that precise identification of the margin for
individual tumors may be challenging and supports the use of conservative guidelines
that take into account the variability in required margins, such as prediction interval
upper bounds.
The PI margins identified in this study were defined such that an observer using
these margins on a new patient could have a high confidence (78%–91%) of leaving 0%,
5%, or 10% residual cancer (or high-grade cancer) area beyond the CTV boundary. The
CTVs defined based on the composite of the T2W+DCE+ADC GTVs required the
smallest margins. These three-sequence PI margins for high-grade cancer ranged from
4.5–9.0 mm, 1.5–7.5 mm and 1.5–4.5 mm for 0%, 5%, and 10% residual high-grade
cancer area. For covering low and high-grade cancer, the PI margins were higher, ranging
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from 6.0–11.0 mm, 5.5–10.0 mm, and 3.0–9.5 mm. These margins are higher than
recently reported margins for adequate tumor coverage [13]. The reported margins are
not directly comparable, as the previous report aggregated histology-MRI boundary
distances across all tumors and observers. However, there are two additional key
differences. First, our analysis was performed in 3D whereas the previous report looked
only at a single slice of histology (the slice with the maximum cross-sectional area).
Second, the patients included in the margin estimation in the previous study had higher
patient Gleason scores (2 G3+3, 1 G3+4, 3 G4+3, 2 G4+4 and 2 G4+5) than patients
included in our margin estimation (2 G3+3, 18 G3+4, 1 G4+3). Less aggressive cancers
are harder to detect [21], and may also be harder to delineate reliably.
Three-sequence CTVs required the smallest margins, and, with few exceptions,
CTVs defined based on the composite GTVs from two sequences required smaller
margins that those defined based on a single sequence. This suggests there may be a
trade-off between the size of the required margins and the amount of target volume
contouring required. Alternatively, there may be potential for tools that facilitate
contouring on fused, co-registered mpMRI to reduce required margins.
Interpreting the need for different margins for different CTV types is complex. As
a simplified illustration, suppose that GTVs on sequence A were consistently 2 mm
isotropically outside GTVs on sequence B. A 6-mm-margin CTV on sequence A would
be identical to an 8-mm-margin CTV on sequence B, and contouring on sequence A with
a 2 mm smaller margin would confer no advantage. The true situation is more complex,
as GTVs on different sequences are not necessarily concentric. Notably, however, the
composite GTVs (defined as the union of single-sequence GTVs) may be larger, in
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general, than the single-sequence GTVs, which may account, in part, for the smaller
required margins. For the volumetric analysis, this interaction is mitigated by using PI
margins. Although composite CTVs with PI margins have smaller treatment volumes and
cover a smaller proportion of the prostate for some observers, this is not consistent across
observers. Thus, we are unable to conclude that contouring on multiple sequences and
applying smaller margins reduces the CTV volumes required to get adequate histological
coverage with high probability. In particular, where the margins differed by < 2 mm, the
single-sequence CTVs were smaller, but where the margins differed by ≥ 2 mm, the
three-sequence CTVs were smaller. There may, however, be other aspects of treatment
planning where smaller required margins are advantageous. An investigation of the types
of tissue (prostate parenchyma vs. organ-at-risk) covered by these CTVs may clarify
whether there is a clinical need to contour GTVs on all three sequences.
The median volumes of CTVs defined using PI margins ranged from 4–30 cm3,
for CTVs with PI margins for all cancer, and from 2–16 cm3 for CTVs with PI margins
for high-grade cancer, depending on the residual cancer area, the observer and CTV type.
Assessment of whether these CTVs could be feasibly treated depends on many factors
including the treatment modality, and the locations of the CTVs relative to organs at
risks. However, focal laser ablations up to 4.5 cm3 using 2 fibers have been reported [18]
and focal radiation boosting typically targets volumes <10 cm3 [6]. Based on volume
considerations alone, 50–80% of the CTVs with PI margins for 0–10% residual highgrade cancer area could be targeted with a modality capable of treating targets <10 cm3,
and 9–51% could be targeted with a modality capable of treating targets <4.5 cm3. For
the larger CTVs with PI margins for all cancer, 20–63% could be treated with a modality
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capable of treating targets <10 cm3, but only 0–22% could be targeted with a modality
capable of treating targets <4.5 cm3. Although there were outliers with CTV volumes
substantially larger than these treatment volumes, they corresponded to large foci with
extraprostatic extension that would likely not be candidates for tissue sparing focal
therapies such as focal laser ablation.
Considering the trade-offs between time for delineation, required margin and
treatment constraints, one could envision multiple workflows for target volume
delineation in focal therapy planning incorporating PI margins. In one workflow, one
could initially attempt to delineate GTVs on all sequences. If all sequences could be
delineated, smaller margins for three-sequence composite GTVs could be used;
otherwise, the larger margins required for two-sequence composite or single-sequence
GTVs could be used. In an alternative workflow, one could initially delineate a single
sequence and apply larger margins. If the resulting CTV was feasible to deliver and met
guidelines for sparing organs at risk, it could be delivered; otherwise, additional
sequences could be delineated and smaller margins used, potentially resulting in target
volumes that could more feasibly be delivered or that better spared organs at risk.
The volumes of CTVs with PI margins were large compared to the underlying
histological cancer (median linear expansion factor: 2.7–9.3). Some of this expansion can
be attributed to the CTV covering stromal tissue between cancerous glands, particularly
in diffuse cancers. However, the expansion also includes non-cancerous regions within
the isotropic expansions used in this study. This suggests potential value in evaluating
non-isotropic margin expansions, such as different radial and tangential expansions or
expansion constrained to remain within the prostatic zone containing the GTV.
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Some of the unmodeled variability in required margins may be due to registration
error. Misalignment of a focus on the histological reference standard with respect to the
GTVs could result in an increase or in a decrease in required margins for specified
coverage, depending on their spatial configuration, with an overall effect of increasing
variability and introducing a positive bias (smaller, in general, than the quantified
registration error). Since high confidence prediction intervals are sensitive to extreme
values, the additional variability would introduce a positive bias to the PI upper bound as
well.
The conclusions of this study should be considered in the context of its strengths
and limitations. Estimates of residual and total cancer area could only be made within the
histology sections, representing 3–5 thin surfaces within the mid-gland. If the CTV
coverage characteristics in the apex and base differ from those in the mid-gland, our
conclusions may not generalize to the entire prostate. Expansion of this analysis to
include the apex and base histology is ongoing. The sparsity of the sampling, however, is
a limitation of the clinical workflow, and may contribute to the observed variability. With
4 observers and high interobserver variability, we were unable to draw conclusions about
the expected performance of an unseen observer. Reporting the observer characteristics
separately, however, did elucidate this variability and led to identifying variability as a
key challenge. The sample size in each analysis, limited to each observer's GTVs
separately, combined with the skewed distribution of residual areas, resulted in prediction
interval boundaries that were sensitive to outliers. This was mitigated in our analysis by
using lower confidence levels. Due to the fine scale of the cancer delineations on
histology in our study, the planimetric volume estimates do not include stromal tissue that
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would be included in more typical coarse scale delineations; thus, our volume estimations
may be equivalent to larger histological tumor volumes reported in the literature.
In conclusion, the delineation of GTVs on mpMRI has high interobserver
variability in the optimal sequence(s) to use for delineation and in the expansion margins
needed to achieve a 0–10% residual cancer area with high probability. These margins
were smallest for targets defined by the union of delineations on T2W, DCE and ADC
images: 4.5–9.0 mm, 1.5–7.5 mm and 1.5–4.5 mm for CTVs intended to leave 0%, 5%
and 10% residual high-grade (Gleason score ≥7) cancer area, respectively, and 6.0–11.0
mm, 5.5–10.0 mm, and 3.0–9.5 mm for CTVs intended to leave 0%, 5% and 10%
residual cancer of any grade. However, the smaller margins for the composite threesequence GTVs did not result in consistently smaller CTVs, compared with the CTVs
resulting from the larger margins around single-sequence GTVs. The CTVs resulting
from these margins had volumes that may preclude focal treatment with some volumeconstrained modalities for many patients. In order to facilitate margin recommendations
that yield CTVs that can be feasibly targeted in most patients, reduction of interobserver
and intraobserver variability in delineation should be a priority.
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Chapter 8.
Contributions of the thesis, applications and suggestions
for future work

8.1 Contributions of the thesis
This thesis contributes advances in methods, concepts and knowledge in several
areas related to the four research questions posed in the introduction:


How does registration error impact the statistical power of imaging validation
studies?



What is the performance (in terms of reconstruction error and robustness) of an
extrinsic fiducial-based histology reconstruction method, and how does this compare
to alternative approaches based on image-guided slicing and intensity-based image
registration?



What is the variability of lesion scoring (using consensus-panel-recommended PIRADS guidelines [1]) and contouring on mpMRI?



What are appropriate margins around observers’ target volumes to achieve
histological coverage of detected cancers?
The following sections address contributions related to each question in turn.
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8.1.1 Research question 1: How does registration error impact the statistical
power of imaging validation studies?
Chapter 2 introduced a new approach to evaluating registration error, by
considering registration in the context of imaging validation studies seeking to make
an inference, and evaluating registration error by its impact on the statistical power
of a study. Registration techniques can be evaluated based on their registration error;
however, criteria for whether a registration is sufficiently accurate are applicationdependent [2] and depend on the success criteria for the application. In the context of
studies that aim to make an inference, one success criterion is whether the study outcome
is a true positive, correctly rejecting the null hypothesis. Statistical power is the
probability of rejecting the null hypothesis when it is false. By evaluating registration
error with respect to the statistical power of a study incorporating the registration, we can
express a success criterion for registration in terms of an established success criterion for
the application. Thus, this thesis has advanced knowledge in registration evaluation by
contributing a statistically justifiable approach for evaluating registration accuracy in
studies that culminate in a statistical test.
Chapter 2 also derived and evaluated new power calculation formulae that
relate sample size, the minimum detectable difference and registration error in one
class of imaging validation study. In addition to proposing an approach for evaluating
registration accuracy, we reduced the concept to practice, by deriving statistical power
calculation formulae for studies aiming to detect a significant signal difference between
foreground and background regions defined using a registered reference standard, and
applying the formulae to a case study. The derived formulae enable study designers to
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answer three key questions related to study design. (1) Given a specified sample size and
a specified effect size to detect, what is the maximum acceptable mean error for a
registration method in this study? (2) Given a quantified registration error and a specified
effect size to detect, what is the minimum sample size to accrue? (3) Given a specified
sample size and a quantified registration error, how small an effect can be detected? Thus,
this thesis advanced knowledge in registration evaluation by contributing a statistically
rigorous way to answer key questions in the design of one class of imaging validation
studies.

8.1.2 Research question 2: What is the performance (in terms of
reconstruction error and robustness) of an extrinsic fiducial-based histology
reconstruction method, and how does this compare to alternative approaches
based on image-guided slicing and intensity-based image registration?
Chapter 3 characterized spatial relationships of histology sections relative to
the tissue slices from which they were cut, and identified that an isotropic scaling
deformation accounts for the majority of the in-plane deformation, and that the
front face assumption— that histology sections correspond to the front face of tissue
sections from which they were cut — introduces seemingly small but potentially
impactful reconstruction errors. The process of acquiring histology sections involves
chemically processing tissue slices, embedding them in paraffin, mounting them onto a
microtome, cutting through the tissue slices until full cross-sections are exposed, cutting
4-µm-thick sections of tissue, floating the sections on a water bath and mounting them to
slides. These processes could potentially result in substantial removal of tissue from the
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tissue slice and potentially induce substantial deformation. By comparing intrinsic
landmarks on histology and MR images of the tissue slices, we identified where the
histology sections were cut from within the tissue slices and quantified the deformation.
Since previous histology reconstruction methods have used a wide range of
transformations (rigid [3], similarity [4, 5], affine [6, 7], or thin-plate-spline [8, 9]) to
account for deformation during processing, we assessed how well different
transformations compensated for the in-plane deformation. Since many previous
histology methods [4, 5, 7, 9-12] have made the front face assumption, we assessed its
strength by measuring the depth and orientation of the section within the tissue slice, and
estimated the impact on reconstruction error of making the assumption. The incremental
error due to different in-plane deformations and the front face assumption was seemingly
small (1.4 mm); however, analyzing the resulting reconstruction errors in the context of a
hypothetical imaging validation study of 0.2 cm3 tumors (using the approach presented in
Chapter 2), suggested that the assumption could result in a 1.5 fold increase in sample
size. Thus, the thesis advanced knowledge in histology reconstruction by quantifying the
strength and impact of assumptions that are commonly made in histology reconstruction.
Chapter 4 presented a fiducial-based method for 3D reconstruction of
histology images that was not disruptive to the clinical diagnosis, could be
implemented with little specialized equipment (beyond ex vivo MR imaging), and
compensates for variability described in Chapter 3. As described in Section 1.2.3.3,
there have been three main approaches to histology reconstruction. Image-guided-slicingbased methods that constrain the orientation of gross slicing have the potential to disrupt
standard clinical slicing rules and typically assume histology corresponds to the front face
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of tissue slices. Methods based on additional imaging of the specimen allow more
flexible slicing, but also typically assume histology corresponds to the front face of tissue
slices. Image-registration-based methods have the potential to minimize disruption to the
clinical workflow and mitigate the variability introduced by histology sectioning;
however, they rely on image features that may be disrupted by the presence of cancer or
other abnormalities. The approach presented in this chapter leverages extrinsic fiducials
to reconstruct histology to the context of an ex vivo MR image without making
assumptions about the position of histology relative to their corresponding tissue slices,
thereby (1) allowing flexibility in the gross slicing to suit pathologists' requirements, and
(2) mitigating the variability introduced by histology sectioning. The use of extrinsic
fiducials instead of intrinsic image information allows the method to be robust to imaging
characteristics of the prostate tissue. Thus, this thesis advanced knowledge in histology
reconstruction by presenting a new method for reconstruction that is less disruptive and
more robust than existing approaches.
Chapter 4 also presented an approach to identify pairs of homologous point
fiducials on imaging to support the measurement of the TRE of histology
reconstruction. Identification of homologous point landmarks on histology and MR
imaging has been identified as a challenging problem, and a previous histology
reconstruction method used this as a justification to avoid measuring TRE for their
method [9]. Many other reconstruction methods also reported surrogates for registration
error instead of TRE (overlap of the prostate gland [7, 8], prostate boundary
distances [13, 14], qualitative assessment of prostate cancer tumor alignment [11, 15],
post-optimization similarity metric values [15], or image intensity properties [16]). In this
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chapter, we depicted and described illustrative homologous point landmarks that could be
identified on histology and ex vivo MR, and validated the reconstruction using 184 such
landmark pairs across 34 histology sections. Thus, this thesis advanced knowledge in
histology reconstruction by describing homologous point landmarks that could be used to
measure TRE between histology and ex vivo MRI.
Chapter 4 also presented a direct comparison of the fiducial-based method to
an alternative approach based on image-guided slicing, showing that the fiducialbased algorithm had a lower mean error. Many existing approaches for histology
reconstruction guided the slicing of the prostate specimen in a controlled way to facilitate
reconstruction. In this chapter, we evaluated this approach by directly comparing it to the
fiducial-based method presented in this chapter in terms of the TRE. To the best of my
knowledge, this represented the first direct comparison of two substantially different
approaches to histology reconstruction. We demonstrated that the fiducial-based method
had a lower TRE than the image-guided-slicing-based method. This was consistent with
the observations in Chapter 3 that assuming histology sections correspond to the front
faces of tissue blocks, as was assumed in the image-guided-slicing-based approach,
introduces a small incremental error. Thus, this thesis advanced knowledge in histology
reconstruction by demonstrating the higher accuracy of the presented fiducial-based
approach over the image-guided-slicing-based approach.
Chapter 5 presented a direct comparison of the accuracy and robustness of
the fiducial-based method described in Chapter 4 to an alternative imageregistration-based approach based on maximizing normalized mutual information,
and identified that the image-registration-based approach was not a robust solution
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to histology reconstruction. Decades of research in image registration have produced
flexible tools, such as the normalized-mutual-information similarity metric [17], that have
been widely applied to the registration of images from different modalities. One could
imagine that a flexible image registration approach maximizing normalized mutual
information between histology and ex vivo MR images could trivially yield an accurate
and robust reconstruction without the need for fiducials. In this chapter, we evaluated this
approach by directly comparing it to the fiducial-based method. We compared the
robustness to initializations perturbed away from the reference position defined by
manually identified landmarks, and the accuracy after a practically achievable
initialization. While the fiducial-based approach had negligible sensitivity to
initialization, the image-registration-based approach was sensitive to initialization and
further analysis demonstrated that the similarity metric was less optimal at the reference
point than at convergence points away from the reference point (suggesting that the
similarity metric is a contributor to the lack of robustness). Thus, the thesis advanced
knowledge in histology reconstruction by demonstrating that a non-customized imageregistration-based approach using the normalized mutual information did not yield a
reconstruction technique robust to initialization error. This does not, however, preclude
the possibility that image-registration-based methods customized to the task could result
in robust histology reconstructions.
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8.1.3 Research question 3: What is the variability of lesion scoring (using
consensus-panel-recommended PI-RADS guidelines [1]) and contouring on
mpMRI?
Chapter 6 investigated lesion scoring according to the established PI-RADS
structured reporting guidelines for mpMRI. We found a correlation between PIRADS overall likelihood score and Gleason grade, and corroborated recent reports
of fair to moderate agreement in PI-RADS scores and a high (85% in our analysis)
PPV for a PI-RADS overall likelihood score of 5. Consensus guidelines for prostate
cancer detection and reporting on mpMRI have been published recently, and
characterizing the performance of observers applying these guidelines may contribute to
the evaluation and optimal use of the guidelines. In this chapter, we looked at the level of
agreement between observers, and the relationship between lesion scoring and
histological cancer. Our analysis of interobserver score agreement yielded a kappa of 0.3
in the PI-RADS overall likelihood score, consistent with recent evaluations of the
guidelines [18, 19] noting fair to moderate agreement. The high positive predictive value
of a PI-RADS overall likelihood score of 5 was also consistent with a recent report [20],
although their observed PPVs were somewhat higher than ours for overall likelihood
scores of 3–5. Although these are not new findings, the contribution of findings from
multiple centers is important to the evaluation of consensus guidelines. The correlation
between the PI-RADS overall likelihood score and prostatectomy Gleason grade on
whole-mount histopathology has not, to the best of my knowledge, been previously
identified, and corroborates a previous finding of correlation between the sum of PIRADS sequence-specific scores and biopsy Gleason grade [21]. Thus, the thesis
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advanced the knowledge of a lesion scoring under a consensus-recommended structured
reporting system by presenting an unreported correlation between the PI-RADS overall
likelihood scores and Gleason grade, and by accumulating evidence regarding the
interobserver variability and predictive value of PI-RADS overall likelihood scores.
Chapter 6 also investigated lesion delineation on multi-parametric MRI and
characterized the variability in delineation between observers and between different
mpMRI sequences. Delineations of cancer target volumes may support delivery of
lesion focused therapies; however, the accuracy and variability of such delineations are
not well characterized. In this study, four observers delineated lesions on different
mpMRI sequences, enabling the measurement of variability in lesion delineation between
observers, and between different mpMRI sequences. Although no clear advantage of any
one sequence emerged, our descriptive measurements of contour agreement quantified
the high variability between observers and between mpMRI sequences, a finding which
had not been previously reported. Thus, this thesis advanced knowledge in lesion
delineation on mpMRI by characterizing the interobserver and intersequence variability
in contouring.

8.1.4 Research question 4: What are appropriate margins around observers’
target volumes to achieve histological coverage of detected cancers?
Chapter 7 evaluated the histological coverage of clinical target volumes
defined on multi-parametric MR images and (1) identified a range of expansion
margins that yielded 90%, 95% and 100% histological coverage with high
probability in study observers; (2) identified that composing delineations on
multiple modalities reduced the required margins, but did not consistently reduce
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target volumes; and (3) identified intraobserver and interobserver variability as a
priority for achieving histological coverage with high probability with target
volumes small enough to feasibly treat. In targeted treatments, a common way to
address uncertainty in target volumes is to add margins to the GTVs, but the appropriate
margins for cancer GTVs defined on mpMRI are not yet established. A recent study [22]
reported that a 5 mm margin around GTVs delineated on mpMRI was sufficient to cover
95% of histologically defined cancer, and 8 mm was sufficient to cover 100%. However,
this analysis aggregated histology-MRI contour distances across all observer and tumors,
and was performed in 2D, ignoring the extent of cancer in the inferior-superior direction
and possibly underestimating the required margins. In this chapter, we evaluated in 3D
the histological coverage of GTVs defined on mpMRI at a range of margins, separating
our analysis by sequence(s) used to define the GTVs and by observer. The key findings,
described above, do not result in a clear recommendation on margins that should be used
for focal therapy trials; however, they provide guidance on ranges of margins that could
be considered for evaluation and elucidated the presence of substantial variability that
may challenge the evaluation of lesion-focused therapies using target volume delineation
on mpMRI. Thus, this chapter advanced knowledge in lesion delineation by reporting
margin sizes to achieve 90–100% histological coverage with high confidence for four
observers and elucidating the interobserver variability in margin sizes and variability in
which sequences are optimal for contouring.
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8.2 Applications and future directions
The methods developed in this thesis support research applications in several
directions. In the following sections, a number of these potential applications will be
discussed, and remaining gaps in knowledge will be described.

8.2.1 Evaluation and refinement of existing and novel imaging
mpMRI has shown potential to support many aspects of the clinical workflow;
however, detection of central gland tumors, assessing cancer aggressiveness and planning
treatment remain challenging. Thus, prostate cancer imaging remains an active research
direction. New imaging technologies are being developed, such as endogenous sodium
imaging [23, 24] and hyperpolarized carbon imaging [25, 26]. New derived images
computed from existing imaging are being developed, such as high b-value DW
images [27], diffusion compartment model imaging [28] and alternative DCE parametric
maps [29]. Computer-aided detection and delineation tools are also being developed [30,
31]. All of these methods need to be evaluated to assess their clinical utility. Because of
the slow natural history of prostate cancer, evaluating novel imaging technology with
respect to outcome may introduce unacceptable delays. Initial evaluation of imaging
technology with respect to a surrogate endpoint, such as agreement with a co-registered
histological reference standard, has the potential to identify promising imaging
technology early for more thorough validation in clinical trials.
This research direction can be pursued already using techniques presented in my
thesis, with adaptations to register the images of interest to the in vivo or ex vivo MRI.
Preliminary investigations of 18F-fluorocholine PET/CT and PET/MR [32], endogenous
sodium imaging [33], radiofrequency time series ultrasound [34] and derived images
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computed from DCE MRI [29] using techniques presented in my thesis are currently
ongoing, and a multi-centre evaluation of additional imaging technologies incorporating
these techniques is scheduled to begin in the near future. However, this research direction
could be facilitated substantially by the automation of an accurate registration from ex
vivo to in vivo MRI with appropriately quantified registration error. Nir et al. [35]
presented an approach that uses magnetic resonance elastography; however, this
technology is not widely available and could require substantial alteration of clinical
imaging to implement. Surface-based techniques for ultrasound to MRI registration in
fused TRUS-MRI biopsy systems [36, 37] may be adaptable to this problem as well.
Histology-based imaging evaluation has the potential to rapidly identify imaging
technologies with the potential for accurate diagnosis, patient stratification and treatment
delivery without invasive procedures and hasten their clinical evaluation and adoption.

8.2.2 Use in clinical training
Accuracy and variability in prostate cancer image interpretation is related to
reader experience. Reading and reporting MRI images with pathological feedback has
been identified as an important component of developing and maintaining expertise in
prostate cancer image interpretation [38, 39]. Educational curricula for delineation (of
whole prostates) have improved contouring variability, and curricula for interpretation
involving (unregistered) pathological feedback have improved accuracy and variability in
prostate cancer detection [40]. The development of an interactive training platform that
presents imaging alongside a co-registered histological reference standard may support
clinicians in developing and maintaining expertise in image interpretation and
delineation.
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The techniques presented in my thesis enable the accurate spatial alignment of
histology with mpMRI. Presenting these data, which are typically not available to
radiologists, in an interactive training platform may support training. However, effective
presentation of this material to maximize learning may pose challenges, and substantial
research and development may be needed to achieve the educational potential of these
data. Educational cognitive psychology may provide direction in addressing some of
these challenges. For example, high cognitive load due to complex interactions between
information from multiple sources may interfere with learning and may need to be
addressed within the training tools [41]. Embedding training tools within the context that
the knowledge will be applied (e.g. in a radiologist's clinical picture archiving and
communication system [PACS]) may improve learning [42]. Integrating such principles
into a training tool may facilitate improvements in clinician performance. Furthermore,
although ongoing training with pathological feedback has been suggested in consensus
findings [38, 39] and unregistered pathology feedback has improved detection rates [40],
it has not yet been demonstrated that training with co-registered pathological feedback
will result in better patient outcomes; this hypothesis needs to be tested to demonstrate
the clinical value of such an educational platform.
A fused imaging-histology training platform that supports clinicians in developing
and maintaining expertise in prostate cancer image interpretation could improve the
accuracy and reduce the intra- and interobserver variability in imaging interpretation and
delineation. This could enable more consistent clinical use of imaging, and more precise
characterization of the diagnostic, prognostic and therapeutic value of imaging. It could
support imaging applications, such as focal therapy planning, where variability remains a
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challenge. Such a tool could also enable the wide-spread adoption of prostate cancer
imaging beyond academic hospitals by enabling clinicians with smaller prostate imaging
case loads to develop and maintain expertise.

8.2.3 Development and evaluation of consensus guidelines for contouring
Consensus guidelines have been established for many stages of the prostate
cancer clinical workflow, including prostate cancer detection [1], focal therapy [39] and
pathology interpretation [43]. Although mpMRI has been recommended for focal therapy
planning [39], there are currently no clinical guidelines for how to contour prostate
cancer lesions on mpMRI for lesion-focused therapies.
This thesis could support the development of consensus guidelines directly by
providing evidence regarding lesion delineation variability and predicted histological
coverage for target volume margins, and indirectly by supporting evaluation of lesion
delineation in future studies. One could also imagine a guideline consensus panel process
that involved (1) the interpretation and delineation of mpMRI by panel members, (2)
comparison to a co-registered histological reference, and (3) consensus discussion about
the results of this comparison. However, consensus guidelines are typically developed
based on multiple sources of information and considering a substantial body of clinical
experience and literature. Further studies, and in particular large multi-centre studies, of
lesion delineation are required to establish the evidence to support consensus.
Consensus guidelines for lesion delineation on prostate cancer imaging could
improve consistency in lesion delineation, support the meaningful comparisons of
outcomes across studies of targeted biopsy and lesion-focused therapies, and facilitate the
translation of such procedures to widespread clinical use.
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8.3 Remaining gaps in histology-imaging fusion methods
This thesis has made contributions towards addressing the 4 criteria for histologyimaging fusion methods described in Section 1.2.3.3 (non-disruptive, spatially accurate,
robust, and widely implementable). There remains room for further improvement in
histology-imaging fusion methods. In particular, there is no appropriately validated
existing method that can register histology collected following standard clinical
pathology protocols to mpMRI images collected using standard radiology protocols,
without collection of intermediate data. Such a method could potentially enable large
studies leveraging retrospective imaging and pathology data, enable studies of older data
with known patient outcome, and enable the incorporation of histology-imaging fusion
into routine clinical reporting. Appropriate prospective evaluation of the accuracy and
variability of such a method is critical because in retrospective or ongoing use, there may
be insufficient information to confirm the accuracy of a fusion. Ideally, the evaluation
would include the estimation of the distribution of target registration errors measured
using homologous point landmarks across a data set large enough to allow the
construction of high-confidence prediction intervals for unseen cases. The evaluation
should also include an assessment of robustness including the variability in accuracy, and
the rate and causes of failed registrations. Although these criteria may be challenging to
meet, further progress towards these ideals would be valuable and meeting them could
potentially transform the use of histology-imaging fusion in prostate cancer imaging.
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Appendix A. Derivation of the variance of
The variance of this distribution is the mean of the covariance matrix elements
, where
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.

Because samples from different regions are independent (assumption 1 in Section
2.2.1) and regions have a constant size (assumption 6 in Section 2.2.1), the covariance
matrix is blockwise diagonal, where each block represents one sampling region. By
isolating the terms of the expected value that are independent of and

, we can express

the sum of the covariance within each block as

A.6

If we express the probabilities as integrations of conditional probabilities, conditional on
the value of the fractional overlap, and then reorder the summation terms, we show that
A.7
and we can show that similar expressions hold for

,

,

,

and

. The conditional probabilities can be expressed as polynomials of , which can
be expressed in terms of population parameters of :
A.8

A.9

A.10

A.11
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A.12

A.13
By substituting these equations into Expression A.6, we can calculate the mean over all
covariance matrix elements to be
A.14
For conciseness, we introduce two new terms:
. With this notation,

and

can be rewritten as

A.15
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Appendix B. Large specimen pathology processing
schedule
London Health Sciences Centre's standard clinical pathology laboratory protocol
for large specimens consists of processing tissue slices through baths of graded alcohols,
xylene, and paraplast on a Tissue-Tek vacuum infiltration tissue processor (Sakura
Finetek USA, Inc., Torrance, USA) following the schedule shown in Table B.1.
Table B.1: Our hospital's standard clinical pathology laboratory protocol for large
specimens.
Solution
80% ethanol, 20%
formalin
95% ethanol, 5% formalin
100% ethanol
100% ethanol
100% ethanol
100% xylene
100% xylene
100% xylene
100% paraplast
100% paraplast
100% paraplast
100% paraplast

Duration
(hours)
1

Temperature
(°C)
40

Vacuum
(inches)
15

Pressure
(PSI)
7

2
1
2
2
1
1
2
1
1
1
1

40
40
40
40
40
40
40
60
60
60
60

15
15
15
15
15
15
15
15
15
15
15

7
7
7
7
7
7
7
7
7
7
7
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Appendix C. Supplementary material to Chapter 6
C.1 Manual correspondence for two distinct lesions
During the interobserver correspondence of suspicious regions, two cases had
spatial relationships where overlap of composite suspicious regions did not yield one-toone lesion correspondences. In the first case, a composite suspicious region A1 from one
observer overlapped in different amounts with two composite suspicious regions B1 (Dice
metric of 0.7) and C1 (Dice metric of 0.09) defined by another observer; in this case, A1
was taken to correspond with B1, and not with C1. In a second case, three observers each
made a score assignment and delineated large mutually overlapping composite suspicious
regions A2, B2 and C2 and the fourth observer made two score assignments and
delineated two smaller composite suspicious regions D2 and E2. It was clear by inspection
of the contours that the fourth observer contoured two subregions of the distinct lesion
contoured by the other observers; in this case, the fourth observer's two lesions were
taken to be a single scored lesion, the PI-RADS scores in the corresponding score
assignments were averaged and the union of the corresponding suspicious regions were
taken to correspond with A2, B2 and C2.

C.2 PI-RADS sequence-specific scores broken down by grade and
volume
In each of the following figures, the PI-RADS sequence-specific scores (i.e. T2W,
DCE and ADC scores) from score assignments are broken down by histological grade or
mean suspicious region volume. Each vertical solid line corresponds to a distinct lesion,
with horizontal dashes at the PI-RADS sequence-specific score for each observer. For
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each grade/volume range, Tukey box plots show the interquartile range (IQR) box,
median (dotted line), mean (dashed line), and range of data within 1.5 × IQR of the IQR
(whiskers). Note that sequence-specific scores, unlike likelihood scores, were not
assigned by default when no score assignment was made, so not all observers are
represented for each distinct lesion.
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Figure C.1: PI-RADS T2W scores broken down by histological grade.

294

65

4+3

70

5

5

PI-RADS DCE score

4.5

4

4

3.5

3

3

2.5

2

2

1.5

1

1
70

75

Non-cancerous

80

3+3

85

Grade

3+4

90

4+3

95

Figure C.2: PI-RADS DCE scores broken down by histological grade.

5
5

PI-RADS ADC score

4.5

4
4

3.5

3
3

2.5

2
2

1.5

1
1

95

100

Non-cancerous

105

3+3

110

Grade

3+4

Figure C.3: PI-RADS ADC scores broken down by histological grade.
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Appendix D. Supplementary material to Chapter 7

Figure D.1: Residual cancer (left) and high-grade cancer (right) for CTVs expanded by
various margins from individual GTVs delineated on T2W images for 4 observers (rows).
Legend shows prediction interval (PI) confidence levels. The 5% and 10% residual area
levels are marked by the horizontal lines.
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Figure D.2: Residual cancer (left) and high-grade cancer (right) for CTVs expanded by
various margins from individual GTVs delineated on DCE images for 4 observers (rows).
Legend shows prediction interval (PI) confidence levels. The 5% and 10% residual area
levels are marked by the horizontal lines.
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Figure D.3: Residual cancer (left) and high-grade cancer (right) for CTVs expanded by
various margins from individual GTVs delineated on ADC images for 4 observers
(rows). Legend shows prediction interval (PI) confidence levels. The 5% and 10%
residual area levels are marked by the horizontal lines.
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Figure D.4: Residual cancer (left) and high-grade cancer (right) for CTVs expanded by
various margins from individual composite T2W+DCE GTVs for 4 observers (rows).
Legend shows prediction interval (PI) confidence levels. The 5% and 10% residual area
levels are marked by the horizontal lines.
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Figure D.5: Residual cancer (left) and high-grade cancer (right) for CTVs expanded by
various margins from individual composite T2W+ADC GTVs for 4 observers (rows).
Legend shows prediction interval (PI) confidence levels. The 5% and 10% residual area
levels are marked by the horizontal lines.
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Figure D.6: Residual cancer (left) and high-grade cancer (right) for CTVs expanded by
various margins from individual composite DCE+ADC GTVs for 4 observers (rows).
Legend shows prediction interval (PI) confidence levels. The 5% and 10% residual area
levels are marked by the horizontal lines.
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Figure D.7: Residual cancer (left) and high-grade cancer (right) for CTVs expanded by
various margins from individual composite T2W+DCE+ADC GTVs for 4 observers
(rows). Legend shows prediction interval (PI) confidence levels. The 5% and 10%
residual area levels are marked by the horizontal lines.
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Figure D.8: Scaling factors of the CTVs with PI margins for high-grade cancer relative
to their corresponding GTVs for 4 observers (rows) for 0%, 5% and 10% residual highgrade cancer area (columns). Y-axis shows the cube root of the volume ratio (the
equivalent scaling factor in each dimension). CTV types are denoted by the first initials
of the sequences (T=T2W, D=DCE, A=ADC), with the PI margins for high-grade cancer
shown above the graph. Box plots show the median, interquartile range (IQR), whiskers
for the closest points within 1.5×IQR from the IQR, and outliers beyond the whiskers.
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Figure D.9: Scaling factors of the CTVs relative to their corresponding aggregated
high-grade foci for 4 observers (rows) for 0%, 5% and 10% residual area (columns). Yaxis shows the square root of the planimetric volume ratio (the equivalent scaling factor
in each dimension). CTV types are denoted by the first initials of the sequences (T=T2W,
D=DCE, A=ADC), with the PI margins for high-grade cancer shown above the graph.
Box plots show the median, interquartile range (IQR), whiskers for the closest points
within 1.5×IQR from the IQR, and outliers beyond the whiskers.
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Dean Barratt.
E. Gibson, Imaging-histology fusion-based validation of prostate MRI for cancer therapy planning.
NIH Molecular Imaging Program Guest Lecture. Bethesda, USA. Apr. 24, 2014. London, UK. Invited
by Peter Choyke.
E. Gibson, Prostate cancer MRI: a new evolving paradigm - what can we learn from MRI-histology
fusion. Citywide Cancer Imaging Seminar. London, Canada. Jan. 22, 2014. Invited by David Palma
and Aaron Ward.
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4.

E. Gibson, Imaging-pathology fusion supporting development of contouring guidelines for prostate
cancer focal therapy planning on multi-parametric MRI. Techna Institute seminar series. Toronto,
Canada. Nov. 18, 2013. Invited by Vladimir Pekar.
5. E. Gibson, Update on CIHR Team Project: Imaging-pathology fusion supporting development of
contouring guidelines for prostate cancer focal therapy planning on multi-parametric MRI. CIHR
Team Grant & OICR Smarter Imaging Program Prostate Workshop. London, Canada. Nov. 15, 2013.
Invited by Glenn Bauman.
6. E. Gibson, The statistics of registration error. Robarts MedIA lecture series 2013. London, Canada.
Sep. 10, 2013. Invited by Jing Yuan.
7. E. Gibson, Histology-based validation of imaging. Wuhan, China. December 17, 2011. Invited by
Mingyue Ding.
8. A. D. Ward, E. Gibson, Update on CIHR Team Project: Imaging–Pathology Registration for ImageGuided Diagnosis and Therapy of Prostate Cancer, CIHR Team Grant & OICR Imaging Pipeline
Platform One Millimetre Cancer Challenge Workshop. London, Canada. November 18, 2011. Invited
by Glenn Bauman. (presentation by all authors)
9. E. Gibson, Using digital histology images to validate patient MRI of prostate cancer. University
Hospital Histotechnologist Lunch and Learn. London, Canada. May 20, 2011. Invited by Debbie
Gaskin.
10. J. A. Gómez, A. D. Ward, E. Gibson, Update on CIHR Team Project: Imaging–pathology registration
for prostate cancer diagnosis CIHR workshop, CIHR Team Grant & OICR Imaging Pipeline Platform
One Millimetre Cancer Challenge Workshop. London, Canada. November 19, 2010. Invited by Glenn
Bauman. (presentation by all authors)

Teaching Experience
2014

2013

2012
2012

2012

2011
2010

The University of Western Ontario
BME 9519B/ECE 9202B/ECE9022/MBP 9519B/ECE 4438B – Advanced Image
Processing and Analysis
2 hour invited lecture
The University of Western Ontario
BME 9511B/ECE 9511B/ECE9511B – Image-guided Interventions
2 hour invited lecture
The University of Western Ontario
BME 9599 – Graduate Seminar – Teaching Assistant
The University of Western Ontario
MBP 4475/MBP 9515/BME 9513 – Introduction to Medical Imaging – Teaching
Assistant
The University of Western Ontario
BME 9519B/ECE 9202B/ECE9022/MBP 9519B/ECE 4438B – Advanced Image
Processing and Analysis
2 hour invited lecture
The University of Western Ontario
ENGSCI 1036A – Programming Fundamentals for Engineers – Teaching Assistant
The University of Western Ontario
ENGSCI 1036A – Programming Fundamentals for Engineers – Teaching Assistant

Teaching Training
2014
2013

The University of Western Ontario
MBP 9573 – Advanced Studies in Biophysics: Design of Medical imaging Labs
The University of Western Ontario
Advanced Teaching Program – 24 hour seminar series
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